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Abstract 
Discrete arginine topologies guide escape of miniature proteins 
from early endosomes to the cytoplasm. 
Jacob S. Appelbaum 
2012 
Polypeptides and peptide mimetics sample a wide chemical space with broad potential 
to modulate cellular function, but their application to cytoplasmic targets is limited be­
cause when added to cells their cytosolic concentration remains low. This limitation is 
due to a diffusion barrier (the plasma membrane) and absence of dedicated import ma­
chinery. Highly cationic peptides and proteins sometimes gain cytosolic access, but how 
they do so is not well understood. Using a small library of cationic miniature proteins, I 
probe the influence of positive charge number and orientation on the ability the minia­
ture protein to access the cytoplasm. Using a novel assay, I identify a cationic miniature 
protein, which we called 5.3, that carries a discrete arginine motif and efficiently reaches 
the cytoplasm. Database searches find that the precise motif identified (an arginine 
present in positions i, i + 4, i + 7, i + 10, and i + 11 of an a-helix) is not present in na­
ture, but that similar motifs are present in natural proteins that interact with cellular 
membranes. Finally, I examine the cellular pathway by which 5.3 reaches the cytoplasm. 
I find that this miniature protein enters the cell via a dynamin and cholesterol depen­
dent endocytic mechanism and is delivered to Rab5+ early endosomes. In contrast to 
the shiga-like toxins, and many non-enveloped viruses (which escape to the cytoplasm 
from the endoplasmic reticulum) as well as other peptides previously identified as 'cell 
penetrating', only 5.3 escapes from early endosomes. These findings should enable the 
future dissection of the precise molecular events underlying cytoplasmic access of pep­
tides and proteins, and may illuminate principles for the engineering of peptides and 
peptidomimetics that access cytoplasmic targets. 
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Permeability barriers presented by lipid bilayers 
Without the ability to separate their contents from the outside world, cells could not be 
considered 'alive'. The cellular limiting membrane, a phospholipid bilayer, is critical to 
the concentration of metabolites, generation and use of energy, segregation of genetic 
material, and sequestration of harmful digestive enzymes or poisons. At the same time, 
lipid bilayers represent frustrating barriers to the physician or biologist wishing to per­
turb the inner workings of a cell for the purposes of scientific experiment or therapeutic 
gain. 
The high resistance presented by lipid bilayers is well known in the field of neurobi­
ology, where the increase in conductance due to the opening of single ion channels can 
be recorded[i]. This is only possible because the membrane (in this case, along with its 
seal to the recording pipette) prevents the crossing of small ions, resulting in a resistance 
of 109 — 10110, which, given a thickness of -5 nM makes the lipid membrane one of the 
most resistive materials known(p ~ 10190 • m, teflon is ~10220 • m, air is ~10160 • m). 
The efforts of physicians and chemists to identify useful drugs has also been a de 
facto investigation of the permeability barrier presented by cell membranes. While many 
drugs act on protein receptors on the cell surface, for drugs to act on intracellular targets, 
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they must reach the cytoplasm. The many examples of bioactive materials, along with 
the negative examples provided by their inert counterparts, has led to a set of guidelines 
for the design of small molecules that are readily absorbed and reach the cytoplasmic]. 
These guidelines include a limit on molecular size (<500 Da), polarity (logP > 5), and 
hydrogen bonding potential ( < 10 H-bond acceptors, <5 H bond donors). Thus the lim­
itations of membrane permeability have designated a large fraction of potential chemical 
compounds as unlikely to be useful. 
This limitation has particularly frustrated efforts to manipulate protein protein inter­
actions within cells. These interactions take place over flat surfaces, generally >6ooA2, 
often being between 1000-2500A2, and thus difficult to target with small molecules. In 
addition, prediction of key residues within the protein-protein interface is a challenge^]. 
While the characteristic physicochemical properties of protein interfaces vary, many con­
tain key polar residues^]. In fact, within the many residues that form a protein-protein 
interface, stabilizing binding energy often results from only several residues (termed 'hot 
spots' [5, 6]) chosen from within a subset of amino acids: phenylalanine, tyrosine, tryp­
tophan, arginine, and isoleucine are over-represented[6]: Small molecules are not well 
suited to achieve specific binding to flat and sometimes polar surfaces. 
Peptides and proteins on the other hand are very well suited to the modulation of 
protein-protein interactions^]. By using a peptide that exhibits a well-defined structure 
in solution, the entropic cost associated with a concerted binding/folding event can be 
paid 'up front'[8, 9, 10], increasing the magnitude of the free energy of binding. While 
important advances in the design of small molecule inhibitors based on the crystal struc­
tures are being made[n, 12], accurate results are often only achievable as comparisons 
between structurally similar small molecules[i3], and de novo identification of high affin­
ity protein ligands has been difficult^, 12]. The situation for peptides is very different. 
Protein epitope grafting[i4, 15, 16], wherein the interacting side chains of a protein or 
peptide ligand are grafted onto a well folded a-peptide domain[i7,15, 18,19, 20, 21, 22] 
or ^-peptide helix[23, 24, 25, 26, 27, 28] enables the facile creation of high affinity ligands. 
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Peptides with low micromolar affinities can be isolated from small, designed libraries, 
often containing only a dozen or so members[i5]. In the case of naturally encoded 
a-peptide miniature proteins, ligand affinity can be improved via phage display[29], 
in the case of non-natural ^-peptides, selection can be accomplished from bead-based 
libraries[3o]. If the molecules thus selected could be engineered to reach their cytoplas­
mic targets, a large selection of rapidly designable active chemical entities would likely 
become available, enabling scientists and physicians to modulate cytoplasmic protein-
protein interactions for the purposes of interrogating function or ameliorating disease. 
Those seeking to engineer cytoplasmic access into peptides and proteins may take 
notice of the fact that pathogens have envolved to achieve the same result for different 
ends: the debilitation and exploitation of a suitable host. The viral life cycle requires 
cytoplasmic machinery for the replication of the viral genome[3i]. Anthrax and tetanus 
toxins cleave synaptobrevin to inhibit neuronal transmission incapacitating the host[32]. 
Shiga and shiga-like toxins from E. coli enter cells of the colon and halt protein synthesis 
leading to cell death and dysentery[33, 34]. The mammalian immune system has also 
evolved specialized cells (antigen presenting cells, APCs) that internalize extracellular 
protein into the cytoplasm^]. Cytoplasmic proteolysis pathways generate peptides 
that are loaded onto peptide binding proteins (the major histocompatability complex, 
MHC) which are then displayed on the cell surface for interrogation by T cells[36, 37, 
38]. A better understanding of the pathway by which APCs internalize extracellular 
protein could very likely be exploited for the purposes of vaccine development^, 40], 
or engaging the immune system to help fight tumors[4i]. 
I've taken both a top-down and bottom-up approach in seeking to better define the 
design principles the enable the cytoplasmic access of small miniature proteins. First, 
using a strategy developed in the Schepartz Lab for the monitoring of protein-protein in­
teractions, I examine the requirements for peptide-MHC association. Next, using a small 
library of cationic miniature proteins, I probe the influence of positive charge number 
and orientation on the ability the miniature protein to access the cytoplasm. Using a 
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novel assay, I identify a cationic miniature protein, called 5.3, carrying a discrete arginine 
motif that efficiently targets miniature proteins to the cytoplasm. Database searches find 
that the precise motif identified (an arginine present in positions i, i + 4, i + 7, i + 10, 
and i + 11 of an a-helix) is not present in nature, but that similar motifs are present in 
natural proteins that interact with cellular membranes. Finally, I examine the cellular 
pathway by which 5.3 reaches the cytoplasm. I find that this miniature protein enters the 
cell via a dynamin and cholesterol dependent endocytic mechanism and is delivered to 
Rab5+ early endosomes. In contrast to the shiga-like toxins, and many non-enveloped 
viruses (which escape to the cytoplasm from the endoplasmic reticulum) and other pep­
tides previously identified as 'cell penetrating', only 5.3 escapes from early endosomes. 
These findings should enable the future dissection of the precise molecular events un­
derlying cytoplasmic access of peptides and proteins, and may illuminate principles for 
the engineering of peptides and peptidomimetics that access cytoplasmic targets. 
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Chapter 2 
Use of Bipartite Tetracysteine 
Display to Probe the Association of 
Cross-Presented Peptides with the 
Major Histocompatability Complex 
2.1 Background 
The mechanistic xmderstanding of biological processes increasingly requires atomic level 
resolution of changes in protein conformation or association state. Recent results suggest 
that cells localize signaling processes on discrete membrane[42] or endosomal[43] regions 
creating a diversity of protein conformations segregated in space. In addition it has 
long been known that taking protein systems out of their natural context can result in 
experimental artifacts. Therefore researchers require the ability to interrogate changes in 
proteins within a cellular environment using a method that provides resolution within 
time and space. Very few, if any, existing methods can satisfy these demands, and thus 
new techniques for the interrogation of protein-protein, or protein-peptide interactions 
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withirv living cells are required. 
Antigen presentation is the process which integrates the responses of innate and 
adaptive immune cells to generate an immune response, and provides a case-in-point 
for the above requirements. The process takes place across cellular contacts between spe­
cialized antigen presenting cells (APCs) and T cells through the interaction of the major 
histocompatibility complex (MHC) glycoprotein on the APC and the T cell receptor on 
the T lymphocytes. While the presence of cytokines in the surrounding media as well 
as the expression of surface 'costimulatory' proteins on the APC can influence the vigor 
with which the T cells responds, the primary factor that determines activation of the acti­
vation of cytotoxic T lymphocytes (CTL) is the tight association of the T cell receptor with 
a complex composed of the class I MHC molecule (MHC-x) and an antigenic peptide. 
Antigenic peptides are derived from proteolytic fragments of proteins both expressed 
in the cytoplasm (endogenous) and internalized (exogenous). Endogenous antigens are 
complexed with MHC-i through specialized chaperones in the endoplasmic reticulum, 
but the mechanism by which exogenous peptide antigens are loaded onto MHC-i re­
mains unknown. 
2.1.1 The spatial requirements of antigen presentation. 
All nucleated mammalian cells utilize the 'classical' MHC-I loading pathway to present 
endogenous antigen for CTL surveillance. Proteins targeted for degradation by polyu-
biquitination are cleaved by the proteasome into oligopeptides that are transported into 
the endoplasmic reticulum (ER) by the transporter associated with antigen processing 
(TAP). In the ER, chaperones mediate association of peptide with MHC-i and the result­
ing peptide-MHC-i complexes are transported to the cell surface for display [38]. 
The presentation of exogenous antigen by MHC-I on the APC surface (a process 
called cross-presentation [44, 45, 46]) presents several conundrums. Perhaps the most 
significant is whether exogenous protein antigen must access the cytoplasm for protea-
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somal degradation. If exogenous proteins do reach the cytoplasm of APCs, presentation 
of derived peptide antigens could proceed in the usual fashion. In the absence of specific 
import machinery, cytoplasmic access of exogenous proteins would represent a severe 
exception to the permeability barrier of the cell. 
At least five distinguishable pathways have been proposed to explain the mechanism 
by which MHC-i molecules acquire exogenous peptide antigen[47, 36]. The simplest (A) 
involves digestion of endocytosed protein in peripheral vesicles that then fuse with re­
cycling endosomes [48] or more acidic compartments (such as the MHC class II loading 
compartment [49]) that catalyze the exchange of antigenic peptide loading on MHC-i 
before transport back to the cell surface. Alternatively, peptides [50] delivered to the 
cytosol, either by (B) endosomal escape or (C) gap junctions [51] could be imported into 
the ER by TAP and loaded via the 'classical' MHC-i pathway. The two remaining path­
ways involve delivery of intact protein to the cytosol via Sec6i. Phagosome-ER fusion 
(D) may deliver extracellular proteins to the ER; the proteins are then retro-translocated 
to the cytosol for proteosomal degradation^]. A similar process (E) could occur in pe­
ripheral endosomes that contain Sec6i and TAP, but are distinct from the endoplasmic 
reticulum[52]. 
The challenge in understanding the formation of exogenous peptide-MHC complexes 
is made more difficult by the variety of complexes present, the need for accurate subcel­
lular localization and the small size (but critical nature) of the peptide in comparison to 
the MHC molecule. In addition, it is the combination of peptide and MHC that must 
be recognized, because the peptides in isolation are inert, and because APCs continually 
express, internalize, and degrade multiple alleles of MHC, with some MHC molecules 
being reloaded and recycled to the cell surface. 
Identification of the compartment in which cross-presented peptide MHC complexes 
first form would provide a way to distinguish experimentally between these hypotheses: 
pathways B, C, and D predict that cross-presented MHC-peptide complexes should as­






Empty MHC-1 ^Sec61 ^ Proteasome OAg Protein 
^Gap Junction • Ag Peptide Ag Loaded MHC-1 TAP 
Figure 2.1: Pathways of Cross-presentation, (a) Endocytosed protein is degraded in pe­
ripheral vesicles creating peptides that encounter empty MHC molecules. The exogenous 
antigen does not enter the cytoplasm, (b) Peptides are delivered to endosomes and then 
to the cytosol. The mechanism of peptide escape from endosomes has not been deter­
mined. (c) Peptides from nearby cells are delivered to the cytoplasm directly via gap 
junctions, (d) Phagosome-ER fusion delivers endocytosed protein to the ER. Protein is 
retrotranslocated to the cytoplasm and is degraded by the proteasome. (e) Phagosomes 
retrotranslocate protein to the cytoplasm, and re-internalize proteasomal peptides for 
MHC-i assembly. No communication with the endoplasmic reticulum is required. 
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independent, and should not be inhibited after addition of the proteasome inhibitor 
bortezamib. Only model A is TAP-independent. Finally, only pathway D predicts that 
intact protein antigen should exist in the ER. While experimental evidence for each of 
these pathways has been observed in various cell line and mouse models, the direct 
(or indirect) visualization of peptide-MHC complexes in the ER or in the peripheral en-
domembrane system has not been achieved. Knowledge of dominant pathways could 
guide development of drugs specifically targeted to blocking presentation of autoanti-
gens, without affecting the rest of the immune system. 
2.1.2 Existing approaches to probe protein-protein interactions and their ap­
plication to cross presentation. 
Attempts at antibody-based immunolocalization of cross-presented peptide-MHC com­
plexes have failed[53, 54, 55, 56]. An alternative common approach to studying the 
subcellular localization of molecules is to tag them with fluorophores synthetically. New 
small organic fluorophores that (with specialized microscopes) provide sub-diffraction 
(i.e. 'super'resolution) are available^]. Covalent attachment of these dyes could pro­
vide information on the proximity of peptides derived from exogenous antigen to MHC-
x but even super-resolution experiments are limited to -20 nm[58], which may define a 
peptide and MHC molecule being localized to the same membrane region, but may leave 
ambiguous whether they are complexed together. 
Forster resonance energy transfer (FRET) operates on smaller distance scales (1-10 
run) but requires tagging both interacting partners with fluorescent chromophores [59]. 
Antigenic peptides are small (8 - xx amino acids), and attaching a fluorescent protein 
(GFP is 238 amino acids) to MHC near near its binding site may perturb the loading 
process; placing a fluorescent protein on the C-terminal tail of MHC does not perturb 
function, but locates the fluorescent protein far from the peptide preventing the possi­
bility of FRET. New methods for detecting protein-protein interactions that rely of the 
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physical association of proteins (protein complementation assays, see [60]) are being de­
veloped, but these require the cooperative folding of protein and peptide to form single 
domains in trans. 
Tagging only the peptide with smaller fluorophores, such as fluorescein will not lead 
to specific detection of MHC-peptide complexes; all of the peptide within a cell would be 
fluorescent. Small solvatochromatic fluorophores have been incorporated as side chains 
of unnatural amino acids within peptide MHC II ligands[6i]. These molecules show 
fluorescence enhancement when buried in the MHC-peptide binding groove, but the 
specificity of the signal in this case was not demonstrated. In addition these molecules 
showed a fluorescence enhancement roughly two-fold above background, a level not 
high enough to permit microscopic examination of the cells. 
Previous attempts to visualize the formation and trafificking of cross-presented peptide-
MHC complexes have been thwarted by the inability of fluorescently labeled antibodies 
to detect specific complexes within live cells [55]. Bipartite tetracysteine display possesses 
unique advantages in this regard, as (1) it requires only a 4 amino acid tag, (2) binding 
is rapid, allowing pulse chase experiments, (3) the complex formed with FlAsH/ReAsH 
possesses high thermodynamic and kinetic stability[62], and ReAsH (4) can polymerize 
diaminobenzidine, enabling detection by electron microscopy (EM) [63, 64, 65]. Applying 
bipartite tetacysteine display to the detection and localization of peptide-MHC com­
plexes should reveal the cellular localization of cross-presented peptide-MHC complexes 
with high resolution. 
2.2 Results 
The laboratory of Roger Tsien has previously shown that recombinant proteins contain­
ing the linear tetracysteine sequence CCPGCC can be selectively labeled with the cell 
permeable 'pro-fluorescent' molecules FlAsH (4,5-bis(i,3,2-dithiarsolan-2-yl)fluorescein) 
and ReAsH (4,5-bis(i,3,2-dithiarsolan-2-yl)resorufin)[66, 63, 64, 67]. FlAsH and ReAsH 
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are not fluorescent on their own, but become so when bound to peptides or proteins 
containing a tetracysteine motif[66]. In developing a strategy called bipartite tetracys­
teine display, the Schepartz Lab split the tetracysteine tag between two proteins so that a 
tetracysteine binding site is reconstituted upon protein protein interaction, but not when 
the two proteins remain in isolation. Treating protein complexes with FlAsH or ReAsH 
resulted in fluorescence increases, but no increase was observed when mutations were in­
troduced that prevented protein-protein interaction [62]. This strategy provides specific 
advantages in cellular imaging. First the molecular recognition of the tetracysteine bind­
ing site by ReAsH requires the cysteine residues to be 5-8 A apart (see below), delivering 
spatial resolution that is unachievable by other means in cells. It also does not require 
the genetic fusion of large fluorescent proteins, and removes the permeabilization step 
necessary in immunofluorescence[66, 63, 64]. To extend this approach to peptide-MHC-
1 recognition, I began by generating a series of peptides and matched MHC-i variants 
that contain judiciously placed dicysteine pairs. I then tested the ability of these MHC-i 
variants to traffic to the cell surface and to bind to cysteine containing peptides. 
2.2.1 A bipartite tetracysteine display strategy to selectively label peptide-
MHC-i complexes. 
The original report of the use of bisarsenical profluorescent molecules to label recom­
binant proteins assumed a target peptide CCRECC was helical[67]. Modeling a well 
structured a-helix suggested that the thiol-arsenic bonds would be placed within the 
proximity required to form a tetradentate binding site with the bisarsenical fluorophore. 
Subsequent optimization of the ligand peptide sequence[68], and the determination of 
the structure of the optimized peptide-ReAsH complex [69] by NMR reveals that the bis­
arsenical fluorophore prefers a hairpin structure (Fig. 2.2a). Analysis of the sulfur-sulfur 
bond distances, as well as the distances between jS-carbons is shown (Fig 2.2b). The 
intra-atomic distances range from -4-7 A for the sulfur atoms, and -5-8 A for the peptide 
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^-carbons. This analysis confirms earlier hypothesestyo, 62, 63, 64, 67] that the forma­
tion of a tetracysteine binding site, whether linear or bipartite, requires sub-nanometer 
approximation of the four cysteine residues. 
The first structure reported of the human leukocyte antigen (HLA) was of the A2 
allelejyi, 72], which has served as a model for MHC-peptide loading. In silico muta­
genesis of these complexes to introduce potential FlAsH/ReAsH binding sites suggests 
two positions - 179 and 183 oh HLA-A2 - as ideal for the requisite Cys-Cys pair: the a-
carbons of these side chains are located approximately 6 A from each other and 6 A from 
the two cysteines in the peptide YLLCCNYKL, which binds HLA-A2 with high affinity 
(KD = 2 nM) [73, 74]. The a-carbon of other amino acids located within the a-helices that 
border the peptide binding groove were also closely approximated to the a-carbons on 
the bound antigenic peptide. These include R89, K90, A93, V97, Tioo, K170, A174, and 
A182. We searched online databases^] for other cysteine pair-containing peptides that 
bind HLA-A2 with high affinity. Identified ligands include IIITCCLLSV (KD = 6.3 nM) 
and MICCDSRIW (KD = 24.6 nM). Pairing selected HLA-A2 variants with peptides 
containing C2 pairs in different locations along the peptide binding groove should al­
low for examination of the proximity requirements for the formation of a bipartite C4 
motif between the MHC variant and peptide. For example, I predict that K90C/A93C 
and Y183C/T187C should form a suitable FlAsH/ReAsH binding motif in combination 
with IIITCCLLSV or MICCDSRIVV, respectively. Additional sites on HLA-A2 suitable 
for C2 installation are shown in figure 2.2d. Wild type HLA-A2 modified with an intact 
tetracysteine (C4) tag serves as a positive control whose ability to bind FlAsH or ReAsH 
should be independent of added peptide. Wild-type HLA-A2 lacking a C2 motif serves 
as a negative control. 
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2.2.2 Expression analysis of generated MHC-i Variants 
I took note of the fact that the insertion of cysteine residues within the MHC heavy chain 
may not be innocuous to the function of the protein. During the synthesis of MHC-
i, nascent proteins are tightly complexed with chaperones in the ER[77, 78]. Release 
from the ER requires proper folding (for which peptide loading is a prerequisite^]), 
and so the presence of MHC-i on the surface of cells implies that these molecules are 
folded properly and loaded with peptide[8o, 81]. Wild-type HLA-A2, when tagged with 
GFP and expressed in cultured epithelial cells, is present both at the surface and within 
intracellular vesicles[49]. To determine whether the introduction of cysteines near the 
peptide binding groove induced perturbations to the subcellular localization of MHC-i, 
we expressed GFP fusions of dicysteine containing HLA-A2 variants in HeLa cells and 
examined the cells by microscopy (Fig. 2.3). 
HeLa cells were transfected with wild-type HLA-A2 tagged to GFP (HLA-A2-GFP) 
or variants containing engineered dicysteines. The presence of expressed HLA-A2 was 
determined by the observation of GFP fluorescence. To determine whether the trans­
fected HLA-A2 variants were present on the cell surface, transfected cells were labeled 
with phycoerythrin (PE) conjugated BB7.2, a monoclonal antibody specific for the folded 
conformation of HLA-A2. As can be seen in figure 2.3b, HeLa cells transfected with wild-
Figure 2.2 (following page): A bipartite tetracysteine-based strategy to detect peptide-
MHC complexes, (a) The structure of ReAsH bound to the peptide sequence FLNC-
CPGCCMEP, as determined by NMR (personal communication from RY Tsien). (b) 
The ReAsH molecule from a, shown without the peptide, but with bound thiol and 
/5-carbon (above) or only bound thiol (below) ligands. The distances between jS-carbons 
and between sulfur atoms is shown, (c) The structure of the peptide binding groove 
of HLA-A2[y6] as determined by X-ray crystallography (PDB structure 1JHT). The sites 
of cysteine incorporation are shown, (d) The combination of variants made. Each vari­
ant contains two engineered cysteine residues, (e) Possible orientations of tetracysteine 
motifs generated upon peptide binding. Each possible tetracysteine site is shown in a 
different color. None of the distances shown are > 10 A from a-carbon to a- carbon, (f) 
A close up view of tetracysteine site 1 (shown in e). The inter-/S-carbon distances are 
shown. This view is rotated 180° from the view in e in order to better illustrate the close 
apposition of the peptide with the a-helix that forms the peptide binding grove. 
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Figure 2.3: Epifluorescence microscopy showing the subcellular distribution of GFP-
tagged dicysteine containing HLA-A2 variants, (a) Experimental Schema. HeLa cells are 
transfected with wild-type HLA-A2 tagged to GFP (HLA-A2-GFP) or HLA-A2 variants 
containing engineered dicysteines. Cells are then stained with BB7.2-PE, an antibody that 
recognizes folded HLA-A2[82], without permeabilization. The presence of red fluores­
cence on the cell surface indicates the presence of properly folded HLA-A2, which when 
overlapped with green can appear yellow. Variants of HLA-A2-GFP that express but do 
not fold, may be retained in the ER or golgi, and should not lead to red surface staining 
with BB7.2-PE. Some variants of HLA-A2-GFP may be unstable and rapidly degraded. 
In this case, neither green nor red fluorescence will be observed, (b) Cell micrographs 
prepared as described in a. Wild-type HLA-A2-GFP is expressed intracellularly and on 
the cell surface after transfection in HeLa cells. R89/A93, K90/A93, Q179/A182, and 
K170/A174 variants also express on the cell surface. Surface expression of Q179/Y183 is 
low. The expression of the V79/T100 variant is undetectable. 
15 
type HLA-A2-GFP display both green intracellular fluorescence and red fluorescence on 
the cell surface. This is indicative of the proper folding and surface expression of the 
transfected HLA-A2 allele. Cells transfected with A2 variants containing engineered di-
cysteines at positions R89/A93 or Q179/A182 show patterns of intracellular and surface 
expression that are qualitatively similar to wild-type. HeLa cells transfected with an A2 
variants containing engineered dicysteines at either positions K170/A174 or Q179/Y183 
show both intracellular GFP and surface BB7.2 labeling, but increased green fluorescence 
signal is located within the intracellular reticular network, indicating the possibility of 
inefficient folding. The A2 variant containing dicysteines at position V79/T100 shows no 
GFP fluorescence or BB7.2-PE labeling, indicating that this variant is not expressed. 
To quantitatively assess whether A2 variants showing surface expression by mi­
croscopy are present at levels similar to wild-type, HeLa cells transfected with wild-
type HLA-A2-GFP or dicysteine containing variants were labeled with BB7.2-PE and 
examined by flow cytometry (fig 2.4). Living cells were identified by their characteris­
tic pattern of forward scatter (FSC) and side scatter (SSC), and their ability to exclude 
propidium iodide. GFP expressing cells were identified by the presence of green flu­
orescence and their levels of surface BB7.2 staining were compared. As can be seen 
in figure 2.4b, HeLa cells transfected with wild-type HLA-A2-GFP show high levels of 
surface BB2.7 staining (green line), but untransfected cells (black line) and cells not ex­
posed to the antibody (grey shaded histogram) do not, confirming that HeLa cells are 
HLA-A2-negative[83] in the absence of transfection, and that transient transfection in­
duces surface A2 expression. Comparing the histograms shown in figure 2-4c-g to the 
histogram in figure 2.4b shows that HeLa cells transfected with variants containing en­
gineered dicysteines at sites R89/A93, K90/A93, K170/A174 and Q179/A182 express 
surface levels of HLA-A2 that are similar to levels obtained for the wild-type allele. 
HeLa cells transfected with HLA-A2 containing an engineered dicysteines at position 
Q179/Y183 show either reduced surface expression or reduced antibody binding. (The 
latter is a possibility, because the BB7.2 epitope is composed of the C-terminus of the «2-
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Figure 2.4: Surface expression of dicysteine containing HLA-A2 variants as assessed 
by flow cytometry. HeLa cells transfected with HLA-A2-GFP or dicysteine containing 
variants were stained with BB7.2-PE as shown in figure 2.3 before analysis by flow, (a) 
Process of analysis. Cells were gated on forward scatter (FSC) and side scatter (SSC) 
to define a 'live cell' population. Cells from the FSC/SSC gate were examined for GFP 
expression and propidium iodide uptake. Cells there were PI- (live) and GFP positive 
were selected for inclusion in the histograms shown in b. (b-g) The cell fluorescence due 
to BB7.2-PE staining of GFP+ cells (green line) is compared to cells transfected with GFP 
and treated with PI (PI-), black line, as well as untransfected cells, not treated with PI 
(gray shaded histogram). 
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helix, wherein Q179 and Y183 are located, and portions of its underlying ^-strand[84].) 
This analysis confirms the conclusions following analysis by epifluorescence microscopy, 
namely, that the introduction of dicysteines at positions R89/A93, K90/A93, K170/A174 
and Q179/A182 do not severely perturb the expression, folding, or transport of HLA-A2 
molecules. The same may also be true for the A2 variant with the dicysteine introduced 
at position Q179/Y183. 
2.2.3 Recognition of tetracysteine motifs within oxidizing cellular environ­
ments. 
The binding of ReAsH or FlAsH to peptide tetracysteine motifs requires arsenic-thiol ex­
change. Because FlAsH and ReAsH will not react with oxidized disulfides [85], the tetra­
cysteine must be completely reduced. Were the above dicysteine containing HLA-A2 
variants to assemble with dicysteine containing peptides, the reconstituted tetracysteine 
motif would be present within the lumen of the endoplasmic reticulum, an oxidizing en­
vironment that promotes disulfide bond formation[86]. The addition of small thioalkanes 
can reduce intralumenal thiols [87] revealing tetracysteine motifs for FlAsH and ReAsH 
labeling[64]. In fact, careful choice of reductant can allow for pulse chase experiments, 
distinguishing tetracysteine motif-containing proteins that are sensitive to cell permeant 
versus cell impermeant reductants, or those that are located within reducing vs oxidizing 
environments^]. 
To determine whether I could detect ER lumenal tetracysteine containing proteins, 
I transfected HeLa cells with an expression vector encoding the HLA-A2 amino acid 
sequence with the peptide sequence CCPGCC prepended to the N-terminus (C4-HLA-
A2-GFP). This C4-HLA-A2 should display labeling with ReAsH that is independent on 
the formation of a bipartite tetracysteine motif composed of MHC and peptide. To con­
firm that treatment with reducing agents could lead to the successful labeling of a tetra­






* Image enhanced with 'unsharp mask' 
Figure 2.5: Detection of tetracysteine motifs within oxidizing environments. HLA-
A2 was tagged on the N-terminus (within the ER lumen) with the peptide sequence 
CCPGCC. (a) Labeling schema. HeLa cells were transfected with C4-HLA-A2-GFP for 
24 hr before treatment with 1 }iM ReAsH, 10 EDT, and 10 mM TBP for 20 min. 
Cells were then washed with HBSS and incubated for 20 min with 100 jiM EDT and 10 
mM TBP to reduce non-specific ReAsH labeling before imaging by epifluorescence mi­
croscopy. (b) Images of a HeLa cells transfected with C4-HLA-A2-GFP and labeled with 
ReAsH as described in a. Fluorescence due to GFP is shown in green, while fluorescence 
due to ReAsH is shown in red. An overlay of the two images is shown on the right, 
where overlap of the green and red signals appears yellow. In the periphery of the cell, 
the red ReAsH signal is concentrated in regions of GFP fluorescence. A zoomed image 
of the region within the white box is shown below. 
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ReAsH and 10 mM tributylphosphine (TBP), a cell permeable reducing agent previously 
shown to reduce thiols present within the golgi lumen[64]. In addition, 10 ^M ethane-
dithiol (EDT) was included in the labeling mixture as a competitor for the non-specific 
interaction of ReAsH with cellular protein thiols. After a washing step with a higher 
concentration of EDT (100 ]iM), red ReAsH signal was visible within endosomes. A dif­
fuse background of red signal within the cell body was also present. Examination of 
the GFP fluorescence showed a pattern of bright puncta combined with thin branching 
and anastomosing tubules forming a reticular network concentrated near the nucleus. 
This pattern is similar to that observed after transfection with wild-type HLA-A2-GFP, 
although with decreased signal originating from the plasma membrane (compare fig­
ure 2.3 with figure 2.5). When the images of GFP fluorescence and ReAsH signal were 
overlaid, the areas of more intense ReAsH signal colocalized with GFP positive vesicles, 
confirming that the presence of ReAsH signal from these vesicles was due to the presence 
of the C4-tagged HLA-A2 molecules. 
2.2.4 Dicysteine HLA-A2 variants are not loaded with dicysteine-containing 
A2-binding peptides. 
Initial trials of 'feeding' dicysteine containing peptide to HeLa cells transfected with 
dicysteine containing HLA-A2 molecules led to high cellular background, and no ap­
preciable signal. To bias the system toward the formation of peptide-MHC complexes 
containing bipartite tetracysteine motifs, we relied on observations that in cells harbor­
ing loss-of-function mutations in the transporter associated with antigen presentation 
(TAP), expressed MHC molecules are retained in the endoplasmic reticulum, but the 
addition of exogenous peptides can lead to peptide loading and stabilization of MHC 
surface expression[88, 74]. Three such TAP- cell lines were available as kind gifts of 
the Cresswell laboratory, RMA-S (mouse H.-2b), T2 (human HLA-A2+//+), and Bufi.280 
(human, HLA-A2"/_, [89]). Both RMA-S and T2 are lymphocytic in origin, and thus are 
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challenging targets in experiments using microscopy for the determination of subcellular 
localization. Bufi28o, on the other hand, is a melanoma cell line (epithelial in origin) that 
adopts a broad flat morphology preferable for microscopy. This cell line harbors a 2 bp 
insertion mutation that inactivates HLA-A2 expression, but transfection with wild-type 
HLA-A2 and TAP rescues the surface expression defect[89]. Thus we chose the Bufi28o 
cell line to test whether the dicysteine containing peptides identified in database searches 
could bind to the dicysteine containing HLA-A2 variants. 
To begin, we first used flow cytometry to confirm that expression of HLA-A2 in 
Bufi28o cells led to low levels of surface expression and was unstable. HeLa cells trans­
fected with HLA-A2-GFP show two histogram peaks when stained with BB7.2-PE. A 
high staining peak (characteristic of transfected cells) and a low staining peak (character­
istic of untransfected cells). When compared to the levels of surface expression of wild-
Figure 2.6 (following page): Surface stabilization of dicysteine containing HLA-A2 variants 
in cells lacking TAP. (a) HeLa cells transfected with wild-type HLA-A2-GFP express high 
levels of stable surface HLA-A2 as detected by BB7.2-PE staining, (b) Bufi28o cells, when 
transfected with wild-type HLA-A2-GFP show low levels of surface expression. For pan­
els a and b, cells showing FSC/SSC profiles and PI negative staining (characteristic of 
living cells) are included in this histogram. Expression of HLA-A2 on the surface of 
Bufi28o cells can be stabilized by incubation for 4 hrs at 37°C with media supplemented 
with 10% serum (c, blue histogram, gated GFP+) orio jiM. YLLCCNYKL, an HLA-A2 
binding peptide (d, grey histogram, gated GFP+). Cells incubated in serum free media 
(red histogram in c, blue shaded histogram in d, both gated GFP+) and GFP- untrans­
fected cells (grey shaded histograms) are shown as controls, (e) Surface stabilization of 
HLA-A2 by serum on Bufi.280 cells compared to the levels of surface expression in HeLa 
cells. Surface expression of HLA-A2 is unstable, (f) After incubation in media supple­
mented with serum overnight, HLA-A2-GFP expressing Bufi28o cells were incubated in 
HBSS without serum for varying times, (g) Mean fluorescence intensity as a function of 
time, (h) HeLa cells expressing HLA-A2 and incubated with or without serum for 4 hr 
at 37°C show similar levels of surface HLA-A2. (i) A schema for the determination of 
the surface stabilization of dicysteine containing HLA-A2 variants by dicysteine contain-
ing peptides. Bufi28o cells transfected with HLA-A2 variants are incubated overnight in 
serum free media with or without YLLCCNYKL peptide before staining with BB7.2-PE to 
measure the levels of surface HLA-A2. (j) Measurement of HLA-A2 surface stabilization 
on Bufi28o cells by dicysteine containing peptide. In every case examined, the levels of 
surface HLA-A2 were the same (R89/A93, K90/A93, K170/A174) or lower (Q179/A182) 
in the presence of peptide (red histograms) than in its absence (blue histograms). 
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type HLA-A2 when transfected into HeLa cells (fig. 2.6a), the same allele transfected 
into Bufi28o cells showed lower expression levels (fig. 2.6b). This low level of expression 
could be increased by incubating the cells in media containing serum, or in serum free 
media supplemented with 10 pM YLLCCNYKL, a high-affinity HLA-A2 binding peptide 
(fig. 2.6c and d). While incubation with peptide increases surface expression, the levels 
are still low compared to the steady state level in HeLa cells (fig. 2.6e). Peptides stabilize 
levels of surface expression transiently; removing the cells from media containing serum 
results in a time dependent decrease in surface folded HLA-A2 (fig. 2.6f), with a half-life 
of approximately 2.5 h (fig. 2.6g). By contrast, when HeLa cells expressing HLA-A2 are 
incubated in the presence or absence of serum for 4 hr, the levels of surface HLA-A2 are 
similar (fig. 2.6h). These results confirm that expression of HLA-A2 on the surface of 
TAP-/~ cells is not long lived, but can be increased through the addition of exogenous 
peptide, either in the form of serum, or in the form of specific HLA-A2 binding peptides, 
such as YLLCCNYKL. 
To test whether YLLCCNYKL stabilized dicysteine containing variants of HLA-A2, 
I transfected Bufi 280 cells with plasmids encoding HLA-A2 incorporating dicysteine 
residues at positions R89/A93, K90/A93, K170/A174 or Q179/A182. The cells were 
then incubated in serum free media or in serum free media supplemented with 10 }iM 
YLLCCNYKL. After overnight incubation at 37°C, the levels of surface HLA-A2 were 
examined by flow cytometry (for schema see fig. 2.6i). As can be seen in figure 2.6j, the 
levels of surface expression of HLA-A2 variants incorporating dicysteines at positions 
R89/A93, K90/A93 or K170/A174 were similar regardless of the presence or absence of 
the HLA-A2 binding peptide. For the HLA-A2 variant harboring cysteine residues at 
positions Q179/A182, the addition of the peptide decreased surface expression. Taken 
together, these results indicate that while the YLLCCNYKL peptide stabilizes the surface 
display of wild-type HLA-A2, it fails to stabilize the surface display of any of the 2C 
variants tested. 
The absence of surface stabilization of HLA-A2 when Bufi28o cells were treated with 
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2C containing peptide suggest that the peptide failed to form complexes with the HLA-
A2 heavy chain. These results make it unlikely that a bipartite tetracysteine motif is 
formed by the close association of heavy chain and exogenously applied peptide, and 
make it unlikely that the specific staining will be observed after treating these cells with 
ReAsH. Indeed, in other experiments, the addition of dicysteine containing peptides sub­
stantially increased the cellular background after ReAsH staining, making the likelihood 
of observing specific peptide-MHC complexes using this method very small. 
2.3 Discussion 
Dicysteine containing HLA-A2 side chains were expressed in TAP-/~ cells, but their 
surface levels were very low relative to wild-type HLA-A2, even though the surface ex­
pression level of these alleles were comparable in TAP+/+ (HeLa) cells. These data are 
in line with findings that TAP plays a role in the folding of MHC-i heavy chains[38], not 
just peptide loading, and supports the hypothesis that the addition of cysteines to the 
heavy chain represents a challenge to the folding of MHC-i that is made more difficult by 
the absence of TAP. The MHC-i loading machinery consists of the MHC-i heavy chain, 
^-microglobulin, TAP, tapasin, ERp57, and the chaperones and calreticulin. Exclusion 
of ERp57, an ER resident protein disulfide isomerase, from the MHC-i loading complex 
through the expression of a tapasin mutant[9o] or ERp57 deletion[78], results in aggre­
gate formation. These aggregates contain tapasin, unfolded MHC-i, as well as other 
proteins. One current model is that tapasin forms a bridge connecting TAP and MHC-i 
with ERp57 and calreticulin[9i]. In this model, ERp57, MHC-i and tapasin should as­
sociate independently of TAP. In fact, in vitro experiments have shown that tapasin and 
ERp57 are the minimal functional unit of the peptide loading complex[77]. Thus, why 
the deficiency of TAP should lead to a selective decrease in the surface expression of 
dicysteine containing HLA-A2 molecules, even in the presence of exogenously added 
HLA-A2 binding peptides, remains a mystery. 
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When DNA encoding dicysteine containing HLA-A2 molecules was transfected into 
TAP+/+ HeLa cells, the proteins were detected on the cell surface, but whether these 
molecules were loaded with peptide was not tested. I found that the addition dicysteine 
containining HLA-A2 binding peptides did not stabilize dicysteine containing HLA-A2 
heavy chains on the surface of TAP-/~ cells, even though these same sequences did 
stabilize the surface expression of wild-type HLA-A2. One possibility for this difference 
is that the combination of mutations within dicysteine containing HLA-A2 heavy chains 
and dicysteine containing HLA-A2 binding peptides prevent association and stable fold­
ing of the complex. 
Alternatively, these data may point to an additional role for TAP in the MHC-i pep­
tide loading complex. Unfolded MHC-i binds to calreticulin and tapasin for incorpo­
ration into the loading complex [91]. Even though MHC-i does not bind to TAP in the 
absence of tapasin[9x], it remains unstudied whether efficient recruitment of MHC-x into 
a complex with ERp57 and tapasin is affected by the absence of TAP. 
The hypothesis that MHC-x recruitment into the peptide loading complex is slower 
in the absence of TAP would explain the findings above. In the case of the wild-type 
allele, such efficient recruitment may not be necessary, because the protein may fold 
with an efficiency high enough to maintain reasonable expression levels. On the other 
hand, in the case where cysteine residues are added to the heavy chain, the absence of 
swift recruitment to the protein disulfide isomerase ERp57 may lead to a kinetic trap of 
improperly folded HLA-A2. Rapid recruitment to the tapasin-ERp57 loading machinery 
in the presence of TAP may occur before such misfolding occurs, in the absence of TAP, 
the expression of HLA-A2 with additional cysteines thus may be severely hindered. 
While this study was ultimately unsuccessful in defining the MHC-x cross presen­
tation pathway, it did provide several important lessons. These lessons take two forms: 
principles for choosing target pathways likely to be successfully interrogated by bipartite 
tetracysteine display, and required features of strategies interrogating cross presentation. 
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2.3.1 Future Directions I: Strategies for interrogating cross presentation 
As illustrated earlier, cross presentation represents a number of particularly vexing chal-
leges. The activation of T cells may occur with very few peptide-MHC complexes (<3 
for CD8+ T cell killing [92, 93]), so the detection must be exquisitely sensitive. These 
peptide-MHC complexes may be distributed across multiple areas of the cell, requireing 
the ability to detect single molecules. Indeed it is now appreciated that T cells could 
recognize single molecules long before microscopes could do so[94]. Thus most of the 
productive approaches to detecting the cellular pathways have used T cell responses 
as a functional read-out of whether pathways for cross-presentation remain intact af­
ter experimental purterbation. And specific theories regarding the cellular trafficking of 
membrane and endosomal contents are tested as they arise. 
Three studies[95, 96, 97] suggested that the fusion of the endoplasmic reticulum (ER) 
with maturing phagosomes could explain the cross presentation of antigens derived from 
intact protein. The theory, now wide-spread, is that ER retrotranslocation machinery 
would pull denatured proteins from the ER to the cytoplasm. A functional role for 
the ER associated degradation (ERAD) machinery in cross-presentation was provided 
soon after the initial studies [98, 99], however the notion that the membrane that fused 
with nascent phagosomes originated from what was canonically considered the ER was 
challenged[ioo]. Thus a picture in which the ERAD machinery may be functional out­
side the ER has emerged, or that phagosomes may fuse with ER-like vesicles containing 
enzymes thought to be resident only in the ER. Recent studies have suggested that the 
core component of the ERAD machinery, P97, can be recruited to early endosomes by 
poly-ubiquitinated mannose receptor[ioi]. Functional studies arresting the maturation 
of early or late endosomes may shed light on vesicular pathways required for cross pre­
sentation. 
Are exogenously derived peptides segregated from endogenous antigen during cross-
presentation? At least one group [96] has argued that proteasomes are associated with 
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the cytoplasmic side of phagosomes and the proteolysis products may be imported back 
into phagosomes from which they were previously exported. This would provide a way 
to segregate two classes of MHC-i, one that was loaded in the phagosome, and another 
that was loaded in the ER. Presumably the antigenic origins of these two populations 
are distinct, and the cell could regulate their trafficking differently. No data exists to 
support this model. However, research has shown that some MHC-x does pass out of 
the ER into phagosomes where it is loaded and traffics to the cell surface without passing 
through the golgi (identified through endoglucosidase H sensitivity)^]. Thus at least 
two populations of peptide loaded class I proteins exist: those that have passed through 
the golgi, and those that have not. 
All of the pathways enumerated in figure 2.1 are likely to be operable at different 
times and in different cells. Nevertheless, the mechanism of cross-presentation of anti­
gens derived from endocytosed proteins is perhaps the most interesting from a cell bio­
logical standpoint. Despite its importance from the standpoint of vaccine development 
and understanding basic cellular processes, no available techniques are truly well suited 
to answer the questions presented in the beginning of this chapter. 
With improvements in live cell microscopy, photodynamic /photoactivation approaches 
may be able to determine which population of MHC heavy chains carry cross presented 
peptides. In an alternative approach, one could imagine purifying high-mannose heavy 
chain and examining the mass spectra of the eluted peptides. This may provide one 
way to determine whether cross-presented antigen is selectively loaded on phagosomal 
MHC-i rather than in the ER. 
2.3.2 Future Directions II: Targets of choice for bipartite tetracysteine display 
The experiments outlined here were targeted not only at gaining a better understanding 
of antigen cross-presentation, but also at gaining a better understanding of methods and 
criteria for the use of bipartite tetracysteine display. One principle that has emerged 
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from in vitro protein labeling studies is the need for site flexibility in selecting protein 
regions in which to incorporate bipartite tetracysteine motifs[io2]. The factors presenting 
challenges during this work have illustrated guidelines for future choices of cellular 
systems and pathways likely to be successfully interrogated by this technique. 
At least four priciples for success have emerged. Systems likely to be successfully 
interrogated by bipartite tetracysteine display have (i) high levels of expression of a ho­
mogenous target, this leads to high concentrations of tetracysteine targets for labeling. (2) 
It is preferable that biological manipulations can leads to the presence versus the absence 
of the formation of the bipartite tetracysteine motif, this removes the need to distinguish 
between 'levels' of labeling, a distinction that requires a dynamic range roughly 5-10 
times larger than that required to determine a binary (present vs absent) response[xo3]. 
(3) The presence if the tetracysteine motif near the cell surface allows the use of total 
internal reflection (TIR) fluorescence microscopy (TIR-FM), a technique that selectively 
excites the ~ioo nm of the cell closest to the water-glass interface[i04], and can eliminate 
much the cytoplasmic background seen after ReAsH staining. (4) The tetracysteine motif 
should be located in the cytoplasm, to remove the need for acute reduction of oxidized 
thiols. 
In retrospect, the bipartite strategy outlined above for the detection of crosspresented 
MHC-peptide complexes incorporated none of these priciples. With advances in micro­
scopic techniques and approaches, advanced image process, new profluorescent fluo-
rophores, or a better understanding of the 'optimal' bipartite tetracysteine motif, some 
or all of these restrictions could be relaxed in the future. 
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2.4 Experimental Methods 
2.4.1 In silico mutagenesis and structural analysis of MHC-i and ReAsH-
FLN CCPGCCMEP 
To determine the intra-atomic distances likely to for a suitable tetracysteine motif for the 
binding of ReAsH, the PDB file containing the lowest energy conformer from the NMR-
determined structure of ReAsH complexed to the peptide FLNCCPGCCMEP was loaded 
into MacPyMol (www. pymol. org). The PDB coordinates were provided by Roger Tsien. 
The distances between atoms were determined using the 'Measurement' tool in PyMol. 
The distances between sulfur atoms or ^-carbons (cysteine side chains) were measured 
and are shown in figure 2.2. 
To determine possible sites of mutagenesis on the HLA-A2 heavy chain, the PDB file 
lJHT [76] was examined. This structure contains HLA-A2 bound to the antigenic peptide 
ALGIGILT. Surface residues exposed residues (surface exposure > 2.5A2) were identified 
using the f indSurfaceResidues (script available at http: //www.pymolwiki .org/ 
index .php/Category: Script_Library). In this structure the antigenic residues in 
IGIL (amino-acids 4-7) are surface exposed. Residue 2 (L) shows a surface exposure of > 
o 
2.5 A, however, the leucine side chain is pointing into the peptide binding groove, while 
O 
residue 3 (G) shows a surface exposure of < 2.5 A, but the backbone atoms are unburied. 
The assignment of this residue as buried may be because the side chain of residue 4 (I) 
is pointing out from the peptide binding grove, covering this amino acid. Thus residues 
3-7 were selected as possible sites for cysteine incorporation. Next, residues containing 
atoms within 8A of any atom within peptide residues 3-7 were selected. Surface exposed 
residues within this selection were chosen as an initial set from which to design possible 
cysteine incorporation sites. These residues are listed in table 2.1. Modeling the distances 
from the a—carbon residues revealed that some combinations of these side chains existed 
in preferable geometry, and these were selected for mutagenesis. 
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Residue Reason for Inclusion/Exclusion Could Pair With 
R89* Included A93 
K90 Included A93 
A93 Included R89, K90 
H94 Points away fom binding groove 
V97 Included T100 
R98 Points away fom binding groove 
T100 Included V97 
T146 Too far from peptide 
T147 Too far from peptide 
K170 Included A174 
W171 Side chain buried 
A174 Included K170 
H175 Points away fom binding groove 
V175 Kink in a-helix, no obvious pair 
Ai 77 Included Qi79 
Qi79 Included A177, A182 
A182 Included Q179 
Y183 Included Q179 
Table 2.1: Residues of HLA-A2 selected for installation of cysteines. Residue R89 was 
selected by visual inspection, the other residues were selected by the criteria that they 
contain > 2.5 A of solvent exposed surface, and contained atoms <8 A from from atoms 
contained within the residues 3-7 of the antigenic peptide. 
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2.4-2 Generation of dicysteine containing HLA-A2-GFP variants 
Mutations within the helical segments of HLA-A2 adjacent to the peptide binding groove 
were installed using QuikChange mutagenesis. Primer design was accomplished using 
the QuikChange primer design program on the Stratagene website. Primer sequences 
are listed in table 2.2. A plasmid containing the cDNA for HLA-A*020i was a kind gift 
of Ira Mellman and Lelia Delmarre, and was used as a template for the mutagenesis 
reactions. 
To install an N-terminal tetracysteine motif, QuikChange mutagenesis was used to 
instal an NgoMIV site within the coding region of HLA-A*020i, C-terminal to the signal 
sequence. The installation of this restriction site did not alter the amino acid sequence 
of the protein. Next, after desalting using G-25 microspin columns, oligos NC4-Tag 
and NC4-Tag_R were annealed in T4 DNA ligase buffer. The annealed oligo pair and 
the plasmid containing the inserted NgoMIV were both digested with the NgoMIV. The 
plasmid was treated with antarctic phosphatase, and both the insert and plasmid were 
purified using a PCR cleanup kit from Qiagen. The insert was then ligated into the vector 
using T4 DNA ligase, and transformed into e.coli. Positive transformants were screened 
by restriction digest and confirmed by DNA sequencing. 
2.4.3 Immunofluorescence of HLA-A2-GFP and dicysteine containing vari­
ants 
HeLa cells were transfected using Fugene HD (Roche) according to the recommended 
protocol. The following day, #1.5 round glass coverslips were coated with alcian blue 
by submerging the coverslips in a solution of 1% (w/v) alcian blue in water. The so­
lution (and coverslips) was boiled under close supervision using microwave heating for 
20 seconds, after which the solution was left to cool at room temperature for 10 min. 
After cooling, the alcian blue solution was recovered, and the coverslips washed exten­
sively in deionized water. The coverslips were sterili2:ed by submersion in 75% ethanol 
3i 
Primer Name Note Sequence (5' - 3') 
HLAA2R5 Reverse Seq CAGCGTGGTGAGTCATATGCGTTT 
HLAA22F Forward Seq AGAGGATGGAGCCGCGGG 
HLAA23F Forward Seq CGCGGGGAGCCCCGCTTCAT 








Qi79_Ai82 // GGCCCATGTGGCGGAGTGCTGGAGATGCTACCTGGAGGGCACG 
Qi79_Ai82_R // CGTGCCCTCCAGGTAGCATCTCCAGCACTCCGCCACATGGGCC 
Qi79_Yi83 n CATGTGGCGGAGTGCTGGAGAGCCTGCCTGGAGGGCAC 
Qi79_Yi83_R // GTGCCCTCCAGGCAGGCTCTCCAGCACTCCGCCACATG 
g72C Add NgoMIV site CCAGACCTGGGCCGGCTCTCACTCC 
g72c_R it GGAGTGAGAGCCGGCCCAGGTCTGG 
NC4-Tag CAGCGCCGGCTTTTTAAATTGCTGCCCCGGGTGCTGCATGGAACCGGGAAGTAGTGGAAGTAGTGCCGGCGAGC 
NC4-Tag_R // GCTCGCCGGCACTACTTCCACTACTTCCCGGTTCCATGCAGCACCCGGGGCAGCAATTTAAAAAGCCGGCGCTG 
Table 2.2: Oligonucleotides used in this study. All are listed 5'-3'. The 'R' indicates the oligonucleotide is the reverse-complement 
of another entry with the same designation, or designed to sequence in the 3'-5' direction. 
in water, and allowed to dry on a kimwipe in a cell culture hood. After drying the cov­
erslips were placed in a 12 well tissue culture plate. Transfected HeLa cells were lifted 
from their culture flask by treatment with trypsin, diluted in media, and approximately 
50,000 transfected HeLa cells were added to each coverslip-containing well and allowed 
to adhere overnight. The following day, cells were stained by incubation in FACS buffer 
(Hanks Balanced Salt Solution, HBSS, Gibco Cat# 14025, with 0.5% (w/v) bovine servun 
albumin added) containing a 1:500 dilution of BB72-PE for 1 hr. After labeling, cells 
were washed extensively in labeling buffer, and then lightly fixed and nuclei labeled 
by submersion in fixation buffer (4% paraformaldehyde in PBS) containing 300 nM 4',6-
diamidino-2-phenylindole (DAPI) for 5 min at RT, after which they were washed and 
mounted on glass slides using GelMount (Biomeda) or FluoroGel (Electron Microscopy 
Sciences). The slides were imaged using a 40X LD-NeoFluar objective on a Zeiss Axiovert 
200M. Images for GFP, PE and DAPI fluorescence were aquired using Zeiss filter sets 44, 
43, and 49, respectively, on a MRm camera and analyzed using ImageJ. 
2.4.4 Flow cytometric analysis of surface-expression of HLA-A2-GFP and di­
cysteine containing variants 
HeLa or Bufi28o growing in plastic tissue culture treated plates were transfected using 
Lipofectamine2000 (Invitrogen) according to the manufacturers instructions. After grow­
ing overnight, the cells were washed twice with PBS (without calcium or magnesium) 
before lifting from the growth substrate by incubating at 37°C for 30 min in 2 mL PBS 
supplemented with 1 mM each EDTA and EGTA. The cells were collected by centrifu-
gation (500 x g, 7 min) and resuspended in FACS buffer. The cells were then placed 
in a round bottom 96 well microtitre plate and labeled by incubation for 1 hr at 4°C in 
150 jWL of FACS buffer containing a 1:500 dilution of BB7.2-PE. After labeling, the cells 
were washed twice in FACS buffer, and resuspended in 500 FACS buffer containing 
1 ^g/mL propidium iodide. The cells were maintained on ice until analysis by flow 
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cytometry (FACSCalibur, BD). Histograms were constructed in Flowjo (TreeStar) after 
excluding dead cells by gating on forward and side scatter, and selecting a propidium 
iodide negative population. Channel compensations were conducted at the time of ac­
quisition using control samples containing only a single fluorophore. In some cases, the 
mean fluorescence intensity (MFI) is shown. This value is the geometric mean of at least 
10,000 cells falling within live gates defined by forward scatter, side scatter, and PI fluo­
rescence. In some cases, these values are gated on GFP+ cells, in which case the number 
of cells analyzed before GFP gating was >10,000. 
2.4.5 ReAsH staining of tetracysteine-tagged HLA-A2-GFP 
HeLa cells grown on glass bottom dishes (MatTek) were transfected with C4-HLA-A2-
GFP using Fugene according to the manufacturer's instructions. After overnight expres­
sion, the cells were washed twice with HBSS and incubated for 20 min at 37°C in 200 ^L 
ReAsH labeling solution containing 1 ReAsH, 10 }iM EDT, 10 mM tributylphosphine, 
1 mM CaCl2 and 1 mM MgCl2 in PBS (Gibco Cat# 14190). The cells were then washed 
twice with 2mL PBS and incubated for 20 min at 37°C in 2 mL ReAsH wash solution con­
taining 100 jiM EDT, 10 mM tributylphosphine, 1 mM CaCh and 1 mM MgC/2 in PBS. 
The cells were washed twice with PBS and incubated for 10 min at room temperature 
in 2mL HBSS containing 300 nM Hoescht 33342 before imaging. Images were acquired 
using a 40X LD-NeoFluar objective on a Zeiss Axiovert 200M. Images for GFP, ReAsH 
and Hoescht fluorescence were aquired using Zeiss filter sets 44, 43, and 49, respectively, 
on a MRm camera and analyzed using ImageJ. To better visualize ReAsH labeling of 
endosomes, some images were enhanced using the 'unsharp mask' filter, in which the 
image is blurred and the blurred image subtracted from the parent image. This has the 
effect of enhancing bright spots and decreasing background. 
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2.4.6 Surface stabilization of dicysteine containing HLA-A2 variants by serum 
Bufi 280 or HeLa cells transfected with HLA-A2-GFP or cysteine containing variants were 
grown in RPMI-1640 + 10% FBS overnight. The following day, the cells were washed 
twice with 2 mL HBSS before incubating (at 37°C) in either HBSS, HBSS + 10% FBS, 
RPMI-1640 (serum free media) or RPMI-1640 + 10% FBS (media + serum), for the indi­
cated length of time. The cells were them washed twice with 2 mL PBS and detached 
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The 
cells were diluted into FACS buffer, collected by centrifugation, and stained for surface 
HLA-A2 as described in §2.4.4. 
To determine the rate of disappearance of surface HLA-A2, Buf 1280 cells grown in 
6 well tissue culture plates were transfected with HLA-A2-GFP and allowed to express 
the protein overnight in RPMI-1640 + 10% FBS. At selected times the following day, indi­
vidual wells were washed twice with 2mL HBSS, and the incubated further for varying 
amounts of time in HBSS without serum. Following incubation the cells were detached 
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The cells 
were diluted into FACS buffer, collected by centrifugation (500 x g, 7 min) and stained 
for surface HLA-A2 as described above. 
2.4.7 Surface stabilization of dicysteine containing HLA-A2 variants by pep­
tide 
Bufi 280 cells transfected with HLA-A2-GFP or cysteine containing variants were grown 
in RPMI-1640 + 10% FBS overnight. The following day, the cells were washed twice with 
2 mL HBSS before incubating for at least 8 hr in either HBSS or HBSS supplemented with 
10 jiM YLLCCNYKL. The cells were them washed twice with 2 mL PBS and detached 
from the plate using 2 mL PBS supplemented with imM each EDTA and EGTA. The 
cells were diluted into FACS buffer, collected by centrifugation, and stained for surface 
HLA-A2 as described in §2.4.4. 
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Chapter 3 
Discrete Arginine Topologies Direct 
Cytosolic Access 
3.1 Background 
Protein drugs-also known as biologicals-represent a rapidly expanding class of ther­
apeutic molecules[i05]. However, their actions are limited primarily to extracellular 
targets[io6, 107] because the size and composition of most polypeptides and proteins 
do not facilitate their uptake into mammalian cells[io8]. It has been known for over 
40 years that addition of cationic charges to a peptide or protein can aid transport into 
cells[i09, 110, in], and many reports have demonstrated the utility of appending basic 
sequences derived from the HIV Trans-Activator of Transcription (Tat), D. melanogaster 
Antennapedia, or simply polyarginine (for example, Arg8) to peptides to increase their 
cytoplasmic access[ii2, 113, 114, 115, 116, 1x7]. Certain highly positively charged pro­
teins also possess cell penetrating properties[n8, X19], but it remains unknown how 
one can leverage these examples to control the precise entry pathway or enhance the 
determinants for uptake. 
Three contrasting mechanisms for cytosolic entry of cationic proteins and polypep­
tides have been proposed. The first (ion pair-guided passive diffusion) posits that guani-
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dinium side chains on the polypeptide form hydrogen bonds with cell surface phospho­
lipids creating neutral ion pairs that passively diffuse across the plasma membrane[i20, 
121]. The second model (endosomal release), asserts that endocytosis is a major portal 
through which cationic proteins and polypeptides enter the cell[io6, 122, 123], followed 
by endosomal release. Previous investigations have attempted to distinguish between 
these two models by blocking endocytosis, via thermal[ii5], pharmacologic[n6,123], or 
genetic means[n6, 124]. The interpretation of these experiments is complicated, how­
ever, by differences in protein/polypeptide concentration and analytical method. Re­
cently, a third mechanism for cytosolic entry was described: at concentrations > 10 
pM incubation of living cells with cationic proteins/polypeptides leads to the formation 
of nucleation zones[i25] that transiently disrupt membranes[i26]. This results in the 
spontaneous release of peptide into the cytosol. In the presence of drugs that inhibit 
endocytosis, incubation of cells at lower concentrations (< 5 pM) of peptide prevents cy­
toplasmic access[n6], implying that, at low concentrations, the molecules studied cannot 
diffuse through the plasma membrane. The many studies using microscopy to examine 
cells fixed by treatment with formaldehyde or methanol[i27] must be reevaluated in light 
of evidence that the fixation process releases fluorescently labeled peptides from endo­
somes, an artifact not observed during microscopic examination of living cells[i27]. Fi­
nally, the high intensity light used for illumination during microscopy can itself facilitate 
the redistribution of fluorescently labeled peptides from endosomes to cytoplasm[i28]. 
Thus, whether, when, and how these cationic molecules escape endocytic vesicles to 
access the cytosol remain unanswered questions. 
Attempts to identify and improve upon the structural determinants of cell perme­
ability are complicated by the above experimental details as well as the fact that neither 
Tat nor Arg8 possesses a defined fold. Miniature proteins are a family of small (36-aa), 
well-folded polypeptides that adopt a characteristic hairpin fold consisting of axially 
packed a- and PPII helices[i29, 130]. Miniature proteins identified through both rational 
design[i5, 17] and molecular evolutional, 132, 19] can modulate protein function by 
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inhibiting protein interactions!^, 18]; both loss of function and gain of function activ­
ities have been observed[i32, 19, 18]. We reported previously that minimally cationic 
miniature proteins containing between 2 and 6 arginine residues embedded within the 
a- or PPII helix were taken up by mammalian cells in culture more efficiently than Tat 
or Arg8[i33, 134]. Now, we turn to investigate whether miniature proteins containing 
arginine reach the cytoplasm. 
3.2 Results 
To learn more about the structural determinants of cytoplasmic access, we designed a set 
of miniature proteins that differed in the number and density of a-helical arginine side 
chains, and tracked their passage into the cell. Using low concentrations (1 jiM) of vari­
ants conjugated to a fluorophore, we found that a minimum of 4 a-helical arginines was 
required for uptake, and cell uptake was enhanced when the arginines were clustered 
on the same a-helix face. Next, a novel and rapid assay for evaluating cytoplasmic ac­
cess revealed that of four cationic miniature proteins taken up by cells, only one reaches 
the cytosol. This miniature protein, which we termed 5.3, possesses a distinct array of 
five dispersed a-helical arginines on three helical faces. Direct comparisons show that 
after treatment for as little as 30 min, the cytoplasmic concentration of 5.3 reaches lev­
els as high or higher than that achieved by Tat or Arg8. Experiments monitoring the 
degradation of proteins that reach the cytosol show that 5.3 displays remarkable stability 
compared to Tat or Arg8, cationic peptides that do not posses a stable fold. These exper­
iments demonstrate that discrete arginine arrangements embedded within a well-folded 
miniature protein can direct cytosolic access. 
3.2.1 Miniature Protein Design 
To examine the effect of charge density and orientation on cell uptake, I prepared a va­
riety of miniature proteins, using avian pancreatic peptide (aPP, structure shown in Fig. 
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3-ia) as a scaffold[i30,129], that contained variety in the number and positioning of pos­
itively charged arginine substitutions. The stability of the aPP fold[i35] allows variation 
to be introduced into solvent exposed residues without compromising structure. The 
eight miniature proteins, as well as the wild-type sequence, together contained between 
one and six arginine residues at various positions on the solvent-exposed a-helical sur­
face of the hairpin fold (Fig. 3.1b). These molecules also contained two arginines near 
the C-terminus (Fig. 3.1c). 
To ensure the arginine residues were displayed as intended, circular dichroism (CD) 
spectra of the miniature protein variants were obtained (Fig. 3.2). Seven of these cationic 
miniature proteins were characterized by CD spectra at 37°C that were virtually indistin­
guishable from that of the parent molecule lacking additional arginines, aPP (Fig. 3.2a). 
The CD spectra of six were temperature-dependent with cooperative transitions between 
49 and 6y°C (Fig. 3.2b,c) suggesting that they each retained a stable and characteris­
tic hairpin fold[i3o]. Miniature protein 6.3, containing the greatest number of arginine 
substitutions (6), showed reduced ellipticity at 222 nm and 208 rim (Fig. 3.2a), along 
with a reduced Tm of 33°C (Fig. 3.2b,c); 6.3 was not studied further. For the remain­
ing molecules, these data suggest that arginine substitution does not significantly alter 
miniature protein secondary structure, and that Fig. 3.1b accurately represents the argi­
nine side chain arrangement in miniature proteins 2.1, 2.2, 3.2, 4.2, 4.3, 5.2, and 5.3. 
3.2.2 Cell Uptake 
Initially we used flow cytometry to assess the influence of arginine number and orienta­
tion on miniature protein uptake. In this technique cells are passed through a capillary 
into a detection chamber illuminated by one or several lasers. Appropriately placed 
photodetectors fitted with bandpass filters detect fluorescent signals. This allows the 
amount of fluorescence associated with individual cells to be accurately and rapidly de­
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Figure 3.1: Description of miniature protein structures and variation in arginine dis­
play. (a) The structure of avian pancreatic polypeptide (PDB:iPPT) contains both a- and 
polyproline-type helices, which are arranged in a hairpin. The interface is formed via 
hydrophobic packing. The focus of this study was on determinants that could be placed 
on the a-helix. (b) A.plot of the relationship between #Rtotni (the number of a-helical 
arginine residues) and #Rf0Ces (the number of a-helical faces on which these arginines 
are displayed) for each aPP variant. The location of each a-helical arginine residue is 
represented by a blue circle on the helical wheel, (c) Amino acid sequences of peptides 















their C-termini (as denoted with superscript F). In our initial studies, we included a 
trypsin wash just before analysis via flow cytometry. Treatment of HeLa cells with 5 
aPPF, 2.1F, 2.2F, or 3.2F resulted in only small increases (< 3 fold) in cell fluorescence, 
while treatment with 4.2F, 4.3F, 5.2F, or 5.3F resulted in increases in cell fluorescence 
between 7 and 40 fold (Fig. 3.3a). We therefore chose to focus on miniature proteins 
showing significant uptake. 
To ensure that increased uptake was a property of peptide sequence and not of fluo-
rophore location or identity, we confirmed these results by synthesizing analogs labeled 
instead on their N-termini with tetraethyl rhodamine sulfate (denoted with superscript 
R), a dye with several desirable properties including resistance to photobleaching and 
an emission spectrum unaffected by pH changes and far from the autofluorescence 
spectrum of cells[57]. As found for miniature proteins labeled with fluorescein, rho­
damine labeled miniature proteins containing four or five a-helical arginines were taken 
up efficiently (Fig. 3.3b). Comparison of the relative fluorescence signal of cells treated 
with peptides sharing the same sequence but labeled with different fluorophores reveals 
a striking similarity, suggesting uptake is largely influence by the nature of the pep­
tide, and not purely a characteristic of the fluorophore tag. We found that incubating 
HeLa cells for longer time periods increased the fluorescence signal associated with cells 
(Fig.. 3.3c), suggesting that peptides were being internalized in an ongoing, rather than 
stochastic, process. Comparison of the fluorescent signal after 90 min vs 30 min reveals 
that the rate of uptake is highest for miniature proteins containing clustered arginines 
(4.2s and 5.2s) whose fluorescence intensities increase by 160% and 281% during this 
time period, and is lower for TatR and Arg8R. 
Importantly, flow cytometry places no restrictions on where a fluorescent signal origi­
nates. Fluorescent molecules on the cell's surface, within the cytoplasm, or within intra­
cellular vesicles all contribute to the total cellular fluorescence. To distinguish molecules 
within cells, from those that remain on the cell's surface, previous researchers have at­
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Figure 3.2: Circular dichroism (CD) of miniature proteins used in this study, (a) Wave­
length dependent CD spectra of peptides (25 ^M) in PBS at 37°C. (b) Temperature de­
pendent ellipticity at 222 nm of peptides shown in a. (c) Calculated Tm of thermal melts 
shown in b. [This data collected by Betsy Smith.] 
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Relative Peptide Internalization 
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Figure 3.3: Cell uptake of cationic miniature proteins, (a) A plot of mean cellular fluorescence at 530 nm of HeLa cells treated with 
fluorescently tagged miniature proteins (5 [iM, 30 min). (b) Comparison of the relative uptake of fluorescein and rhodamine labeled 
miniature proteins sharing the same sequence. HeLa cell treated as in a, or with 1 ]iM rhodamine labeled miniature proteins for 
30 min at 37°C. The mean fluorescence intensity (MFI) is normalized to the value for aPP. (c) Time dependent internalization of 
cationic miniature proteins. HeLa cells treated with 1 fiM rhodamine labeled miniature proteins at 37°C for 30, or 90 min or treated 
at 4°C ('0 min') before analysis, (d) Cellular fluorescence after treatment with 1 }iM rhodamine labeled miniature proteins in the 
absence of endocytosis and removal by trypsin treatment. HeLa cells were treated for 30 min at 4°C were then treated with trypsin 
(0.05%, 10 min, 37°C) or PBS before washing and analysis by flow cytometry, (e) Fraction of cell-associated fluorescence (d, black 
bars) remaining after trypsin treatment (d, red bars), (f) Internalization efficiency of rhodamine labeled miniature proteins. [The 
data in part a was collected by Betsy Smith] 
binding substrate such as heparan sulfate[i38], or by degrading surface-bound protein 
with trypsin[i38,127]. I therefore verified that trypsin treatment removed miniature pro­
teins that were bound to the cell surface. Membrane traffic was arrested by incubating 
cells at 4°C[i39, 140] for 15 min prior to and during a 30 min treatment with 1 pM 4.2s, 
4-3R, 5-2r, 5-3R, TatR, Arg8R or aPPR as a negative control. After incubation, cells were 
washed three times with PBS and incubated with trypsin (0.05% at 37°C for 15 min) or 
PBS (as a control) before analysis by flow cytometry (Fig. 3.3d). Cationic miniature pro­
teins 4-2R, 4-3r, 5.2R and 5.3s bound to cells between 2.7-fold and 35-fold more than aPPR 
and in some cases (5.2s and 5.3s) to an extent comparable to TatR and Arg8R. For all 
peptides, trypsin treatment decreased the fluorescent signal between 77-89% (Fig. 3-3e). 
Because peptides and proteins that enter the cell are inaccessible to trypsin added to the 
culture media[ii3], these data confirm that at 4°C, incubation of cells with 1 pM cationic 
miniature protein leads to little if any cell uptake, and confirms that the vast majority 
of material bound to the cell surface is degraded and/or effectively removed by trypsin 
treatment. 
Our finding that incubating cells in the cold substantially decreases the amount of 
internalized fluorescence signal indicates that at 4°C neither cationic miniature proteins 
nor Tat or Arg8 can enter the cell by diffusing through the plasma membrane. Two hy­
potheses could explain this result. First, at 4°C the lipid character of the membrane may 
be altered is such a way as to become less permeable to the peptides studied. Alterna­
tively, the internalization of membrane is required for cell uptake, a process arrested at 
4°C. These theories are not mutually exclusive. Nevertheless, this finding also provided 
an opportunity to compare the efficiency of internalization, defined herein as the amount 
of peptide internalized relative to that bound to the cell surface. In the absence of endo-
cytosis (4°C), the amount of surface bound peptide was quantified using flow cytometric 
analysis of cells that had been treated with 1 pM 4.2R, 4.3s, 5.2R, 5.3s, TatR, Arg8R or 
aPPR, but not with trypsin(Fig. 3.3d). Values obtained after incubating cells at either 4°C 
or 37°C (Fig. 3.3c) were normalized to this value. As can be seen in figure 3.3^ aPPR 
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and 4-2R are internalized inefficiently, showing fluorescence values after 30 min roughly 
equal to the amount originally bound to their surface. By contrast, 4-3R, 5-2R and 5.3** 
are each internalized efficiently, incorporating more than 4 times the amount of peptide 
originally bound to their surface. TatR and Arg8R show intermediate values, revealing 
that the display of arginine side chains on cationic miniature proteins can be engineered 
to induce highly efficient uptake by cultured cells. 
These data show that cell uptake depends on arginine density and number; miniature 
proteins containing four arginine residues clustered on two helical faces were taken up 
to a greater extent than those containing four arginines on three helical faces (Fig. 3.3a,b). 
Molecules containing five a-helical arginines were taken up to a similar extent irrespec­
tive of density, revealing that among these molecules the impact of arginine arrangement 
was smaller. Consistent with our previous work[i4i], the cationic miniature proteins 
5.2R and 5.3R are taken up to a greater extent and with higher efficiency than TatR and 
Arg8R, despite the fact that they possess twice the mass and fewer (7 rather than 8) 
positive charges. 
3.2.3 Cationic miniature proteins do not cause plasma membrane disruption. 
Three limiting models have been invoked to explain the trafficking of cationic peptides 
and proteins across the plasma membrane. The first posits that high local concentrations 
of positively charged peptides cause membrane disruption[i25]. This is followed by 
sudden release of peptide into the cell and triggers a membrane repair response [126]. 
A second model invokes ion-pair guided passive membrane diffusion[i2i, 120]. The 
final model invokes endocytosis followed by endosomal release (vide infra). Membrane 
disruption can alter cell physiology leading the leakage of cytoplasmic contents and cell 
death[i42]. Therefore, we first confirmed that the integrity of the cell membrane is not 
disrupted in the presence of 1 jjM cationic miniature protein. 
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Figure 3.4: Absence of membrane permeabilization after treatment with Dex-labeled 
cationic miniature proteins. HeLa cells were incubated with 1 jiM of the indicated dex-
amethasone labeled miniature protein or peptide in the presence of 200 nM Syto Orange 
(a cell permeable dye) and 200 nM Sytox Blue, a dye that is not cell permeable but 
binds to nuclear DNA when cell membranes are disrupted. Saponin (10 ytg/mL) a deter­
gent that permeabilizes mammalian cell membranes was used as a positive control, (a) 
Schema showing experimental design; cells with intact membranes exclude Sytox blue 
and are red only, cells with permeabilized membranes are red and blue, (b) Images of 
cells treated as described in a with the indicated peptides. Very few show blue signal in 
the nucleus, indicating intact cell membranes. 
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treated HeLa cells with peptides in the presence of two dyes, one that is cell permeable 
(Syto Orange), and one that is not (Sytox Blue). In the absence of membrane disruption, 
cell bodies are labeled with the permeable dye and exhibit red fluorescence. No blue 
fluorescence is observed from cells with intact membranes, however membrane disrup­
tion allows for a high affinity interaction between Sytox Blue and DNA leading to bright 
fluorescence within the nucleus (see Fig. 3.4a). As can be seen in figure 3.4b, HeLa 
cells treated in media, indicated as (-) CTRL, show only red fluorescence, but after treat­
ment with a saponin, a detergent capable of permeabilizing mammalian cell membranes, 
bright blue fluorescence becomes visible within the nucleus. To test whether treatment 
with IJAM cationic miniature proteins would lead to similar membrane compromise, we 
treated HeLa cells with miniature proteins or peptides as indicated under analogous 
conditions in the presence of Sytox Blue and Syto Orange for 30 min at 37°C. As can be 
seen in figure 3.4b, very few cells show blue fluorescent nuclei, indicating that dexam-
ethasone labeled cationic miniature proteins do not lead to membrane disruption. This 
result suggests that at low concentrations and under these condition, neither cationic 
miniature proteins nor Tat or Arg8 enter cells through this mechanism. 
3.2.4 Cationic Miniature Proteins Reach The Cytoplasm 
In many cases, cationic proteins/polypeptides showing cellular uptake by flow cytom­
etry remain trapped in endosomes and fail to reach the cytosol[i28]. Previous work 
has shown that the cytosolic localization of a peptide- or peptoid-dexamethasone (Dex) 
conjugate can be detected using a glucocortocoid receptor-driven luciferase assay[143]. 
Interaction of a Dex-labeled peptide or peptoid with the ligand-binding domain of the 
glucocorticoid receptor (GR) in the cytosol induces transcription of luciferase that is de­
tectable in cell lysates 40-48 hours later. We sought to evaluate cytosolic localization on a 
more rapid time scale, and took inspiration from reports that dexamethasone treatment 
of cells in culture led to rapid (15 min) translocation of a GR-green fluorescent protein 
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fusion (GR-GFP) from the cytosol to the nucleus[i44]. If this rapid translocation was also 
observed in the presence of peptide-dexamethasone conjugates, then live cell microscopy 
could provide a rapid assay for cytosolic localization in living cells. 
To validate this approach, HeLa cells were transfected for 12 - 18 h with the gene 
encoding GR-GFP, and then incubated for 30 min with between o and 10 pM dexametha-
sone (Fig. 3.5a). When dexamethasone was absent from the incubation media, these cells 
exhibited GFP signal throughout the cytoplasm and the nucleus (Fig. 3-5e). Addition of 
dexamethasone to a final concentrations between 3 nM and xo led to a concentration-
dependent decrease in the cytosolic GFP signal and a concomitant increase in the nuclear 
GFP signal (Fig. 3.5a). We quantified these changes using the automated image process­
ing package CellProfiler[i45] (Fig. 3.5b,c) to measure the GFP signal in the nucleus as 
well a 2 Jim (40 pixel) region surrounding region of the cytosol. I report the ratio of 
the median GFP intensity in the nucleus and the surrounding region as a 'translocation 
ratio'1 (TR, Fig. 3.5c). TR values near 1 indicate equivalent intensity between the nu­
cleus and the surrounding region. Treatment of HeLa cells with 1 dexamethasone 
for 30 min resulted in an increase in the translocation ratio from 1.07 ± 0.02 to 3.93 ± 0.14 
(p = 1.92 x 10~22, vs untreated cells, two-tailed t-test), roughly 90.5% of value achieved 
with a 10-fold higher concentration(Fig. 3 5d). We therefore chose this concentration for 
subsequent studies. 
When HeLa cells transfected with GR-GFP were treated for 30 min with 1 jiM aPFDex, 
virtually no change in GR-GFP localization (Fig. 3.5c) or the calculated translocation 
ratio (1.41 ± 0.09, vs 1.25 ± 0.04, p = 0.1473, two-tailed t-test, see also Fig 3.6b) was 
observed. Among HeLa cells that were treated with media alone, the translocation ratio 
was not significantly correlated with the level of expression of GR-GFP (R = 0.21, Fig. 
3-5f). These data are consistent with the observation that aPPR fails to enter cells and 
indicate that simply adding the dexamethasone label is not sufficient to confer upon an 
'Others (e.g., Ding et al. (1998) J Biol Chem 273, 28897-28905) have reported similar values, which they 
have named nuclear/cytoplasmic ratio, however because this term could be misconstrued to indicate the 
relative concentration of GFP within these compartments, I have used the term translocation ratio instead. 
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Figure 3.5: Dose dependent increase in translocation ratio following exposure to dex­
amethasone. (a) Schematic of quantitation method. Cell images were examined using 
CellProfiler to create a region containing the nucleus and a surrounding zone. The ratio 
of the median intensity in these two regions is reported as the translocation ratio, (b) 
Representative images of HeLa cells transfected with GR-GFP and treated with various 
concentrations of dexamethasone as indicated. Red outlines show regions defined as nu­
cleus and surround, (c) Translocation ratio observed plotted against the concentration of 
dexamethasone added. Fitting these points to a hyperbolic curve yields an EC50 = 21.83 
nM and a Hill coefficient of 0.97. 
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otherwise cell impermeable peptide the ability to reach the cytoplasm[i43]. These data 
also support the use of the translocation ratio as a useful measure of the relative ability 
of Dex-labeled compounds to reach the cytoplasm of target cells. 
I next evaluated the extent to which Dex-labeled miniature proteins, as well as Tat 
and Arg8, induce the nuclear translocation of GR-GFP (Fig. 3.6). HeLa cells transfected 
with GR-GFP were treated for 30 min with 1 4.zDex, 4.3Dex, ^.zDex, 5.3°", TatDex, 
or Arg8Dex and the translocation ratio calculated. Treatment of HeLa cells with 5-3Dex 
led to a large increase in translocation ratio (3.1 ± 0.1) both compared to an untreated 
sample (-) (p = 2.68 x 10-48, ANOVA with Bonferroni post-test) or one treated with 
appDex (p _ J % x io~16). Treatment of HeLa cells with 4.2°", 4.3°", or 5.2°" led 
to a small or absent increase in nuclear GFP signal, and translocation ratios (1.18 ± 0.04, 
1.92 ± 0.10,1.77 ± 0.11 respectively) that were not significantly different from cells treated 
with aPPDez. We also measured the nuclear accumulation of GR-GFP after treatment 
with Arg8Dez or TatDex, which in both cases was increased over control samples treated 
with aPPDex (Arg8Dex = 2.19 ± 0.13, p = 0.0053; TatDex = 2.85 ± 0.10, p = 2.54 x 10~9), 
and comparable to cells treated with 5.3°**. These comparisons are illustrated in figure 
3.6b. 
The above data could be explained in several trivial ways. One explanation is that the 
concentrations of Dex-labeled cationic miniature proteins and peptides used here could 
lead to permeabilization of the cell membrane and direct access of the peptides studied 
to the cytoplasm. However I previously verified that the plasma membrane retains the 
ability to exclude the small organic dye Sytox Blue (Fig 3.4), making this possibility un­
likely. Second, the peptide could be rapidly degraded, releasing free dexamethasone into 
the cell and surrounding media, activating the GR and leading to its nuclear accumula­
tion. Third, and perhaps less likely, by covalently linking dexamethasone to the cationic 
miniature protein, a high affinity molecule is created, capable of activating the GR at 
extremely low concentrations. I tested these final two possibilities directly by assaying 
the proteolytic stability of the miniature protein backbone and by measuring the ability 
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of dex-labeled cationic miniature proteins to compete with dexamethasone for the ligand 
binding site of recombinantly expressed human glucocorticoid receptor in vitro. 
To verify that the affinities of dexamethasone labeled cationic miniature proteins and 
peptides for the human glucocorticoid receptor in vitro were similar to each other, we2 
used a commercially available validated glucocorticoid screening assay, POLARSCREEN 
GREEN®. In this assay, recombinant human glucocorticoid receptor is mixed with a fluo­
rescently labeled steroid analog (FLUORMONE), that possesses a high affinity for the min-
eralocorticoid binding site. In the absence of competitor molecules, FLUORMONE binds to 
GR and exhibits high polarization. As increasing concentration of competetor molecule 
is added, FLUORMONE is displaced from the binding site. As its effective molecular size 
is now reduced, the molecule tumbles in solution more quickly, and exhibits a polariza­
tion value that is decreased. Fitting these data to a hyperbolic curve reveals the IC50, 
the concentration of competetor molecule that results in a half-maximal decrease in the 
polarization value of FLUORMONE. 
Addition of cationic residues within the a-helix of the aPP scaffold resulted in a 
trend of decreasing ability of Dex-labeled cationic miniature proteins to compete for the 
GR binding site (Fig 3.7). The affinity of aPPDex for the GR (IC50 = 1.0 nM, 95% CI 
= [0.6,1.7]) was similar to dexamethasone itself, (JC50 = 0.85 nM, 95% CI = [0.5,1.4]), 
whereas the affinity of 5.3°"' was lower (IC50 — 35.9 nM, 95% CI = [25.1,51.3]). Minia­
ture proteins 4.2°", 4.3°", and peptides TatDex and Arg8De* gave intermediate val­
ues (between 2.7 - 8.6 nM), all slightly poorer than unconjugated dexamethasone (see 
Fig 3.70-h). Because the apparent affinity of 5.3°" is lower than the other molecules stud­
ied in this panel, its increased ability to activate the glucocorticoid receptor in cells must 
invoke either a non-competetive mechanism or a higher effective concentration within 
the cytoplasm, or both. 
2This work was completed with the assistance of Justin Holub 
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3.2.5 Cell Penetrating Cationic Miniature Proteins Reach The Cytosol Intact 
A trivial explanation for the results obtained above is that cationic miniature protein 5.3 
as well as Tat, and Arg8 are degraded by endosomal proteases, releasing the dexametha­
sone label, which, by itself, can efficiently cross cell membranes and induce the nuclear 
localization of GR-GFP. Thus, I sought to confirm that the peptide backbone of miniature 
protein 5.3 is not degraded under the conditions in this assay, that is to say, within the 30 
min incubation period after the peptides are added to HeLa cells and before they are an­
alyzed by epifluorescence microscopy. To examine possible metabolism of 5.3, HeLa cells 
were treated with 1 rhodamine labeled cationic miniature protein under conditions 
analogous to those used for flow cytometry above (Fig. 3.3). The cells were then pel­
leted, washed with PBS, and lysed using a detergent buffer. The insoluble material was 
cleared from the lysate by a brief centrifugation (10 min, xoooog) after which the super­
natant containing soluble cell lysate was diluted into 15% ethanol in water and injected 
onto an HPLC fitted with a C8 (100 x 2.1 mm, 100A pore) collum. Because we expected 
the concentration of this solution to be low, we employed a high sensitivity Shimadzhu 
HPLC fitted with a fluorescence detector capable of sensing the presence of attomoles of 
rhodamine. The fluorescence HPLC traces obtained are shown in figure 3.8. As can be 
seen in panels a and c, the fluorescence chromatogram of miniature proteins obtained 
from the cell lysate are virtually unchanged from the chromatogram on an input sample. 
By contrast, the chromatograms of TatK and Arg8R show an increased number of peaks 
in chomatogram obtained from lysate as compared to the chromatogram obtained from 
the input sample. 
It is likely in the above experimental set up that some of the peptide obtained after cell 
lysis was bound to extracellular surface proteoglycans or was present in endosomes. We 
addressed this issue in two ways. First, to emove peptide bound to the cell surface, we 
repeated the above experiment, but included a brief incubation with trypsin following 
peptide treatment to remove surface bound peptide (Fig. 3.9). While small amounts 
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Figure 3.6: Translocation of GR-GFP after treatment with dexamethasone and dex-
labeled miniature proteins, (a) HeLa cells transfected with GR-GFP (which appears 
black) after treatment with 1 1 }iM Dex-labeled cationic miniature protein for 30 
miri at 37°C. (b) Quantification of the changes visible in a. ns, not significant. *p < 0.05, 
* * *p < 0.001, ANOVA with Bonferroni post-test. 
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Figure 3.7: Competition binding of dexamethasone labeled cationic miniature proteins 
or peptides with GR. (a) Schematic representation of the assay; GR protein is mixed with 
Fluormone® (a fluorescently modified steroid) and varying concentrations of dexam­
ethasone labeled miniature protein or peptide. Competition for the steroid binding site 
decreases the polarization of Fluormone. (b) Table of JC50 values and 95% confidence 
intervals (95% CI) obtained from fitting data in panels c - h. The data are fit to the 
equation mP = Pmin + (P,nax - p„,„,)/(l + \0^S(\Con,petitor\)-LoSlCx)y ^ abihty of ^Dex 
to compete with Fluormone® for the steroid binding site of GR is as good as or worse 
than that of dexamethasone or other Dex-labeled molecules tested. Competition binding 
of (c) aPPDe* , (d) 4.2°", (e) 4.3 D", (f) 5.3°", (g) TatDwr, or (h) Arg8D" with Fluormone® 
for GR. Competition of dexamethasone with Fluormone® for GR binding is shown in 
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Figure 3.8: Absence of degradation of cationic miniature proteins. 2 x 105 HeLa cells 
were treated with 1 jj.M rhodamine labeled cationic miniature protein or peptide for 30 
min in HKR buffer, before washing and lysis. Cell lysates were then examined by HPLC. 
HPLC traces of cationic miniature proteins are essentially unchanged between the cell 
lysate (black traces) and a control sample spiked with peptide not exposed to cells (red 
trace). Cell lysate from HeLa cells treated with rhodamine labeled Arg8 or Tat show the 
appearance of numerous additional peaks, indicating modification or degradation of the 
peptide backbone. 
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Figure 3.9: Absence of intracellular degradation of cationic miniature proteins. 2 x 105 
HeLa cells were treated with 1 rhodamine labeled cationic miniature protein or pep­
tide for 30 min in HKR buffer, washed twice and treated with 0.05% trypsin for 10 min 
at 37°C, after which the cells were washed again and lysed in RIPA buffer. Cell lysates 
were then examined by HPLC. HPLC traces of cationic miniature proteins are essentially 
unchanged between the cell lysate (red traces) and a control sample containing the start­
ing material but not exposed to cells (blue trace). RIPA buffer alone shows a single peak 
(due to the presence of detergent, data not shown, grey traces). The retention time of 
rhodamine alone is shown as a control (black trace). 
of aPPR were recovered from cells after lysis and treated with trypsin (Fig. 3.9a), this 
amount was increased for cells treated with 5.3s (Fig 3.9b). In neither case was material 
with retention times distinct from starting material recovered. By contrast, multiple 
peaks were detected in lysates from cells treated with Arg8R and TatK (Fig. 3.9c, d). These 
data confirm the results above, and suggest that increased recovery from cell lysates is 
due to the intracellular presence of 5.3. Further more, the miniature proteins studied are 
minimally degraded within the time frame of the experiment. 
Second, to specifically ask whether cationic miniature protein 5.3, Tat, or Arg8, were 
present in the cytoplasm, we employed a cell fractionation strategy that exploits the bac­
terial pore-forming toxin streptolysin O (SLO) [146]. This peptide inserts into cholesterol 
containing membranes undergoing a conformational change [147] leading to oligomer-
ization at 37°C creating membrane lesions that are approximately 20 nm in size[i48] and 
are repaired in a Ca++ dependent manner[i49]. At 37°C, and in the absence of Ca++, the 
presence of these membrane lesions leads allows soluble cytoplasmic contents to diffuse 
into the surrounding media (or surrounding proteins to diffuse into the cell[i5o]), while 
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larger organelles, and vesicles remain inside the cell. Thus incubation in the presence of 
SLO allows one to recover the cytoplasmic contents of a cell without disrupting endoso-
mal membranes or releasing lysosomal contents. Others have cautioned, however, that 
even commercial preparations of SLO possess widely differing activities[i5i]. Incubation 
of cells with excess peptide can lead to aggregation and pore formation independently 
of cholesterol, decreasing the specificity of the process[i5i]. 
To verify that SLO induces cell permeabilization and to identify the concentration 
required for efficient recovery of cytoplasmic material, we incubated HeLa cells with 
various concentrations of SLO on ice using a protocol previously described[i52, 153, 
154, 146]. In brief, HeLa cells were detached from the growth flask by incubation in 
PBS containing EGTA/EDTA, washed and aliquoted into 96-well plates. The cells were 
then resuspended in ice cold solutions containing 5 mM dithiothreitol (DTT) in PBS 
with various concentrations of SLO added and incubated on ice for 15 min to allow the 
peptide to bind to the cell surface. (The presence of DTT is required for reduction of 
a critical cysteine within the SLO peptide[i55].) The cells are then washed with PBS 
and shifted to 37°C to allow oligomerization of SLO inducing pore formation[i47, 148] 
and releasing cytoplasmic contents. At this point, the cells can be pelleted and the 
supernatant containing the cytoplasmic extract recovered or the cells within the pellet 
tested further. 
Following this protocol, HeLa cells were treated with PBS containing 5 mM DTT and 
between 7 pg/mL and 180 pg/mL SLO, leading to between 49% and 99% permeabilized 
cells (data not shown). HeLa cells treated with 20 pg/mL SLO showed between 85% 
and 89% +PI cells (Fig. 3.10a), indicating that this concentration of SLO permeabilized 
the majority of cells, that decreasing the amount of SLO would decrease the fraction of 
cells permeabilized. Because little advantage would be gained by increasing the amount 
of SLO, and due to the possibility of non-specific acitivity with higher concentrations, 
we tested this concentration for the release of the lysosomal enzyme ^-hexosaminidase. 
HeLa cell treated with PBS or PBS containing SLO as above were pelleted by centrifu-
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gation and the overlying supernatant recovered, while the cell pellet was then solu-
bilized using a detergent (RIPA) buffer, which is known to release ^-hexosaminidase, 
and in which this enzyme is active. Equal cell equivalents of supernatant from PBS 
and SLO treated cells, as well as the cell pellet from SLO treated cells were diluted in 
an acidic assay buffer containing 7.5 mM 4-nitrophenyl-N-acetyl-^-D-glucosaminide, a 
chromogenic ^-hexosaminidase substrate. Hydrolysis by /5-hexosaminidase leads to re­
lease of 4-nitrophenol, which absorbs 405 nm light, enabeling spectrophotometric quan­
titation. After incubation at 37°C for 1 hr, the reaction is stopped and the absorbance 
measured. The vast majority (>95%) of the enzymatic activity in SLO treated cells re­
mained within the cell pellet (Fig. 3.10b), while only 2.5 ±0.1% of the ^-hexosaminidase 
activity was present in the supernatant. These data indicate little, if any, permeabiliza-
tion of the lysosomal membranes takes place when HeLa cells were treated under these 
conditions. Because ^-hexosaminidase is present in early endosomes as well[i56], it is 
unlikely that signficiant permeabilization of this compartment occurs. These data do not 
exclude the possibility that permeabilization of the secretory organelles such as the endo­
plasmic reticulum or the golgi apparatus occurs, however, using fluorescence microscopy 
we do not observe fluorescence in these compartments (see Figs. 4.6 on page 109, 4.1 on 
page 99, and 4.5 on page 108). 
Having established that our SLO treatment protocol permeabilizes approximately 
85% of the treated cells without disrupting endolysosomal membranes, we next asked 
whether we could detect intact or degraded rhodamine labeled cationic miniature pro­
teins within cytoplasmic extracts. 2 x 105 HeLa cells were treated with 1 pM aPPR, 5.3s, 
5.2s, TatR, or Arg8R at 37°C for 30 min before washing and tyspsin treatment. Cyot-
plasmic extracts were generated using SLO as described above and examined by fluo­
rescence HPLC. Little or no fluorescence was detectable in cytoplasmic extracts treated 
with aPPR, while fluorescence peaks were identified in cytplasmic extracts generated 
from cells treated with 5.3^, 5-2R, TatR, or Arg8R (Fig. 3.11). Comparing starting material 
to recovered cytoplasmic extracts revealed that fluorescence material present in cytoplas-
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Figure 3.10: Confirmation that SLO induces cell permeabilization. (a) HeLa cells were 
treated with PBS (control) or PBS containing 20pg/mL SLO (+SLO) for 10 min on ice, 
after which they were washed and resuspended in PBS containing lpg/mL propidium 
iodide. Exclusion of propidium iodide requires an intact cell membrane. Treatment with 
SLO increased the fraction of PI positive cells from 7.6% to 85%. (b) SLO treatment does 
not release the lysosomal enzyme ^-hexosaminidase. HeLa cell treated with PBS or PBS 
containing SLO as in a were pelleted by centrifugation and the overlying supernatant 
recovered. The cell pellet was then solubilized using RIPA buffer. Equal cell equivalents 
of supernatant from PBS and SLO treated cells, as well as the cell pellet from SLO treated 
cells were incubated with a chromogenic /^-hexosaminidase substrate. Enzymatic reac­
tivity was assayed by increased absorbance at 405 nm. Greater than 90% of the enzymatic 
activity in SLO treated cells remains within the cell pellet. 
mic extracts from cells treated with TatR (Fig. 3-iid) or Arg8R (Fig. 3.ne) did not have 
the same retention times as the starting peptides. This could indicate covalent modifica­
tion of the peptide itself or strong non-covalent association of cellular protein, however 
this latter possibility is unlikely because HPLC conditions (0.1% TFA in ACN/H20) are 
strongly denaturing. Cytoplasmic extracts from HeLa cells treated with 5.3s or 5.2s each 
showed single peaks of fluorescence material with retention times that matched starting 
material (Fig. 3.11b,c). The area under the peak was larger for 5-3R than 5-2R, consistent 
with the GR-GFP translocation assay (Fig. 3.6 on page 53) showing that greater nuclear 
translocation is observed after treatment with 5.3s than with 5-2R. 
After endocytosis, internalized material is exposed to proteolytic hydrolases within 
the endolysosomal compartment, typified by the cathepsin family of acid-activated cys­
teine proteases. We wondered whether the enhanced activity of 5.3^ within the GR-GFP 
translocation assay might be due to differential resistance or sensistivity to these pro­
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teases. The former could increase the effective concentration within the endosome, the 
latter could release dexamethasone which is cell permeable. To distinguish between 
these possbilities, we treated aPPR, 5.3s, 5.2s, TatR, and Arg8R with endosomal cathep-
sins B, D, and L for 30 min at 37°C in acidic (o.x M sodium citrate, pH 4.7) and reducing 
(5 mM DTT) conditions. The reactions were stopped by cooling to 4°C and dilution in 
0.1% TFA in ACN/H2O, prior to analysis by fluorescence HPLC (Fig. 3.11). Incubation 
with Cathepsin D completely modified the cationic miniature proteins test as indicated 
by the absene of any peak with the same retension times as the starting materials (Figs. 
3.na,b,c), while little difference was observed following incubation of Cathepsin D with 
TatR or Arg8R (Figs. 3.nd,e). Incubation of 5.2R with cathepsin B resulted in the gen­
eration of multiple additional new peaks on the HPLC trace, although at the end of the 
30 miri incubation signficiant starting material remained indicating partial modification 
of this peptide (Fig. 3.11c). Similar results were obtained after incubation of 5.3^ with 
cathepsin B, though the consumption of starting material was less extenstive (Fig. 3.11b). 
Cathepsin L failed to modifiy any of the cationic miniature proteins tested, but did com­
pletely consume Arg8R (Fig. 3.ne). No detectable modification of TatR took place after 
incubation with cathepsins B, D, or L (Fig. 3.1 id). These results indicate that digestion 
products of aPPR, 5.3s, 5-2R, TatR, and Arg8R by endosomal cathepsins are readily de­
tectable by HPLC, suggesting that were these present within cytoplasmic extracts they 
would have been identified. Furthermore, because all cationic miniature proteins are sus-
ceptable to cathepsin B, these results decrease the possibility that the results observed are 
due to the differential sensitivities of these molecules to endosomal degradation. Were 
the results of the GR-GFP translocation assay due to release of dexamethasone follow­
ing, for example, degradation of tj.zDex by cathepsin D, we would expect this molecule 
to show more, rather than less activity than 5.3°^. 
These results suggest that quantitative comparisons of the amounts of cytoplasmic 
rhodamine labeled peptide should be possible by generating cytoplasmic extracts using 
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Figure 3.11: Recovery of cationic miniature protein 5.3, unmodified, from the cytoplasm. 
HPLC analysis of cytplasmic extracts generated using SLO from 2 x 105 HeLa cells 
treated for 30 min at 37°C with a solution containing x pM of the indicated peptides 
(green traces) are shown. HPLC alanysis of the purified peptides (starting material, red 
traces) and rhodamine alone (black traces) are shown for comparison. In addition, reac­
tions containing 50 pmol peptide and 5pg of the indicated cathepsin were incubated at 
37°C for 30 min prior to HPLC analysis (blue, purple, and green traces). 
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peak of the fluorescence HPLC trace. Data above support the hypothesis that these ex­
tracts are not significantly contaminiated by peptide present in the lysosome or bound to 
the cell surface. To quantitatively compare the relative fraction of 5-3R and 5.2^ released 
into the cytoplasm, we treated duplicate samples with ijiM rhodamine labeled cationic 
miniature proteins 5.3s or 5.2^ for 30 min at 37°C before either generating cytoplasmic 
extracts using SLO or total cell lysate using RIPA buffer (Fig. 3.12). This process was 
repeated in triplicate. Fluorescence HPLC traces for samples generated are shown in fig­
ures 3.12b and 3.12c. Quantitative integration of the identified peaks (Fig. 3>i2d) in total 
cell lysates showed that for cells treated with 5.2s or 5.3s, 11.7 it 0.8 pmol and 10.1 ± 0.3 
pmol per 2 x 105 HeLa cells were recoved, respectively. Cytoplasmic extracts of HeLa 
cells treated with 5.2 s or 5-3R contained 0.31 ± 0.06 pmol and 0.44 ± 0.04 pmol per 2 x 105 
HeLa cells, respectively. The fraction of 5.2s and 5.3R present in the cytoplasmic extracts 
(as compared to the total cell lysate) are 2.64 ± 0.54% and 4.37 ± 0.32% respectively, nearly 
66% more for 5.3** than 5.2s (p = 0.0516). The variability in these measurements makes 
quantitative comparisons preliminary, as the difference, though showing a strong trend, is 
not statistically significant. 
This indicates that peptides TatR and Arg8R are degraded or otherwise altered by 
the cells within the time course of these experiments. On the other hand, 5.3s remains 
unchanged. 
Taken together these results support the conclusion that treatment with 5<3Dex in­
duces the activation and nuclear translocation of GR-GFP because this peptide possesses 
an array of arginine residues that serve to target it to the cytoplasm. 
3.2.6 Cationic Miniature Protein 5.3 is a monomer 
Avian pancreatic polypeptide dimerizes[i57,158] in solution with a dissociation constant 
KD = 4.1 x 10 6 M 1 at pH 7U30]. It is possible that the incorporation of arginine 
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Figure 3.12: Direct observation that the 5.3 motif increases the cytoplasmic presence of 
miniature proteins, (a) Schema. Duplicate samples of 2 x 105 HeLa cells were treated 
with ijjM rhodamine labeled miniature protein for 30 min at 37°C. The cells were washed 
with 150PL PBS, then treated with 0.05% trypsin for 10 min at 37°C, and washed a second 
time. To generate total cell lysates, the sample was lysed by the addition of 4011L RIPA 
buffer and incubation on ice for 30 min. To generate cytoplasmic extracts, the cells were 
incubated with 5OJ1L of an ice cold solution containing 2opg/ mL SLO and 5 mM DTT in 
PBS for 15mm at 4°C. The cells were washed twice with l^opL of PBS before warming to 
37°C to allow pore formation. The cell pellet was separated from the cytoplasmic extract 
by centrifugation (2 min x 300g). HPLC traces of RIPA and SLO extracts from HeLa 
cells treated with (b) 5.2s or (c) 5.3s. The retention time of the starting peptide is shown 
by the vertical dashed grey line. The latter peak in the RIPA samples is due to light 
scatter from the presence of detergent, (d) Quantitative analysis of recovered peptide. 
The total amount of peptide recovered in RIPA and SLO extracts from samples is shown, 
based on standard curves generated from injecting known quantities of rhodamine and 
integrating the area under the major peak, (e) The fraction of peptide released into the 
cytoplasm, i.e. the fraction of peptide in the SLO sample compared to the RIPA sample, 
is shown for each of three replicates. 
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toxic to cells, and the aggregation of arginirie rich peptides on the surface of cells can 
cause membrane disruption[i26,125]. While I previously showed that treatment of HeLa 
cells with 1 5.3°" did not cause membrane disruption, I asked whether, at similar 
concentrations, 5.3 existed in a different associated state than other miniature proteins. 
I also wished to draw a comparison between the association state of unlabeled 5.3 and 
when labeled with dexamethasone, to understand whether installing the dexamethasone 
label altered the association state. 
To accomplish this task, we turned to analytical ultracentrifugation (ALOU59], a 
well-established method to determine the association state of proteins[i6o], including 
aPP[i57], In this method, sample solutions containing protein are placed under a cen­
trifugal force. After equilibrium is reached the concentration of protein as a function of 
the rotational radius (and thus angular velocity, co) is determined using a spectropho­
tometer. The equilibrium profile obtained (usually plotted as protein concentration vs 
radius) depends on relative buoyant densities of the protein (v) and solution (p), as well 
as the diffusion rate of the protein (D), which is sensitive to molecular size. The dif­
fusion rate and the buoyant density are sensitive to oligomerization state. Obtaining 
sedimentation profiles under several different angular velocities allows fits to models 
using available software[i6i, 162]. 
The simplest model of sedimentation begins with a single ideal species, whose con­
centration at radius r from the center of rotation defines a sedimentation profile depen­
dent on v, p, to, and molecular weight (M) as follows: 
C ( r )  =  C ( r 0 ) e M ( 1 - ^ ) f 1 ^  
A general monomer-nmer self-associating system (n • A ^ An) results in a superposi­
tion of two sedimenting ideal species (one with the molecular weight of the monomer, 
the other with a molecular weight n times larger), whose concentrations at all points 
along the solution column satisfy the law of mass action, and thus define an association 
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constant (Ka). 
The examination of aPP by analytical ultracentrifugation has been previously reported[i30, 
157,158]. Therefore we began by repeating the equilibrium sedimentation (Fig. 3.13) in 
the previously reported buffer (phosphate buffered saline, PBS), as well in the buffer used 
for the above studies of protein uptake (HKR buffer). Analysis of aPP in PBS showed 
self-association (fig. 3.i3b-d). The single ideal species whose sedmidentation best-fit the 
data has a molecular weight of 8501 (which is 2.01 times the actual molecular weight of 
aPP, fig. 3.13b). Fitting the equilibrium sedimentation profiles to a monomer-dimer equi­
librium (fig. 3.13d) yields lnKa = 15.608, which corresponds to a dissociation constant, 
Kp = 1.66 x 10~7 M. Repeating this analysis with aPP dissolved in HKR buffer, resulted 
in a sedimentation profile that also showed self-association. The molecular weight of a 
single ideal species that best fit the sedimentation profile was 8313 (1.96 times the molec­
ular weight of aPP, fig. 3.13^- Fitting the sedimentation profile to a monomer-dimer 
equilibrium (fig. 3.13b) yielded In Ka — 15.726, or Kp = 1.48 x 10~7 M. These values 
are within the range previously reported (Kp = 5 x 1(T6 to 2 x 1(T8 M) [158, 130]. To 
test whether the installation of the dexamethasone label leads to a change in the asso­
ciation state, we repeated the above analysis using aPPDex. This molecule also showed 
self-association (best-fit single ideal species MW = 12080, fig. 3-i3j), however fitting the 
sedimentation profile to a general monomer-'Nmer' model revealed that the association 
was less energetically favorable. The model showing the best fit to the sedimentation 
Figure 3.13 (following page): Analysis of aPP and its dexamethasone labeled variant by 
analytical ultracentrifugation. The buoyant density of aPP (a and e) and aPPDex (i) were 
calculated according to the method of [163], while the density of the solutions were 
calculated based on the buffer components using the program SEDNTERP. The sedi­
mentation profiles of aPP in PBS (b, c, d) and HKR (f, g, h) buffers as well as aPPDex 
in HKR buffer (j, k, m) after reaching equilibrium at 36,000, 42,000 and 50,000 rpm are 
shown. Fits to single sedimenting species (b, f, j) and general monomer-oligomer (c, g, 
k) are shown. For each general monomer-oligomer model, the sedimentation profiles 
were fit to an integer association state (d, h, m) closest to the best-fit variable n from the 
monomer-oligomer model. The residuals from each fit are shown below the graph of the 
sedimentation profile. 
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profile was a monomer-trimer equilibrium, with lnJ«Cfl = 18.620 (fig. 3.13m), which cor­
responds to a binding isotherm showing an inflection point (the concentration at which 
50% of the miniature protein is monomelic) at 5.23 x 10~5 M. To aid in interpretation 
of these numbers we modeled the association states (see fig. 3.14) of aPP and aPPDex 
as a function of concentration, comparing results when using equilibrium constants pre­
viously reported[i3o]. The curves using the values for aPP in PBS and HKR buffers 
(determined in this study) overlap nearly completely (fig. 3.14a). The values determined 
previously show less extensive association of aPP at similar concentrations. The dex­
amethasone modified variant, aPPDex remains at least 99% monomeric at concentrations 
up to 5 f/M. Thus, under the conditions used above, when aPPDex is added to cells at a 
concentration of 1 jiM, the protein is monomeric. 
We next set out to assess whether, when added to cells in the conditions used above, 
cationic miniature proteins 5.3 and 5.3°^* were also monomeric. Examination of 5.3 and 
5.3°" revealed that both of these miniature proteins weakly self-associate. Beginning 
with a model of a single ideal species and allowing the molecular weight to vary, the 
sedimentation profiles fit best to species of molecular weight significantly higher than 
the actual molecular weights of the miniature proteins. Using a general fitting strategy 
where the association state, n, and In Ka are optimized yielded oligomerization states of 
3.79 and 2.84 for 5.3 and 5-3°ex respectively. Fitting the sedimentation profiles to integer 
association states (i.e. 4 in the case of 5.3 and 3 in the case of 5-3Dex) yields a monomer-
tetramer fit for the sedimentation profile of 5.3 with In Ka = 31.995, while a monomer-
trimer fit for the sedimentation profile of 5.3°" yields In Ka = 21.029. The concentrations 
at which 50% of the miniature proteins 5.3 and 5.3°" are present as monomer are 15.7 
and 17.9 ^M, respectively. At the concentration used in the studies above (i.e. 1 jtM), 
both the dexamethasone-labeled and unlabeled miniature protein are > 99% monomeric. 
Thus there is little, if any, difference in the association state between aPPDe* and 5.3°" 
at the concentrations used. This data support the conclusion that the installation of 
arginines on the helical portion of 5.3 result in its uptake and cytoplasmic localization, 
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and that this effect is not due to change in the oligomerization state of the protein. 
We found that at 1 all three miniature proteins (aPP, 5.3, and 5.3°") are pre­
dominantly monomeric. Comparing the modeled transitions of 5.3 and 5.3°" results 
in nearly complete overlap, indicating that the weight fraction of monomeric miniature 
protein is not altered by the addition of the dexamethasone. Furthermore, at 1 ̂ M, the 
concentrations at which these proteins are applied to cells, these miniature proteins are > 
99% monomeric. Thus cationic miniature protein 5.3 is a monomer in solution at the con­
centrations used in these studies, and this conclusion is not dependent on the presence 
or absence of the dexamethasone label. 
3.2.7 Natural Helices containing Arginine 
The results reported here suggest molecules that contain a discrete a-helical arginine 
array can hijack endocytic machinery to cross into the cytosol. We wondered whether 
a similar a-helical arginine array might be found in natural proteins whose biological 
role demands the perturbation of membrane structure. Alternatively, if we found helical 
arginine arrays in proteins not known to interact with membranes, it would raise the 
possibility that membrane interaction was an unrecognized function. 
3.2.7.1 An arginine-rich helix search 
We began searching the PBD database for structures containing helices by extracting the 
amino acid sequence for each helix from the structure file. Structures deposited before 
1995 were not analyzed, because these structures do not include records for secondary 
structure. My search yielded a list of 360,446 helical sequences from 37,479 peptide 
chains. Many of these represent reflected or homo- and hetero-oligomerized protein 
chains within the crystallographic asymmetric unit, and therefore share the same se­
quence as another helix within the same structure. After filtering out these occurrences, 
we are left with 217,015 helical sequences. 
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Figure 3.14: Association states of aPP and aPPD" as they vary with concentration. A 
self-consistency modeling approach was utilized to determine the weight fractions of 
monomeric (closed circles) and oligomeric (open circles) miniature protein by solving the 
mass action equation for self-associating systems at total protein concentrations between 
10~10 and 10~3 M. The concentration used when studying the effects of peptides on cells 
(1 piM) is shown with a dotted green line. The parameters for aPP in either PBS or 
HKR buffer and aPP0e* in HKR buffer were determined from the data shown in figure 
3.13. The parameters for aPP in Tris-buffered saline (TBS; 25 mM Tris, 50 mM NaCl, 
pH 8.0) were reported previously[i3o]. (a) At similar concentrations, the fraction of 
oligomeric aPP is similar in PBS (blue) and HKR (orange) buffers, but lower in TBS. (b) 
Miniature protein aPPDex is monomeric at the concentration used in these studies. [The 
Excel program for modeling the assembly of oligomers was contributed by Cody Craig.] 
Figure 3.15 (following page): Cationic miniature protein 5.3 and its dexamethasone la­
beled variant are monomers. Physical parameters of 5.3 (a) and 5.3°" (e) calculated by 
the method of [163]. The density of the solution, p, was calculated based on buffer com­
ponents using SEDNTERP. The sedimentation profiles of 5.3 (open circles, b, c, d) and 
5-3Dwt (open circles, f, g, h) after reaching equilibrium at 36,000, 42,000, or 50,000 rpm are 
shown, (b) Best-fit monomer-tetramer model (lines) and residuals (below). The residu­
als do not show systematic deviation. The fit yeilds lnJKfl = 31.395. (c) Residuals from 
a model single ideal species shows systematic devation and a molecular weight higher 
than 5.3 indicating self-association, (d) A general monomer-nmer model fit reveals an 
association state n — 3.79 ± 0.03. (f) Best-fit monomer-trimer model (lines) and residuals 
(below). The residuals do not show systematic deviation. The fit yeilds lnK„ = 21.029. 
(g) Residuals from a model single ideal species shows systematic devation and a molec­
ular weight higher than 5.3°" indicating self-association, (h) A general monomer-nmer 
model fit to these data reveals an association state n = 2.84 ± 0.01. (i) Summary table 
of the derived parameters from fitting sedimentation equilibrium profiles. For compari­
son, the values for aPP, reported by [130] are shown. (j)The weight-fraction of miniature 
protein existing as a monomer (closed circles) or in an oligomeric comples (open circles) 
in solution as a fuction of concentration. These data are modeled based on parameters 
shown in i. [The Excel program modeling fraction monomers was contributed by Cody Craig.] 
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To search for sequences enriched in arginine, we used a sliding window approach 
in which the number (and orientation) of arginines was tabulated within an 18 amino 
stretch, the length of the helix in 5.3. Of the 216,876 helical sequences, I found 2,531 
that contained 4 or more arginines: 1649 sequences contained 4 arginines within an 18 
amino acid window, while 399 contain 5 or more arginines. We next looked for helices 
in which the arginines were clustered in the same side of the helix. Over short stretches, 
the position of amino acids within a-helices show a seven-fold repeating arrangement 
over two turns of the helix, so that starting with position i on the first turn, i + 3, i + 4, 
are closely apposed on the rung above. Position i + 7 is oriented above position i. Using 
the positional index of arginines and taking the numerical indices modulo 7, we filtered 
the arginine rich helices for those members that contain 4 or more arginines in the i, 
i + 3, and i + 4 position for any i along the helix length. We found 1484 helical sequences 
(derived from 449 structures) that fulfill these criteria. Because these sequences contain 
at least one set of three adjacent faces with a total of 4 arginine residues, they can be seen 
as variants of miniature proteins 4.3. This conception would place miniature proteins 4.2 
and 5.2 as subsets of the 4.3 and 5.3 family. However, because these variants were less 
effective at obtaining cytosolic access, I chose to consider them separately. Filtering the 
above 449 structures for members containing exactly 4 or 5 arginine residues on three 
helical faces yields 14 protein chains containing 5 arginine residues within a window of 
18 amino acids arranged on 3 helical faces. Interestingly, none of these proteins contained 
the exact arginine arrangement seen in 5.3 (arginines located in positions i, i + 4, i + 7, 
i + 10, and i + 11). A similar search for proteins containing exactly 4 arginines within 
an 18 amino acid window and located in i, i + 3, and i + 4 positions yielded 167 hits, 
identifying these proteins as members of the 4.3 family. 
3.2.7.2 Functions of natural arginine rich helices 
The list of 5.3 motif-containing natural proteins contains too few members to quanti­




f Extract Helix ^ 








(3) Arginine content of helices 
(2048 unique) 6,965 
21,447 
Arginine Rich Helices 
I 
(4) ( Identify ^ 
V Chains ) 
Unclustered 
(6) ( Contains >4 ^ 
V R.2 or R3 ) y clustered Rs J 
I 
^ No other R^j 
Clustered 
Orientation of Arginines 
Clustered or Unclustered 
(7) 
ft.2-like 
R = 4 166 
R = 5 2 
ft.3-like 
R = 4 239 
R = 5 14 
Figure 3.16: Schema for the identification of arginine-rich helices from the PDB. The 
entire PDB is searched for helical segments (1), which are then filtered for duplicated 
sequences within the same structure (2) and sorted based on arginine content (3). Out of 
216,876 helical sequences, 2,048 unique sequences contain >4 arginine residues within an 
18 amino acid window. Helical chains were then sorted as 'clustered' or 'unclustered', 
(4), a shown in the helical diagram. (5) 1172 sequences contained exactly 4 arginines, 
dispered across the entire helical surface. These were excluded from further analysis 
because they do not conform to the arrangement of arginines in 4.3. (6) Sequences con­
taining >4 clustered arginines aranged on exactly two faces were designated 'R.2-like', 
whereas sequences containing arginines arranged on exactly 3 faces were designated 
'R-3-like', where R is the number of arginine residues in the helix. These were filtered to 
exclude mutliple sequences from the same structure. (7) Results of the helix search: 239 
4.3-like proteins and 14 5.3-like proteins were identified. 
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membrane-perturbing proteins. Members include a transcription factor (the thyroid nu­
clear hormone receptor) and several ribosomal proteins. It is unsurprising that proteins 
whose biological role is the interaction with negatively charged nucleic acid include pos­
itively charged segments. None the less, it is intriguing to observe that this set also 
includes CHMP3[i64], a member of the ESCRT-III complex involved in membrane scis­
sion whose a-helical arginine array (identified in our search) is essential for its interaction 
with cellular membranes and ESCRT-III function[i65]. The presence of the adenomatous 
polyposis coli (APC) tumor suppressor gene in our hit list is also intriguing. This pro­
teins interacts tightly with the cytoskeleton at adherens junctions through a complex 
that includes Cdc42 and Raci, proteins that link the process of endocytosis to the actin 
cytoskeleton. A previous study identified the activity of Raci as required for the actin 
reorganization that precedes the uptake of Tat and Arg8. 
Broadening the search to examine the list of 4.3 motif-containing natural proteins re­
sults in additional insight, and strengthens the hypothesis that arginine rich helices inter­
act with the actin cytoskeleton and are active motifs for uptake. Proteins containing argi­
nine rich segments that play a role in the endocytic machinery either directly or through 
interaction with actin include complexin, spectrin alpha chain, phosphatidylinositol-
binding clathrin assembly protein (CALM, a homolog of AP180), vinculin, and PLEKHA4, 
a PI3P binding protein. Also identified was BipD: a self-chaperoning protein found on 
the needle tip of the type 3 secretion system. 
Literature searches illustrate the functional involvement of regions in which acidic 
residues are found, there are few examples of studies mutating arginine residues specifi­
cally. In the case of BipD, the helices in which the acidic residues are found are predicted 
to undergo a conformational shift, during the activation of the 'needle' to translocate vir­
ulence factors into target cells[i66]. In the case of vinculin, the basic residues surround a 
patch that interacts with phosphoinositi.des[i67]. In the case of CALM, these are not re­
quired for binding to PI(4,5)P2 [168,169,170], but comprise the c-terminus of the CALM 
proteins ANTH domain and are conserved between CALM and AP180. Four arginine 
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PDB CODE UniProt Accession UniProt Name Sequence 
Arrangement _ 
5.3-like protiens a b c d e f g 
- - - - Cationic Miniature Protein 5.3 {thisstudy) 2 0 0 1 2 0 0  RDLIRFYRDLRRYLNW 
2GD5 Q9Y3E7 Charged multivesicular body protein 3 (CHMP3) 1 2 0 0 2 0 0  RKEXRWDRQIRDIQREE 
1EH1 Q9WX76 Ribosome-recyding factor 2 0 0 3 0 0 0  RAVRQYAEEGRVAIRNIR 
1YSH Q5I7K9 60S ribosomal protein L30 2 0 0 2 0 0 1  RLILVESRIHRLARYYKR 
1WQ6 Q06455 Protein CBFA2/Fusion Protein AML-ETO 0 0 0 3 2 0 0  EKTRRSLTVLRRCQEADR 
1MHE P61769 HLA class I histocompatibility antigen, alpha chain E 1 0 0 2 0 0 2  RETRSARDTAQIFRVNLR 
1M5I P25054 Adenomatous polyposis coli protein 2 0 0 2  1 0 0  RAQRRIARIQQIEKDILR 
3M9E P18113 Thyroid hormone receptor beta 0 0 2 1 0 0 2  SKRLAKRKLIEENREKRR 
1Y69 P0A807 Ribosome-recyding factor 3  1 0 0 1 0 0  RGEAEQARVAVRNVRRDA* 
1EK8 P0A805 Ribosome-recyding factor 3  1 0 0 1 0 0  RGEAEQARVAVRNVRRDA* 
1IS1 Q8GRF5 Ribosome-recyding factor 3 1 0 0 1 0 0  RGEAEGGRVAVRNIRRDA 
2WWL P0A7W7 30S ribosomal protein S7 1 0 0 3  1 0 0  RPVRRNALAMRWIVEAAR 
1KEJ P09838 DNA nudeotidylexotransferase 0 3  1 0 0 1 0  SRQFERDLRRYATHERK 
1KA2 Q8U3L0 Carboxypeptidase 1, unreviewed 2 0 0 2  1 0 0  EYERGIVRVLDRSIRIAR 
1QQN P19120 Heat shock cognate 71 kDa protein (Hsc70) 0 0 2 0 0 1 2  NKRAVRRLATACERAKRT 
4.3-like protiens (selected) 
1ID3 P61830 Histone H3 0 0 1 2 0 0 1  PVGRVHRLLRR 
3NFT Q63K37 Translocator protein BipD 1 0 0 2 0 0 1  TVFDDARVAVRGHARAQR 
1TR2 P18206 Vinculin 1 0 0 2 0 0 1  GATSIARRANRILLVAKR 
1UPQ Q9H4M7 Pleckstrin homology domain-containing family A member 4 0 0 2 0 0 1 1  TLEDLRGWLRALGRASR 
16VP P06492 VP16 0 0 1 1 0 0 2  FCSALYRYLRASVRQLHR 
Figure 3.17: Natural proteins containing arginine-rich helices identified from searching the PDB. Proteins containing helical seg­
ments that are consistent with the 5.3 and 4.3 motifs are shown. The PDB code for each protein, the corresponding Uniprot 
accession number, and the protein name are shown together with the number of arginine residues in each helical postion as well 
as the amino acid sequence of the arginine rich segment. 
residues also present within the same c-terminal region of the ENTH domain but these 
residues are split over two-helices with a kink in the middle. The biological function and 
the identity of the lipid interacting residues of PLEKHA4 remain untested. 
Whether or how these proteins utilize arginine rich helices remains unknown. Argi­
nine rich helices may play a specific role in modifying membrane structure through inter­
action directly with lipid, or may serve other functions. Drawing functional comparisons 
between cationic miniature proteins and natural cytoplasmic proteins that contain argi­
nine rich helices is complicated by the fact that these proteins exist (at least initially) on 
the opposite side of the cell membrane. Nonetheless, the presence of cytoplasmic pro­
teins that contain this structural motif is encouraging. The role of BipD may be more 
analogous to cationic miniature proteins because it functions on the extracellular face of 
membranes. Experimental comparisons may reveal unknown functions of basic residues 
within the type 3 secretion system, alternatively studying the mechanisms of proteins 
containing arginine rich helices may reveal clues that improve our ability to design cy-
tosolic miniature proteins. 
Thus, compared to searches looking only for overall positive charge[ii9, 1x8], our 
analysis of structural determinants for miniature protein entry greatly expands the num­
ber of potential proteins in nature that may contain cell-penetrating or at least mem­
brane-perturbing function. The ability of cationic miniature protein 5.3 to rapidly es­
cape from early endosomes is a unique feature, not shared by canonical cell penetrating 
peptides, and represents a starting point for the optimization of well-folded functional 
cell penetrating proteins useful as pharmacologic tools capable of modulating cytoplas­
mic protein function. More sophisticated comparisons than the one presented here may 
illuminate shared features of these and other arginine rich proteins. 
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3.3 Discussion 
The interfaces that form between and among proteins and DNA-often large, flat, and po-
lar-do not resemble those that bind small molecule substrates or traditional irihibitors[i32] 
Targeting these 'undruggable' interfaces is a task well suited to protein and peptide lig-
ands, but can only be successful if such molecules reach their cytosolic targets. Unfor­
tunately, the very properties that endow peptide mimetics with their promise-size and 
polarity-are precisely those properties forbidden by Lipinski's rules[2]. The challenge, 
therefore, is to identify the determinants that guide the uptake of peptide-like molecules 
and the mechanisms through which they gain cytosolic access, generating a new set of 
rules applicable to large peptidic molecules. Advancing this goal has been constrained 
by the absence of a rapid and robust assay capable of distinguishing between peptide-like 
molecules trapped within endosomes or those that have escaped into cytosol. 
Here we took advantage of previous observations that the cytoplasmic-to-nuclear 
translocation of the glucocorticoid receptor (GR) takes place within minutes[i44] and 
recent developments in automated high-content image analysis, to develop an assay that 
exploits the nuclear to cytoplasmic ratio of a GR-GFP fusion protein as a proxy for the 
cytoplasmic entry of traditionally impermeant molecules tagged with dexamethasone. 
Compared with a first-generation assay developed by Kodadek and colleagues[i43], the 
one reported here provides a readout in intact living cells within 30 min (as opposed 
to 48 hours) using an epifluorescent microscope and eliminates the requirement for cell 
lysis or enzymatic substrates, substantially reducing cost. 
Beginning with a panel of miniature proteins that contained variety in the number 
and orientation of arginine residues, I found that the structure of the miniature protein 
scaffold aPP was tolerant to incorporation of up to five arginine residues. Next, by 
synthesizing fluorescently labeled variants, I found that the incorporation of arginine 
resulted in molecules that were taken up more efficiently by cells that the parent molecule 
aPP. For molecules containing four arginines, the magnitude of the effect dependend on 
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the relative orientation of the positively charged residues, with the clustered arginines 
present in 4.2 resulting in greater uptake than the more dispersed arginines found in 4.3. 
In the case of molecules containing five arginines, the magnitude of the effect was similar 
regardless of their orientation. 
Among the four miniature proteins I identified as being actively taken up by cells, I 
found clear differences in the ability to activate the GR when covalently linked to dexam­
ethasone. GR activation by dexamethasone-labeled peptides and miniature proteins im­
plies their presence in the cytoplasm. An alternative hypothesis is that the peptides and 
miniature proteins studied are substantially degraded during the course of the experi­
ment, leading to spurious activation of the GR by released (and perhaps cell permeable) 
dexamethasone-peptide fragments. HPLC analysis of aPPR and 5.3s recovered from cell 
lysates (Fig 3.8) shows that miniature proteins remain unmodified during the course of 
the experiment excluding this possibility. Thus, the activation of the GR is due to the 
arrival in the cytoplasm of the intact miniature proteins, and not due to the effect of a 
degradation product. 
For many cell penetrating peptides, cellular uptake results from an endocytic process 
leaving the peptides trapped within a membrane bound endosome and unable to reach 
their cytosolic target. It is tempting to invoke a hypothesis that endosomes are 'leaky' and 
that peptides escape to the cytoplasm with similar rates. Even if this were this the case, 
the differences in GR activation by 4.2°^*, 4-3Dex, 5.2°" and 5.3°" are not explainable 
by differences in their endocytic rate (4.2s, 5.2s, and 5.3s are each taken up to a similar 
extent). Indeed 4-3R is taken up to a lesser extent than 4.2s, but 4.3°" is a superior 
activator of GR than is 4.2°", though the difference is small. Differences in affinity for 
the GR receptor itself also do not explain these differences, as the in vitro affinity of 4.2°" 
and 4.3°" for the GR is similar. A parallel argument holds true for peptides 4.2 and 5.3: 
both are taken up to a similar extent, but treatment with lpiM 5.3°" leads to greater 
activation than does treatment with /\.zDex. This comparison is strengthened by the fact 
that 5-3°ex has a decreased affinity for the GR, requiring a higher effective concentration 
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to achieve the same fractional occupancy. Taken together, these findings identify 5.3 as a 
cationic miniature protein capable of efficiently reaching the cytosol without disrupting 
the cellular membrane. 
How do the findings of 5.3 compare to cannonical peptides used to impart cytosolic 
access? This comparison is somewhat complicated by the fact that lysates from cells 
treated for 30 min with TatR or Arg8R show the appearance of degradation products. 
This raises the possibility that the GR induction seen after treatment with TatDex or 
Arg8Dex may be, in part, due to the action of degradation products rather than the intact 
peptide. These data do not distinguish whether the eventual degradation of TatR and 
Arg8R takes place within endosomes or the cytoplasm. If these molecules are degraded 
within the cytoplasm, they may remain useful as modules to direct peptidomimetics to 
cytoplasmic targets. The observed instability of Tat and Arg8 stands in contrast to the 
stability of 5.3, a benefit of well-folded miniature proteins. This caveat not withstanding, 
direct comparisons of 5.3Dex to TatDex and Arg8Dex reveal that translocation ratios are 
similar for 5.3°" and TatDe* (p — 0.147), but that the translocation ratio after treatment 
with S-3°ex is higher than after treatment with Arg8Dex (p = 0.3 x 10~9) suggesting that 
Arg8 is less efficient at reaching the cytoplasm. 
Comparison among these three peptides further supports the conclusion that inter­
nalization and cytoplasmic access are separable, as cellular uptake of Arg8R is superior 
to TatR, both of which are inferior to 5.3 s. Thus, some of the peptides studied here 
contain arginine motifs that display only efficient uptake (4.2, 5.2) or only cytoplasmic 
localization (Tat). While Arg8 is intermediate in both uptake and cytoplasmic access, 
miniature protein 5.3 effectively combines both of these features and displays increased 
proteolytic stability. These comparisons reveal that the process of cellular uptake and 
cytoplasmic access are governed by discrete structural determinants and that peptides 
and miniature proteins may be optimized to possess either or both of these functions. 
In summary, this study led to the identification of 5.3, a cationic miniature protein 
whose rapid cytosolic localization is equivalent to or better than Tat and Arg8. This 
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comparison revealed that contrasting structural determinants control cellular uptake and 
cytoplasmic localization. Uptake is favored by clustered a-helical arginine side chains, 
whereas cytoplasmic access requires a more dispersed arginine array. 
How can the arginine residues mediate cytosolic localization? The differences in argi-
nine/lysine number and orientation in 5.3, Tat, and Arg8 can affect side chain pKa (and 
thus overall charge at a given pH), the ability to form neutral ion pairs with phospho­
lipid head groups, or affinity for as-yet-unidentified cellular targets. How this difference 
in charge state and or distribution could result in increased cytosolic access is unknown. 
If these molecules are internalized into endocytic vesicles, it is possible that the distinct 
arginine array in 5.3 favors the formation of a critical protonated species in the moder­
ately acidic environment of the early endosome (pH « 6.5). Tat and Arg8 on the other 
hand, may require the lower pH present in lysosomes inorder to generate an equivalent. 
It is equally possible that the discrete arginine array in 5.3 represents an specific export 
signal for cellular machinery that has not yet been identified. 
3.4 Experimental Methods 
3.4.1 Miniature protein synthesis and purification. 
All miniature proteins and peptides were synthesized using a Liberty Automated Mi­
crowave Peptide Synthesizer (CEM) and standard solid phase synthesis techniques. Cou­
pling reactions were performed using 5 equivalents of amino acid, 5 equivalents HBTU, 
and 10 equivalents of diisopropylethylamine in DMF. FMOC groups were removed us­
ing 20% piperidine in DMF containing 0.1 M HOBT to minimize aspartamide forma­
tion. Following synthesis, the peptides were cleaved from the resin by adding 5 mL 
of a solution containing 95% TFA, 2.5% water, 2.5% TIPS and incubating at 38°C for 30 
min using a microwave accelerator (MARS system, CEM). The solution containing the 
crude peptide was precipitated by the addition of 40 mL cold ether. The precipitate 
was dried under a nitrogen stream and lyophilized before purification via reverse phase 
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HPLC (YMCbasic column, 150mm x 10mm ID) using a linear gradient of CH3CN in 
water (both acidified with 1% TFA). Purified miniature proteins or peptides were col­
lected and lyophilized, then reconstituted in water and kept at -4 °C protected from 
light. The purity and identity of purified miniature proteins was characterized by ana­
lytical HPLC (>95% in all cases) and either a Voyager (Applied Biosystems) MALDI-TOF 
(matrix-assisted laser desorption-ionization time-of-flight) spectrometer (337 nm laser, 
a-cyano-4-hydroxycinnaminic acid matrix), or a Waters QTof LC-MS. For molecular for­
mulas, calculated masses, and measured (m/z) ratios of polypeptides and miniature 
protein domains see figure 3.20. Labeled miniature proteins and peptides were assessed 
for purity by analytical HPLC. Peptides and miniature proteins were injected on a Shi-
madzhu HPLC equipped with a fluorescence detector, a UV-Vis detector and fitted with 
an Agilent Poroshell 120 SB-C18 column (100 mm x 3.1 mm ID, 2.7 pm particle size). A 
linear gradient of 10 - 100% CH3CN in water (both acidified with 0.1% TFA) was used 
as a solvent system. Fluorescein labeled compounds were detected via fluorescence (ex­
citation 450 nm, emission 500 nm). Rhodamine labeled compounds were detected via 
fluorescence (excitation 550 nm, emission 580 nm). Dexamethasone labeled compounds 
were detected via absorbance at 280 nm. Traces are shown in figure 3.18 and figure 3.19. 
3.4.1.1 Fluorescein labeled miniature proteins. 
Fluorescein labeled miniature proteins were generated from purified peptides containing 
an appended C-terminal cysteine residue. The purified unlabeled product was reacted 
with 5-(iodoacetamido)fluorescein to generate the fluorescein-labeled miniature protein 
as follows: to 500 ^L of a 100 mM phosphate buffer, pH 7.25 was added 1 jjmol of 
the miniature protein, then water to a total volume of 2.5 mL. Separately, 5 mg of 5-
(iodoacetamido)fluorescein (Sigma Cat. #19271) was dissolved in 2.5 mL DMF. This DMF 
solution was added to the aqueous miniature protein solution and the reaction was in­
cubated in the dark at 25 °C for 2 hours. To generate unlabeled miniature proteins, the 
C-terminal cysteine was capped by reaction with iodoacetamide under analogous con-
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Figure 3.18: HPLC analysis of selected cell permeable miniature proteins. 
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ditions. The reaction mixture was purified using reverse phase HPLC using the column 
and solvent system described above. 
3.4.1.2 Rhodamine labeled miniature proteins and peptides. 
Rhodamine labeled miniature proteins were generated by carrying out labeling reactions 
on resin using an appended N-terminal lysine. For this purpose we employed an amino 
acid monomer in which NK is BOC-protected and N£ is protected with an FMOC group. 
The Ne was deprotected using microwave acceleration and incubating the resin twice 
with 20% piperidine in DMF at 8o°C for 7 min. The resin was then washed thoroughly 
with DMF. To label peptides with tetraethyl rhodamine, to the deprotected resin was 
added 10 eq of Lissamine Rhodamine B sulfonyl chloride and 10 eq of diisopropylethy-
lamine in 5 mL DMF at room temperature overnight. The resin was thoroughly washed 
with DMF and DCM before global deprotection and cleavage using the conditions for 
unlabeled peptides described above. Crude rhodamine labeled peptide was precipitated 
in 40 mL of cold ether and lyophilized. Peptides were purified by reverse phase HPLC 
as described above. Peptides lyophilized from HPLC solvents were stored in water at 
4°C protected from light. 
3.4.1.3 SDEX labeled miniature proteins and peptides. 
SDEX labeled miniature proteins and peptides were generated in a manner analogous 
the generation of rhodamine labeled miniature proteins; after appending an N-terminal 
lysine residue bearing an FMOC protecting group in the side chain, the Ne was depro­
tected using microwave acceleration by incubating the resin twice with 20% piperidine 
in DMF at 8o°C for 7 min. The resin was then washed thoroughly with DMF. To the 
deprotected resin was added 5 eq SDEX, 5 eq HATU, 5 eq of HOAT, 5 eq of DIPEA, and 
5 eq of 2,6-lutidine in 5 mL DMF. The reaction was shaken overnight at room tempera­
ture. The resin was thoroughly washed with DMF and DCM before global deprotection 
and cleavage using the conditions for unlabeled peptides described above. Crude SDEX 
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labeled peptide was precipitated in 40 mL of cold ether and lyophilized. Peptides were 
purified by reverse phase HPLC as described above. Peptides lyophilized from HPLC 
solvents were stored in water at 4°C protected from light. 
3.4.2 Concentration Determination. 
Concentrations of labeled miniature proteins were calculated using the extinction coef­
ficients of the strongest absorbing chromophores. In the case of unlabeled miniature 
proteins, the extinction was determined directly from the amino acid sequence3_ In the 
case of labeled peptides, fluorescein absorption at 500 nm in 8 M urea, 100 mM Tris-
HC1, pH 9.0 was measured using the molar extinction coefficient 78,000 M-1cm_1 at 
500 nm (Invitrogen). The concentration of rhodamine labeled variants was determined 
in water using an extinction coefficient of 87,000 M-1cm-1. The concentration of SDEX 
labeled variants were determined using an extinction of 12,000 M_1cm_1 at 242 nm in 
DMSO[i7i]. 
3.4.3 Circular Dichroism. 
CD spectra of unlabeled peptides were recorded from samples containing 25 ^M peptide 
in PBS as described[62]. 
3.4.4 Activation of GR by dexamethasone labeled peptides and miniature 
proteins. 
HeLa cells transfected with PK7-GR-GFP for 24 - 36 hr were plated (104/well in 200 
ViL) the day prior to experiments in 96 well glass bottom plates (Matrical). The media 
was replaced with HKR buffer containing 300 nM Hoescht and the cells incubated for 
30 min at 37°C. The media was then replaced with 150 jiL HKR buffer or HKR buffer 
containing 1 jiM dexamethasone labeled cationic miniature protein or peptides or 1 ^M 
dexamethasone as a positive control. The cells were incubated for a further 30 min at 
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37°C before epifluorescence imaging using a Zeiss Axiovert 200M microscope fitted with 
a mRM digital camera, a 63 x 1.3NA PlanApo objective and an EXFO-Excite illumination 
source. Dual color epifluorescence images were acquired using the following filter sets: 
Hoescht, Zeiss Filter Set #49 (ex G 365 nm, FT 395, em BP 445/50 nm); EGFP, Zeiss Filter 
Set #44 (ex BP 475/50 nm, FT 500, em BP 530/50 nm). 
3.4.5 Image analysis using CellProfiler. 
The image analysis algorithm used by CellProfiler is customizable and contained within 
a 'PIPELINE' that describes a series of image manipulation and evaluation steps, such 
as reading the image, adjusting the intensity, and identifying objects. Each step has 
several options. We found that the translocation ratio was generally robust, provided 
nuclei were accurately identified. Using the image of Hoescht fluorescence and Otsu's 
method of automatic thresholding, nuclei were identified and segmented using 3 class 
thresholding. The middle class was assigned to background. Closely approximated 
objects were separated using 'Laplacian of Gaussian' modeling, and touching nuclei were 
divided using the 'shape' option. Nuclear regions were expanded by 2 y.m to generate 
an enlarged region. The nuclear region was subtracted from enlarged region to generate 
a ring surrounding the nucleus (surround). The diameter of the surrounding region was 
chosen to be 2 ^m larger than the nucleus, within the range (1-3 ̂ m) used by previously 
reported high content screens[i72,173]. The ratio of the median intensities of the nuclear 
and surrounding region of the GFP or mCherry (as appropriate) image were collected 
for every cell examined. Those cells falling below a threshold of intensity (10% of the 
maximum intensity of the image) were discarded as 'untransfected'. Typically, 20-60 
transfected cells from 15-30 images were examined for each experimental condition. 
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34*6 Examination of Membrane Integrity via Cell Impermeable Dyes. 
The loss of membrane integrity was examined via assaying nuclear fluorescence after 
exposure to Sytox Blue (Invitrogen), a cell impermeant dye that fluoresces brightly when 
complexed with DNA. Syto Orange 85 (also Invitrogen) was used as a cell permeable 
counter stain. HeLa cells plated in glass bottom microtitre plates were exposed for 30 
min at 37°C to x dexamethasone labeled cationic miniature protein or peptide in 
HKR buffer containing x Sytox Blue and x Syto Orange. Buffer without peptide 
or containing xo pig/mL Saponin was used as negative and positive controls respectively. 
After incubation cells were washed briefly in HKR buffer, and examined immediately 
via epifluorescence microscopy (Zeiss Axiovert 200M). Sytox Blue fluorescence was vi­
sualized using Filter Set 49, Syto Orange 85 was visualized using Filter Set 43. Images 
were analyzed using ImageJ. 
3.4.7 Competition binding of dexamethasone labeled miniature proteins or 
peptides with Fluormone® for the glucocorticoid receptor. 
Differences in the affinity of dexamethasone-labeled molecules for the human glucocor­
ticoid receptor were assessed via competition binding. For this purpose, we employed 
a Glucocorticoid Receptor Competitor Assay Kit (Invitrogen). Varying concentrations 
of dexamethasone-labeled miniature protein or peptide (or dexamethasone as a control) 
were suspended in 48 ^L Screening Buffer (xo mM NaP04, pH 7.4; 20 mM Na2Mo04, x 
mM EDTA, 2% DMSO) and incubated with 2.5 nM FLUORMONE GSX and 4 nM recombi­
nant human GR for 3 h in the dark at room temperature. Following incubation, the fluo­
rescence polarization of each solution was measured on an Analyst AD plate reader (LJL 
Biosystems). Each data point represents the average fluorescence polarization (± stan­
dard deviation) of three separate experiments. Data were plotted as polarization (mP) 
vs. Logfinhibitor] and fit to the following equation using GraphPad software (Prism): 
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_ _ . Pmax-Pirun 
mP = Prrun -| 
1 + 10((C]-^(^50)) 
where mP is the polarization of the sample, [C] is the concentration of the test compound, 
Pmax is the polarization of the sample when no competitor is added, and Pmin is the 
polarization that represents maximum competition. 
3.4.8 Peptide Degradation. 
Approximately 200,000 HeLa cells were treated with rhodamine labeled cationic minia­
ture proteins and peptides as described for experiments using flow cytometry to measure 
peptide uptake. These cells were pelleted in 96 well microtitre plates (300#, 3 min) and 
lysed in 40 }iL RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.4, 50 mM EDTA pH 7.4, 0.1% 
SDS, 1% Triton X-100) on ice for 30 min. The insoluble material was cleared from the cell 
lysate via centrifugation (io,ooog, 10 min) and 20 ^L of the supernatant was diluted into 
400 }iL of 15% CH3CN in water. These samples were analyzed via reverse phase HPLC 
(Shimadzu Instruments) fitted with a fluorescence detector and a C18 column (Poroshell 
120 SB-C18, 2.7pm, 100 mm x 3 mm ID, Agilent; Fig. 3.8) or a C8 column (Kinetex C8, 
2.6pm, 100 mm x 2.6 mm ID, Phenomenex; Fig. 3.9). 
3.4.9 Resistance to Cathepsin Acid Proteases 
50 pmol aPPR, 5.2r, 5.3s, TatR, or Arg8K were incubated with 5 pg cathepsin B, D, or L for 
30 min at 37 °C in xo pL of 20 mM sodium citrate-phosphate buffer (pH 4.7) containing 
150 mM NaCl. At the end of the incubation, the reaction was stopped by adding 40 
pL of a solution containing a 84:15:1 ratio of water:EtOH:TFA before analysis by HPLC 
(Shimadzu Instruments) fitted with a fluorescence detector and a C8 column (Kinetex 
C8, 2.6pm, 100 mm x 2.6 mm ID, Phenomenex). 
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34-10 Generation of Cytoplasmic Extracts using SLO 
To generate cytosolic extracts, we first we verified that we could selectively release the 
cytoplasmic contents of HeLa cells using the published procedures. 2 x 105 HeLa cells 
were treated with 20 pg/mL SLO in PBS containing 5 mM DTT (20 min, 4 °C), washed 
(three PBS washes, 150 pL each), and resuspended in 40pL PBS. To allow oligomerization 
of membrane bound SLO and pore formation, cells were incubated at 37 °C for 15 min. 
Cells were separated from cytoplasmic extracts by centrifugation (2 min x300g) and the 
supernatant (cytoplasmic extract) retained. 
To monitor the fraction of cells permeabilized ijopL of PBS containing ipM propid-
ium iodide (PI), a marker of permeabilized cell membranes, was added to the cell pellet 
following slow treatment and the cells examined by flow cytometry. Under these condi­
tions, 85 to 89% of the cells accumulated PI, indicating that the plasma membrane had 
been disrupted. To examine the contents of the cytoplasmic extracts, the insoluble ma­
terial was cleared from the cytoplasmic extracts via centrifugation (io,ooog, 10 min) and 
20 fiL of the supernatant was diluted into 40 JIL of 15% CH3CN and 0.1% TFA in water. 
These samples were analyzed via reverse phase HPLC (Shimadzu Instruments) fitted 
with a fluorescence detector and a C8 column (Kinetex C8, 2.6pm, 100 mm x 2.6 mm ID, 
Phenomenex). To confirm that these conditions did not release material present within 
lysosomes, 2 x 105 HeLa cells were treated with SLO at 4 °C, washed, resuspended in 
PBS, and incubated at 37 °C for 15 min as described above. The cells were then pel­
leted by centrifugation (2 min x300g) and the supernatant recovered, after which the 
cell pellet was treated with detergent lysis buffer (RIPA buffer) to solubilize the mem­
branes. Total cell lysate from an equal number of HeLa cells that were not treated with 
SLO served as a positive control. These three fractions (total cell lysate, supernatant 
from SLO treated cells, and the solubilized cell pellet) were then incubated with a so­
lution containing 7.5 mM 4-nitrophenyl-N-acetyl-p-D-glucosaminide (Sigma-Aldrich) in 
0.1 M citrate-phosphate buffer, pH 4.7. 4-nitrophenyl-N-acetyl-j3-D-glucosaminide is a 
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chromogenic substrate for the lysosomal enzyme j3-hexosamididase which, via hydroly­
sis, releases 4-nitrophenol whose presence can be spectrophotometrically monitored via 
absorbance of 405 nm light. 
3.4.11 Analytical Ultracentrifugation 
Miniature proteins were dissolved in either PBS or HKR buffer at 60, 20, or 10 jiM con­
centration and loaded into 6 chambered cells. Buffer blanks without peptide were used 
as controls. The cells were loaded into the rotor, and spun in a Beckman XL-i analytical 
ultracentrifuge with absorbtion optics at increasing speeds (36,000, 42,000, 50,000, and 
60,000 rpm). Peptide sedimentation profiles were assessed at both 280 nm and 230 nm, 
using a o.x mm step size for the scan position. In this way, scans were completed each 
hour. The approach to equilibrium was monitored using the MATCH function of HET-
EROANALYSIS, in which the root-mean-square-deviation (rmsd) between successive scans 
is calculated. Centrifugation at each speed was continued for a minimum of 6 hr, until 
the rmsd was no longer decreasing, or until the rmsd was < 0.005 between successive 
scans. At this point to rotational speed was increased or, after reaching equilibrium at 
60,000 rpm, the run was stopped. 
Data analysis began with the calculation of physical parameters. Solvent density, 
p, was calculated using SEDNTERP, while partial specific volume 07) was calculated by 
hand using the method of [163], making adjustments for the inclusion of the c-terminal 
amide, as well as the presence (or absence) of a dexamethasone coupled to an N-terminal 
lysine. The extinction coefficient for unlabeled miniature proteins was calculated directly 
from the amino acid sequence[i74]. For dexamethasone labeled molecules, the absorb­
tion of dexamethasone at 280 nm (863 M_1 cm-1) was added to the value calculated 
from the amino acid sequence. The absorbance of dexamethasone labeled molecules and 
unlabeled molecules at 230 nm was measured relative to the absorbance at 280 nm. The 
molar extinction coefficient at 230 nm for dexamethasone labeled miniature proteins was 
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determined using the relative absorbances: £230 = -A230 x 3^-
Next scans of sedimentation profiles obtained after the sample arrived at equilibrium 
were loaded into HETEROANALYSIS. Scan points representing the solution column were 
selected manually. In some cases, individual points were excluded because of spurious 
increases in absorbtion. Refitting the data with these points included, led to no change 
in the calculated association constant of the final model. To examine the presence of a 
self-association, data were first fit (using non-linear least-squares regression) to a model 
representing the sedimentation of a single ideal species: 
C(r) = C(r0)eM(1_^~~^!^ + B0 
where M is the molecular weight, RT is the product of the universal gas constant and 
the temperature in kelvin, C(ro) is the apparent concentration of the sedimenting species 
at an arbitrary reference point in the solution column (the miniscus), and C(r) is the 
apparent concentration at radius r, and Bo is an arbitrary adjustment for the background 
absorbtion of the solution. The usuable range of absorbance represents the limits of 
accurate measures of C(r), usually taken to be between 0.1 and 1, acceptable fits generally 
show rmsd < 0.01 and small Bo, usually < 0.01. A best-fit molecular weight significantly 
higher than the calculated molecular weight is evidence of self-association. 
Next, to examine possible association states of the studied molecule, the data are fit 
to a general model of reversible two-state (monomer, n—mer) self-association, using the 
observation that at equilibrium, the law of mass action specifies that the concentration 
of multimer at all points along the column is satisfies Ka • C%(r) = CnM(r), where Cm(r) 
and C„M(r) are the concentrations of the monomer and n—mer, at radius r respectively. 
The model is specified by the following equation 
Ctotaiir) = Cm(ro)eM{l-Vp)^i^ +Ka (Cm(r0))n+ B0 
in which all variables are specified, with the exception of Ka, Bq and n. 
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Finally, the sedimentation profiles are fit to an integer association state using the 
general two-state monomer-to-n—mer model above, except n is fixed at the integer closest 
to the best fit n found when n was allowed to vary continuously. 
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Figure 3.19: HPLC analysis of labeled peptides used in this study. 
9i 
Name Sequence Formula Calc (+m/z) Meas 
aPP GPSQPTYPGDDAPVEDLIRFYNDLQQYLNVVTRHRYCACRTYLFLH2 CI9SH289NM06ISI 4399 4400 
2.1 GPSQPTYPGDDAPVEDLIRFYNDLQRYLNVVTRHRYCATKYL-«H2 -196H 293N560MSI 4427 4430 
2.2 GPSQPTYPGDDAPVEDQRFYRDLQQYLNWTRHRYC^-NHZ -I97H295N57O60S1 4441 4445 
3.2 GPSQPTYPGDDAPVEDLIRFYRDLQRYLNWTRHRYCACETV,-NH2 3l98H 299N580s9Sl 4469 4475 
4.2 GPSQPrTYPGDDAPVRDLIRFYRDLQRYLNWTRHRYCACE'VL-NH2 C199H3MN61O57S1 4496 4502 
4.3 GPSQFrTYPGDDAPVEDURFYRDLRRYLNWTRHRYCA»L»L.NH2 -199H303N60O58S1 4497 4504 
5.2 GPSQPTYPGDDAPVRDLIRFYRDLQRYLRWTRHRYC^-NHZ C20lH31lN63O5«Sl 4538 4545 
5.3 GPSQPTYPGDDAPVRDLIRFYRDLRRYLNWTRHRYC^-NH? "200H308N63O56S1 4524 4531 
6.3 GPSQPTYPGDDAPVRDLRRFYRDLRRYLNWFRHRYCACET*L-NH2 -200H3O9N67O57S1 4567 4573 
Name Fluorescein Labeled Sequences Formula Calc (+m/z) Meas 
aPPF GPSQPTYPGDDAPVEDURFYNDLQQYLNWTRHRYCflu-NH2 C215H302N55O65S1 4729 4735 
2.1F GPSQP"TYPGDDAPVEDLJRFYNDLQRYLNWTRHRYCflu-NH2 C216H306N57O64S1 4758 4763 
2.2F GPSQPTYPGDDAPVEDURFYRDLQQYLNWTRHRYCfuj-NH2 C217H308N58O64S1 4777 4778 
3.2F GPSQPTYPGDDAPVEDURFYRDLQRYLNWTRHRYCflu-NH2 C218H312N59O63S1 4800 4806 
4.2F GPSQP"TYPGDDAPVRDLIRFYRDLQRYLNWTRHRYCfu,.NH2 C219H317N63O61S1 4827 4834 
4.3F GPSQPTYPGDDAPVEDURFYRDLRRYLNWTRHRYCfuj-NH2 C219H316N62O62S1 4828 4828 
5.2F GPSQP7YPGDDAPVRDLIRFYRDLQRYLRWTRHRYCfiu-NH2 C221H323N64O60S1 4870 4871 
5.3F GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRYCflu.NH2 C220H321NMO60S1 4855 4855 
6.3F GPSQPTYPGDDAPVRDLRRFYRDLRRYLNWTRHRYCfuj-NH2 C220H322N68O60S1 4989 4903 
Name RJiodamine Labeled Sequences Formula Calc (+m/z) Meas 
sPPR KRhodGPSQPTYPGDDAPVEDLJRFYNDLQQYLNWTRHRY-NH2 C223H323N57O66S2 4907 4906 
4.2R KRhodGPSQPTYPGDDAPVRDL[RFYRDLQRYLNWTRHRY-NH2 C227H338N64O61S2 5008 5007 
4.3R KRhodGPSQPTYPGDDAPVEDLIRFYRDLRRYLNWTRHRY-NH2 C227H337N63O62S2 5005 5004 
5.2R KRh<xJGPSQPTYPGDDAPVRDLIRFYRDLQRYLRWTRHRY-NH2 C229H344N66O60S2 5046 5045 
5.3R <RhodGPSQPTYPGDDAPVRDLIRFYRDLRRYLNWTRHRY-NH2 C22SH342N66O60S2 5032 5031 
raf1 K^GRKKRRQRRRPPQY-NHZ C112H181N41O24S2 2550 2549 
Args" KRhodRRRRRRRR-NH2 C81H138N37O15S2 1934 1935 
Name Dexamethasone Labeled Sequences Formula Calc (+m/z) Meas 
appDex K^PSQFTYPGDDAPVEDURFYNDLQQYLNWTRHRY-NH2 C23LH326FLN55064SL 4828 4826 
4.2Dex KDb*GPSQPTYPGDDAPVRDLIRFYRDLQRYLNWTRHRY+IH2 C225H341F1N62O60S1 4926 4925 
4.3d®* KDe)tGPSQPTYPGDDAPVEDLiRFYRDLRRYLNWTRHRY-,jH2 C22SH34OFLN6L06LSL 4927 4926 
5.21*" KCKatGPSQPTYPGDDAPVRDURFYRDLQRYLRWTRHRY-KH2 C227H347FLN64059SL 4968 4968 
5.3De» K0e*GPSQPTYPGDDAPVRDLIRFYRDLRRYLNVVTRHRY-NH2 C226H345FLN64059SL 4954 4951 
ratf** KCtoGRKKRRQRRRPPQY-NH2 CXI0H182F1N39O23S1 2472 2472 
Arg8Dex K^RRRRRRRR-wre C79H141F1N35O14S1 1856 1857 




Cationic Miniature Proteins Reach 
The Cytoplasm By Escaping From 
Early Endosomes 
4.1 Background 
While there is little controversy that under certain conditions some 'cell-penetrating' pep­
tides can reach the cytoplasm of cells when added to the surrounding media, very little 
is considered accepted regarding how they do so. Some models for cytoplasmic access 
focus on direct plasma membrane permeation[ 175 ], perhaps aided by ion-pair guided 
diffusion[i2i, 120], the creation of inverse micelles[io6], membrane disruption[176, 125, 
142], or peptide self-association[i77] with the possible formation of pores[i78,179]. Oth­
ers advocate that peptides cannot cross the plasma membrane directly, but rather enter 
the cell through endocytic mechanisms[i8o]. Within this latter category, there has been 
much debate on the particular mechanism of endocytosis that is responsible for the in­
ternalization of the peptide into endosomes, however, by itself, the mechanism by which 
peptides arrive in endosomes sheds little light on how escape to the cytoplasm may oc­
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cur. Nevertheless, because the field has focused so much on this question, a brief review 
is pertinent. 
4.1.x Endocytic mechanisms of cationic peptide internalization 
The mechanistic understanding of endocytosis has become much more sophisticated 
in the last 10 years, but with this sophistication comes some confusion. Several re­
cent reviews have restored order through the reinstatement of (in some cases, previously 
developed[i8i]) experimental classification schemes[i82,183]. Three types general endo­
cytosis should be considered, the first two being phagocytosis and endocytosis mediated 
by clathrin or other coat proteins, the third being endocytosis by mechanisms that are 
not characteristic of the first two types. Whether nascent endosomes require dynamin 
activity to separate from the plasma membrane is also a useful feature for classification. 
Phagocytosis is generally a process limited to phagocytic cells (macrophages, den­
dritic cells, etc), is stimulated by the presence of large (i.e. > 0.5 [184]) particles, 
involves large changes in the distribution of the plasma membrane and is sensitive to 
cytochalasin-D, an inhibitor of actin polymerization. The process may involve dynamin, 
but its activity in this case is not due to membrane scission[i85], but rather its ability 
to recruit Rab5 to the phagocytic cup[i86, 187]. Because cationic miniature proteins are 
monomeric in solution, the role of phagocytosis is less important in these studies. 
Clathrin-mediated endocytosis is the major mechanism by which coated vesicles me­
diate endocytosis[i88, 189]. The clathrin coat is responsible for the initial deformation 
of the plasma membrane (a clathrin coated pit), and adaptor proteins recruit cargo into 
the growing bud. Transferrin is constitutively internalized by this pathway[i90, 137] 
as is activated epidermal growth factor receptor[139]. Fluorescently labeled versions of 
these proteins have been used as markers for vesicles originating from this pathway. 
Caveolin is a second protein localized to the interior leaflet of plasma membrane invagi­
nations, and appear to be the preferential site of entry for certain virus, including SV-
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4o[i9i/192,193], however its role in mediating endocytosis is being reevaluated[x94,195, 
196]. The other major coat proteins, COPI, COPII, are generally not active at the plasma 
membrane[i97]. Dynamin is absolutely required for clathrin mediated endocytosis[i98, 
199]. 
The study of endocytosis mechanisms capable of internalizing small particles with­
out the participation of clathrin is a growing field, with a rapidly increasing number of 
example pathways. In general, these pathways are induced by the inhibition of other 
pathways, making them more difficult to study. Mayor and Pagano[x82] suggest seg­
regating these pathways into those that relying on either RhoA, Cdc42, or Arf6, with 
the latter two being independent of dynamin activity. Importantly all three of these 
pathways seem to be sensitive to perturbations in the lipid C0ntent[200, 201], and in par­
ticular depletion of cholesterol[202], from the plasma membrane. Cholesterol depletion 
decreases (but does not completely inhibit) clathrin mediated endocytosis[203, 204]. 
Taken together the following experimental results are expected. Small cargo can en­
ter via mechanisms that are (1) dependent on dynamin, (2) dependent on dynamin and 
cholesterol, or (3) independent of dynamin (and dependent on cholesterol). Clathrin me­
diated endocytosis falls into the first catagory, and cargo taken up by this route should 
colocalize with fluorescently labeled transferrin or EGF. The latter two catagories segre­
gate RhoA and Arf6 pathway (2) from the Cdc42 pathway (3). Inhibition of dynamin 
clathrin mediated endocytosis may stimulate clathrin independent pathways, so this 
must be kept in mind when interpreting experimental findings. Peptide uptake may 
occur by one or several of these mechanisms. 
4.1.2 Trafficking of endocytosed peptide 
While there may be a multitude of internalization pathways, a great simplification is 
achieved by the finding that the itineraries of these pathways converge. In the case 
of clathrin, once the clathrin coated pit pinches off from the plasma membrane, the 
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phosphoinositides on the membrane are rapidly metabolized from phosphoinositol-4,5-
bisphosphoate (PI(4,5)P2) to PI3P, and leading to the recruitment of the small GTPase 
Rab5[205]. Rab5+ endosomes undergo homotypic fusion (i.e. fusion with other Rab5+ 
vesicles) to form the compartment known as the 'early endosome'[2o6, 207]. While 
the molecular events regarding Rab5 aquisition are less well understood in the case 
of other endocytic pathways, the cargo internalized by the Cdc42 dependent[2o8] and 
Arf-6 dependent[209, 210] pathways are delivered to Rab5+ vesicles. This has led to the 
current hypothesis that all endocytosed cargo is delivered to the Rabs+ early endocytic 
compartment. 
The early endosomal compartment serves as a cargo sorting station[i8i]. Sorting 
molecular cargo destined to return to the cell surface takes place by actin dependent 
spatial segregation into specialized domains within the early endosomes[2ii]. These 
domains then bud off to form tubular/vesicular structures that fuse with the plasma 
membrane, recycling the cargo back to the cell surface. In the absence of material being 
recycled to the plasma membrane, early endosomes exchange Rab5 for Rab7[2i2, 2x3] 
forming 'late endosomes', which then fuse with lysosomes[x40, 214]. Cargo destined for 
other cellular locales travel through late endosomes, but the mechanism by which they 
are selectively delivered to their destinations is not understood. 
4.1.3 Reaching the cytoplasm 
As stated above cationic miniature proteins may reach the cytoplasm by crossing the 
plasma membrane directly or by escape from an intracellular vesicle. The ability of 
cationic miniature protein 5.3 to access the cytoplasm in the absence of endocytosis 
would strongly suggest the ability to cross the plasma membrane directly. In the absence 
of this ability, the question arises, from which endosomal population does 5.3 escape? It 
would also be useful to compare the identify to the answer for 5.3 to the vesicles from 
which other peptides can escape to the cytoplasm. 
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The molecular character of endosomes changes with their maturation. As endosomes 
mature, they increase in byouant densitiy, acquire different lipid and protein compo­
nents, and increase their lumenal concentration of acid. The ability to reach the cyto­
plasm may be induced by one or more of these bulk physicochemical properties, or it 
may be due to the recruitment of a protein ligand that facilitates the specific exist of 5.3 
or another cell penetrating peptide. 
4.2 Results 
Three limiting models have been invoked to explain the trafficking of cationic peptides 
and proteins across the plasma membrane and into the cytosol. The first posits that high 
local concentrations of positively charged peptides cause membrane disruption[i25]. We 
previously confirmed that the integrity of the cell membrane is not disrupted in the 
presence of 1 pM cationic miniature protein (see Fig. 3.4, on page 46). A second model 
invokes ion-pair guided passive membrane diffusion[i2i, X20]; while the third model 
invokes endocytosis followed by endosomal release (vide infra). We sought to distinguish 
between remaining models in two ways. First, we asked whether rhodamine labeled 
cationic miniature proteins are taken up into the same vesicles as transferrin, a classic 
marker of endocytosis; finally, we asked whether inhibitors of endocytosis block the 
uptake of these same molecules. 
4.2.1 Cationic miniature proteins traffic first into endocytic vesicles 
To distinguish between the two remaining mechanisms of uptake, we began by treating 
HeLa cells with rhodamine labeled miniature proteins in the presence of AlexaFluor-488-
transferrin (Tf488) and quantifying colocalized fluorescence using confocal microscopy 
(Fig. 4-x). Transferrin, a protein whose trafficking serves as a predominant model for 
the study of endocytosis[x83] is rapidly internalized from the plasma membrane into 
endocytic vesicles[x39, 2x5]. Thus, the localization of rhodamine labeled miniature pro­
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tein in transferrin positive vesicles would suggest that those vesicles were endocytic in 
nature, originating from the plasma membrane. We incubated HeLa cells at 37°C for 30 
min with Tf488 (25 nM) and 1 }iM 4.2s, 4.3s, 5.2s, 5.3^ TatR or Arg8R. The cells were 
washed with media, and labeled with Hoescht (to visualize DNA). Images were then 
obtained by spinning disk confocal microscopy without fixing the cells in order to avoid 
the possible release of peptide from intracellular vesicles that can occur following fixa­
tion by treatment with formaldehyde or methanol[i27, 140]. As expected, when excited 
with 488 nm light, HeLa cells treated with Tf488 showed small, discrete areas of green 
fluorescent signal distributed throughout the cytosol. Addition of aPPR led to little or no 
red fluorescent signal and little or no change in the green signal due to Tf488, confirming 
earlier results (Fig. 3.3) that aPPR is not taken up efficiently by HeLa cells. In contrast, 
HeLa cells treated with 1 jiM 4-2R, 4.3s, 5.2^, 5.3s, TatR or Arg8R showed bright red flu­
orescent puncta throughout the cytosol in a distribution that overlapped with the green 
fluorescence seen with Tf488 and at levels that qualitatively reproduce the trends detected 
by flow cytometry (Fig. 3.3). With one exception, the fluorescent signal from Tf488 and 
the rhodamine labeled molecules were highly correlated (R/m,Rhodamine - 0.619 - 0.779), 
suggesting that transferrin and cationic miniature proteins/peptides 4.2s, 5.2R, 5.3R, TatR 
or Arg8R are taken up into the same endocytic compartments. Miniature protein 4.3s is 
also taken up into a transferrin+ compartment, but the correlation (R^ss,Rhodamine = 0.493) 
is lower, possibly because the uptake is low (Fig.3.3). 
To assess whether peptide trafficking is affected by fluorophore identity, we directly 
compared the intracellular distributions of rhodamine and fluorescein tagged versions 
of aPP, 4.2, 4.3, 5.2, and 5.3, as well as Tat and Arg8 (Fig. 4.2). While HeLa cells treated 
with 1 fiM aPPF and aPPR exhibited little or no fluorescence, those treated simultaneously 
with rhodamine and fluorescein labeled variants of either 4.2, 4.3, 5.2, or 5.3 contained 
bright puncta with substantial correlation between the rhodamine and fluorescein sig­
nal. Overlap was also observed after treatment with rhodamine and fluorescein labeled 
versions of Tat as well as Arg8. The per-pixel correlation between rhodamine and fluo-
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Figure 4.1: Colocalization of alexaFluor-488-transferrin Tf488 with rhodamine labeled miniature proteins. Perfect colocalization is 
characterized by a Pearson's R value (R) equal to 1, while R values near o represent little or no colocalization. The correlation value 
observed when cells were treated with both Tf488 and alexa-fluor-546-transferrin is 0.905. Rhodamine labeled cationic miniature 
proteins and alexa-546-transferrin are shown in red, Tf488 is shown in green, Hoescht 33342 (nucleus) is shown in blue. 
rescein intensities was found to be highly significant for all cationic miniature proteins 
(R > 0.68) as well as for Arg8 (R = 0.756), and Tat (R — 0.631). These results confirm 
that these molecules traffic to similar locations in the cell regardless of fluorescent label 
location or identity, and recapitulate the similarity in the quantitative analysis of peptide 
uptake above (Fig. 3.3, on page 43). 
Next, we asked whether small molecules known to inhibit endocytosis would block 
the uptake of rhodamine labeled miniature proteins. Dynasore[2i6]is an inhibitor of the 
GTPase dynamin, a protein whose activity is required for clathrin mediated endocytosis 
(CME)[2i7], pinocytosis[2i8, 219], as well as caveolin mediated endocytosis[i9i]. De­
pleting cellular cholesterol through treatment with methyl-/3-cyclodextrin (M/5CD) also 
inhibits these three processes[i9i, 204]. Endocytic pathways that continue despite loss of 
dynamin activity and depletion of cellular cholesterol[2i7] depend on actin remodeling, 
a process inhibited by addition of N-ethyl-isopropyl amiloride (EIPA)[22o]. Addition of 
EIPA does not affect the uptake of CME ligands such as transferrin[22o]. To test the in­
volvement of these pathways in the uptake of cationic miniature proteins, we pretreated 
HeLa cells for 30 min with 80 dynasore, 5 mM Mj6CD or 50 }iM. EIPA before adding 
1 jiM 4.2R, 4-3R, 5-2r, 5-3r, TatR, Arg8R or aPPR. Peptide uptake was allowed to pro­
ceed for 30 min at 37°C in the presence of inhibitor; the cells were subsequently washed 
and visualized by confocal microscopy (Fig. 4.3). The presence of dynasore completely 
blocked the uptake of 4~2R, 4.3s, 5.zR, 5-3R, as well as TatR and Arg8R; suggesting these 
molecules are taken up in a dynamin-dependent fashion. M/5CD completely blocked the 
uptake of 4-2R, 4.3s, 5-2R, 5.3^ and TatR, but not Arg8R. Surprisingly cellular uptake of 
Arg8R was increased in the presence of M/3CD, leading to diffuse fluorescence through­
out the cytosol, a pattern not seen in the absence of the inhibitor (see Fig. 4.1 and Fig. 
4.3). The presence of EIPA also dramatically reduced the uptake of cationic miniature 
proteins, as well as TatR and Arg8R. The results with Arg8R notwithstanding, these 
data support the contribution of various endocytic pathways to the uptake of cationic 
miniature proteins and peptides, and not a model based on passive diffusion. 
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Figure 4.2: Colocalization of rhodamine and fluorescein labeled cationic miniature pro­
teins. HeLa cells were treated with 1 rhodamine and fluorescein cationic miniature 
protein or peptide for 30 min at 37°C before being washed and imaged using confocal 
microscopy. HeLa cells treated with aPPR and aPPF show low fluorescence. The remain­
ing molecules show high fluorescence, and molecules sharing the same sequence (but 
different labels) show high degrees of overlap, with R > 0.68. Scale bars are 20 }im. 
5.3F + 5.3R TatF + TatR Arg8F + Arg8R 
lOl 
Figure 4.3: Uptake of cationic miniature proteins is inhibited by treatments the block endocytosis. HeLa cells were preincubated 
in media (ctrl) or media containing 80 pM dynasore, 5 mM M/3CD, or 50 pM EIPA before the addition of 1 jiM of the indicated 
rhodamine labeled peptide or Tf488 for 30 min. Cells were then washed, labeled with Hoescht (nucleus, blue) and visualized 
without fixation by confocal microscopy. 
4.2.2 Cytoplasmic access requires active endocytosis 
In many cases, cationic proteins/polypeptides showing cellular uptake by flow cytom­
etry remain trapped in endosomes and fail to reach the cytosol[i28]. This raises the 
possibility that cytoplasmic access does not depend on endosomal escape, but rather 
direct diffusion through the plasma membrane. Having shown that cationic miniature 
proteins enter endocytic vesicles, we sought to test whether their cytoplasmic accumu­
lation was the result of endosomal escape or diffusion acros the plasma membrane. We 
were mindful of the fact that exchanging the fluorescent rhodamine label for dexametha­
sone could alter the physical properties of the molecule as well as the manner in which 
it trafficked in cells. Because inhibitors of endocytosis prevented the entry of cationic 
miniature proteins into endocytic vesicles, we wondered whether treatment with these 
same inhibitors would also block cytoplasmic access. Such a finding would support the 
conclusion that diffusion across the plasma membrane, in the absence of active endocy­
tosis, is an ineffective route to the cytoplasm. 
Having identified 5.3°" as a cationic miniature protein showing significant cytoplas­
mic access, and hence significant increases the nuclear-to-cytoplasmic translocation ratio 
of GR-GFP, we set out to determine the pathway by which cytosolic access was achieved. 
Having previously shown that pharmacologically inhibiting endocytosis blocked uptake 
of 5-3r (Fig. on the preceding page), we first asked whether inhibiting endocytosis in 
the same manner also blocked the ability of 5.3°®* to reach the cytoplasm. HeLa cells 
transfected with GR-GFP were pre-treated for 30 min with the aforementioned inhibitors 
prior to the addition of either 1 jiM dexamethasone (positive control), aPPDex (negative 
control), 5.3°", TaiPex, or Arg8Dex for 30 min at 37°C (Fig. 6). The cells were then washed 
and imaged to measure the translocation ratio. None of the endocytosis inhibitors altered 
the GR-GFP translocation ratio calculated for cells treated with aPPDex, which remained 
low after treatment. However, all three inhibitors reduced, to background levels, the 
GR-GFP translocation ratio calculated after treatment with 5.3°", 1atDex, or Arg8Dex. 
103 
Neither EIPA nor dynasore altered the increase in the translocation ratio calculated after 
treatment with dexamethasone, but M/5CD reduced this increase by 53%. This effect may 
be due to direct complexation of free dexamethasone by M/3CD[22i]. 
Because endosomes contain very small volumes, their internal pH is exquisitely sen­
sitive to the activity of proton pumps, including V-ATPases; acidification begins almost 
immediately upon scission of endosomes from the plasma membrane, as their lumen 
no longer communicates with the surrounding media. Bafilomycin is a potent inhibitor 
of the V-type ATPase[222, 223], and its addition to culture media prevents endosomal 
acidification[i23, 222]. To ask whether low vesicular pH was required for cytoplasmic 
escape, we pretreated HeLa cells expressing GR-GFP with 200 nM bafilomycin for 1 h be­
fore exposure to 1 jiM dexamethasone, 5.3°", TatDex, Arg8Dex or aPPDex (Fig. on the next 
paged). Treatment with bafilomycin did not alter the effect of dexamethasone or aPPDex 
on the translocation ratio, consistent with the understanding that dexamethasone freely 
diffuses into the cytoplasm and that aPPDex never enters endocytic vesicles. The increase 
in translocation ratio seen after cells were exposed to 5-3Dex, however, was completely 
blocked by the presence of bafilomycin (p — 1.4 x 10~n). Bafilomycin also blocked the 
increase in translocation ratio seen after treatment with TatDex (p = 5.3 x 10-n) or 
Arg8Dex (p = 8.2 x 10~6). Thus, while 5-3Dex, and to a slightly lesser extent TatDex and 
Arg8Dex, induce robust translocation of GR-GFP, they fail to do so in the absence of en-
dosome acidification. This finding further supports the model that these molecules do 
not penetrate the plasma membrane directly, but rather escape to the cytoplasm from 
acidified endocytic vesicles. 
4.2.3 Escape to the Cytoplasm from Early Endosomes 
Cell surface protein and lipids are constitutively internalized to form cytoplasmic en­
dosomes. One canonical route, typified by transferrin and its receptor, is internaliza­











Figure 4.4: Inhibition of endocytosis blocks cytoplasmic access. Translocation of GR-GFP 
after treatment with 1 pM Dex, 5-3Dex, TatDex, Arg8Dex, or aPPDex in the presence 
(gray) or absence (black) of various small molecule inhibitors. Inhibitors of endocyto­
sis included (a) 80 pM dynasore, (b) 5 mM methyl-B-cyclodextran (MBCD), (c) 50 jiM 
EEPA. (d) Translocation ratio after treatment with cationic miniature proteins and 200 
nM bafilomycin . *p < 0.05; * * *p < 0.001; ANOVA with Bonferroni post test. 
105 
goes rapid modification resulting in dissociation of the clathrin coat and acquisition 
of Rab5[2i5, 205]. The presence of Rab5 recruits cellular factors required for vesicle fu­
sion and maturation, including the phosphotidyl inositol 3-OH kinase, Vps34 [224]. The 
resulting early endocytic compartment mixes via homotypic fusion with other Rab5+ 
vesicles [225, 226], and delivers cargo to other cellular locales through the budding off 
of transport vesicles[2ii] or Rab conversion[2i2, 2x3]. While transferrin is recycled to 
the cell surface, other cargo, including low density lipoprotein, epidermal growth factor 
(EGF)[227, 228] and several types of viruses[i40, 229, 196] are delivered to late endo­
somes, marked by Rab7, for eventual degradation in lysosomes[i40, 227]. To character­
ize the intracellular route taken by cationic miniature proteins to the cytoplasm, we first 
looked for overlap of 5.3R, TatR and Arg8R with markers of endocytic uptake and GFP 
tagged Rab proteins. Then, using small molecule inhibitors and dominant negative Rab 
variants, we tested the cellular activities required for 5.3°", TatDex and Arg8Dex to enter 
the cytoplasm. 
To characterize the pathway by which 5.3°^ moves from the exterior of the cell to 
the cytosol, we began with the observation that 5.3^ colocalizes with transferrin (Fig. 
4.1), a substrate known to internalize into Rab5+ vesicles[2X5]. To ask whether 5.3s 
was also present in Rab5+ vesicles, HeLa cells were transfected with GFP-Rab5 and 
treated for 30 min with 1 jiM 5.3^. When these cells were examined by confocal mi­
croscopy, 66% of the rhodamine signal overlapped with the signal from GFP-Rab5, con­
firming that 5-3R is present in Rab5+ vesicles (Fig. 4.5a). To test whether trafficking of 
5-3R could be arrested at the Rab5 stage, we overexpressed a GTPase-inactive Rab5 mu­
tant, Rab5(379L[225], that blocks delivery of cargo to late endosomes and arrests vesicle 
maturation[2i2, 229, 140, 225]. Observation of HeLa cells overexpressing Rab5®79L-GFP 
and treated with 5.3s showed that nearly all (99%) of the miniature protein localized to 
enlarged GFP+ endosomes (Fig. 4.5b), suggesting that arresting early endosome matu­
ration also arrests trafficking of 5.3** at the Rab5+ stage. Similar results were seen with 
Arg8R and TatR (Fig 4-5d-i). Because Rab5 vesicles rapidly deliver their cargo to down­
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stream vesicles[2i2], we also evaluated colocalization of 5.3s with Rab7-GFP (Fig. 4.5c). 
HeLa cells transfected with Raby-GFP and treated with 5.3s as above, showed that a 
large fraction (87%) of the rhodamine signal was located in the Rab7-GFP compartment, 
confirming that 5.3s enters both early (Rab5+) and late (Rab7+) endosomes. We found 
no overlap between 5.3s, TatR, or Arg8R and galT-GFP[23o, 231], a marker of the golgi 
(see Fig. 4.6). 
To ask whether 5.3 uses intracellular trafficking pathways that are distinct from the 
pathway used by miniature proteins that do not reach the cytoplasm, we directly com­
pared the intracellular trafficking of 5.3 to other cationic miniature proteins, as well as 
to Tat and Arg8 (Fig. 4.7). Examiniation of HeLa cells treated simultaneously with x 
5.3s and 4.2F, 4.3^ or 5.2^ showed strong correlations (R > 0.68) between the fluores­
cence intensity due to the two miniature proteins present in the sample. There was also 
strong correlation between the fluorescence intensity of 5-3F and Arg8R when applied to 
the same sample (R = 0.631), suggesting that 4.2, 4.3, 5.2, 5.3, and Arg8, all occupy the 
same or similar sets of intracellular compartments. This conclusion was also supported 
by the observation that >90% of total integrated fluorescence from 5.3 overlapped with 
the other miniature protein or peptide present in the sample. 
The case was different for the comparison of 5.3 s and TatF: the correlation between 
the per-pixel fluorescence intensities was lower (R = 0.554). Substantial amounts of 
green fluorescence from TatF remained visible on the cell surface (arrowheads, Fig. 4-7d), 
whereas no red fluorescence from 5.3^ was visible at these same locations. In addition, 
there is a noticeable absence of the small fluorescent vesicles containing 5.3 from the 
zoomed image that appear in images from the other samples. In contrast, small vesicles 
are present in the image field, however they contain only TatF and not 5.3s. Conse­
quently, only 32.1% of the green fluorescence originates from locations occupied by 5-3R, 
whereas 92.1% of the red fuorescence originates from locations occupied by TatF. Thus, 
the addition of TatF reduces the presence of 5.3s is small (but not large) endocytic vesi­
cles. This may be due to competition for a limited number of binding sites on the cell 
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Figure 4.5: Miniature protein 5.3s enters via endocytosis into Rab5+ vesicles before traf­
ficking to Rab7+ vesicles. HeLa cells transfected with the indicated GFP fusion protein 
(panels a - i) were treated with 1 pM 5.3R (panels a-c), TatR (panels d-f) or Arg8R (panels 
g-i) before being washed and imaged by confocal microscopy. Colocalization of 5-3R, 
TatR and Arg8R with Rab5-GFP is moderate (panels a, d, g) but can be increased by ar­
resting Rab5 maturation via overexpression of Rab5®79L-GFP. (panels b, e, h). 5-3R, TatR 
and Arg8R are delivered to Rab7+ endosomes (panels c, f, i). 
surface. 
These data suggest that during the first 30 min after treatment, 5-3R, TatR, and Arg8R 
follow a shared path through Rab5+ and then Rab7+ vesicles and provide a starting point 
to ask which, if any, of these trafficking events are required to reach the cytoplasm. 
To identify the point or points along the endocytic pathway at which these three 
molecules escape to the cytsosol, we blocked vesicle maturation by overexpressing Rab5®79L-
GFP and assayed for GR activation following treatment with 5-3Dex, TatDex, and Arg8Dex 
(Fig. 4.8). In this setting cytosolic localization was assessed via dual color microscopy 
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Figure 4.6: Cell permeable cationic miniature proteins are not found within the Golgi. 
HeLa cells were transfected with galactosyltransferase tagged to GFP, (a marker of the 
Golgi) before plating in 96 well glass bottom plates and growth overnight. The me­
dia was replaced with HKR buffer containing (a) x pM 5.3s, (b) TatR or (c) Arg8R and 
incubated at 37°C for 30 min, after which the cells were washed and imaged. No red flu­
orescence (arrowheads) was found within Golgi areas identified by high levels of green 
fluorescence. The fraction of rhodamine signal overlapping green signal (R G G) within 
the golgi region (boxed in white) is low (less than 0.1). Selected vesicles showing red flu­
orescence are indicated with white arrowheads. None overlap with green fluorescence 
signal. Scale bars are 20 ^m. 
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using an orthogonally labeled GR-mCherry. This experiment allowed us to ask whether 
inhibiting Rab5 vesicle maturation also blocked the ability of 5.3Dex, TatDex, and Arg8De* 
to reach the cytosol. Control experiments reveals that the observed translocation ratio 
of untreated HeLa cells expressing Rab5G79L-GFP or Rab5-GFP and GR-mCherry is near 
unity, as expected (Fig. 4.8a). This remained unchanged after treatment 30 min with 1 
aPPDex (translocation ratio = 1.32 ± 0.07, 1.25 ± 0.04, respectively); however, these 
values increased substantially after treatment for 30 min with 1 jiM of dexamethasone 
(Rab5-GFP expressing cells, 2.24 =t 0.15; Rab5Q79L-GFP expressing cells, 2.45 ± 0.21; Fig. 
4.8a). Treatment with 5.3°** results in translocation ratios that are similar regardless of 
whether cells were transfected with GTPase-inactive Rab^79L or wild-type Rab5- Analo­
gous findings are observed when cells were treated with Arg8Dex: the translocation ratios 
calculated are independent of Rab5 activity (1.59 ± 0.12 vs 1.60 ± 0.09). By contrast, over-
expression of Rab5Q79L blocked the ability of TatDex to reach the cytoplasm (1.26 ± 0.03 
vs 1.57 ± 0.04, p = 0.0057) indicating that Tat escapes inefficiently from Rab5+ vesicles. 
These findings suggest that 5.3 and Arg8 escape to the cytoplasm from Rab5+ vesicles, 
but Tat escapes from later along the endocytic pathway. 
To confirm the finding that Rab5 vesicle maturation is dispensable for cytoplas­
mic access, we treated cells with 200 nM wortmannin, a pharmacologic inhibitor of 
phosphoinositide-3-OH kinase (PI3K) and an agent widely used to block the maturation 
Figure 4.7 (following page): Cationic miniature protein 5.3 shares an overlapping intracel­
lular distribution with other cationic miniature proteins, Tat and Arg8. HeLa cells treated 
with 5.3K and (a) 4.2F, (b) 4.3^ (c) 5.2F, or (d) TatF labeled cationic miniature proteins 
show high degrees of overlap. A single confocal slice is shown (left). Zoomed images 
(boxed white area on the wide-field image) are shown for individual fluorescence chan­
nels and an overlay (right), (e) 5»3F also shows substantial overlap with Arg8R. Pearson's 
correlation coefficient (R) calculated between red and green pixel intensities is shown. 
The correlation is high (R > 0.63) for all cases except for 5.3s and TatF (R — 0.554). 
In this case, there is an absence of fluorescence from 5.3 in small vesicles that is seen 
in the other images. TatF also shows fluorescence remaining on the plasma membrane 
(arrowheads), whereas 5.3s does not. Calculation of overlap using Mander's coefficient 
reveals that 92.1% of the red fluorescence overlaps green, whereas only 32.1% of green 
fluorescence overlaps red. 
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Figure 4.8: Cationic miniature protein 5.3 escapes from early endosomes. (a) Transfection 
with Rab5Q79L-GFP does not block the increase of translocation ratio seen after treatment 
with dexamethasone, 5.3°", or Arg8De*, but decreases the translocation ratio measured 
after treatment with Tat0" (p = 0.005). (b) HeLa cells treated with 200 nM wortmannin 
for 30 min before treatment with 1 fiM dexamethasone, 5.3°", TatDev, Arg8°", or aPPDex 
for 30 additional min in the continued presence of the drug. Wortmannin decreased the 
translocation ratio measured after treatment with TatDe* {p = 8.1 x 10~15 ) and Arg8Dev 
(p — 2.3 x 10-5). The effect of wortmannin on the distribution of Rab5 is assessed by 
confocal microscopy, (c) Rab5-GFP expressing HeLa cell, (d) Rab5-GFP expressing HeLa 
cell in the presence of 200 nM wortmannin for 30 min. ns, not significant; *p < 0.05; 
* * p < 0.01; * * * p < 0.001, ANOVA with Bonferroni post test. 
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of Rab5+ vesicles[226, 224]. This concentration of wortmannin was sufficient to induce 
tubulation and enlargement of Rab5+ vesicles (Fig. 4-8d), observations consistent with 
the inhibition of their maturation. As can be seen in Fig. 4.8b, this treatment blocked the 
increase in translocation ratio seen after treatment with TatDex and Arg8Dex by 72% and 
77%, respectively. In contrast, the translocation ratio seen after treatment with 5-3Dex in 
the presence or absence of wortmannin was similar (2.36 ± 0.08 vs 2.76 ± 0.10), confirm­
ing the ability of 5.3°" to escape from Rab5+ vesicles. The difference between results 
obtained after wortmannin treatment and overexpression of Rab5^79L-GFP may be ex­
plained by recent results that wortmannin may arrest vesicles in an early Rab5+ state, 
prior to the recruitment of Rab5 effectors[226, 205]. Taken together, these data suggest 
that arresting vesicle maturation inhibits the cytosolic access of both TatDex and Arg8Dex, 
but that 5.3°" is capable of leaving these earliest vesicles and reaching the cytoplasm. 
4.2.4 Arginine topology affects protonation state transitions during endocytic 
acidification. 
While the above data suggests that cationic miniature protein 5.3 can access the cyto­
plasm by escaping from Rab5+ vesicles, the chemical basis for why this sequence pos­
sesses this property is unknown. Comparisons between the sequence of 5.3, a miniature 
protein that is cell penetrating, and the sequences of aPP, 4.2, 4.3, and 5.2, miniature pro­
teins which do not enter the cytoplasm, provide an opportunity to examine the effects 
of sequence changes on side-chain protonation states and structure. Data presented in 
figure 3.2 show that arginine containing variants of miniature proteins have similar cir­
cular dichroism spectra, suggesting a conserved fold. Large scale structural differences 
among these miniature proteins are thus unlikely to be the basis for their differing prop­
erties. Furthermore, the number of arginine residues alone, 5 versus 4, is not sufficient 
to explain the differences in cell permeability. 
We wondered whether side-chain protonation states could be altered by changes in 
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neighboring amino acids, and whether these differences may explain differences in the 
ability to access to the cytoplasm. Importantly, for the guanidinium side chain group 
of arginine pKa « 12, indicating that this side chain is nearly always protonated in the 
buffered (pH =7.4) aqueous environment surrounding the cell, and shifting to the more 
acidic environment of the endosome is unlikely to alter this state. Therefore we instead 
looked to see if there were acidic side chains whose pKa was shifted such that in they 
would undergo a protonation state transition within the endosome. 
To begin, we submitted the amino acid sequence of aPP, 4.2, 4.3, 5.2 and 5.3 to 
PEPSTR[232] an online structural prediction tool that returns predicted structures based 
on sequence using hidden Markov modeling. These structures were essentially identical 
to the X-ray structure of aPP[i29] bolstering our expectation that these sequences fold 
in a similar manner. Repeating this structural prediction using another method based 
on neural networks (available online at Geno3D[233]) showed the ten lowest energy pre­
dicted conformations of 5.3 based on sequence had an overall RMSD of 0.49A from aPP, 
providing further reassurange that the backbone fold is maintained between these two 
miniature proteins. We compared the sequences of aPP and 5.3 and identified residues 
that are altered in 5.3. These are GIU15, Asn22, Gln25, and Gln26, while Argi9 remains 
unchanged. Finally, we used the software tool PKATOOL[234], an algorithm that predicts 
amino acid pKa based on three dimentional structure, to search for interactions that al­
ter side-chain pKa in aPP and 5.3 using the published X-ray structure of.aPP and the 
predicted structure of 5.3 obtained from PEPSTR. First, we analyzed the side-chain in­
teractions within aPP looking for interactions that would be destroyed by the arginine 
substitutions in 5.3. Second, we asked whether any new interactions would be created 
by the arginine subsitutions within 5.3. Third, drawing on our experimental evidence 
that blocking endosomal acidification blocks cytoplasmic access, we asked which, if any, 
residues within 5.3 would be predicted to undergo a protonation state transition from 
pH 7.4 (the pH of the extracellular medium) to pH 4 (the pH of the lysosome). This 
range is likely overly broad as our data supports a model in which 5.3 can escape from 
114 
the less acidic early endosome. 
Our analysis (shown in Fig. 4.9) reveals that within aPP, GIU15 interacts strongly 
with both Aspi6 (kT/e = 1.003) and Argi9 (kT/e — -1.078). In fact, these interaction 
energies are the second and third largest in magnitude within the molecule, and two 
of only three interactions with |fcT/e| > 1. These residues are also positioned closely in 
space, with Glui5-Aspi6 side chains within 2.8A of each other, and Glui5-Argi9 distance 
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to be ~3-2A (Fig. 4.9a). Using PKATOOL, the charge state of each of these amino acids 
is shown as a function of pH in figure 4.9b. Both GIU15 and Aspi6 begin to undergo 
protonation as the pH drops below 7. One might suspect that the close apposition of 
the glutamic acid with the basic arginine stabilizes this amino acid in the deprotonated 
state, however when a third titratable species is added close by (Aspi6) the overall effect 
is less obvious. Modeling this effect with the PKATOOL shows a reciporical relationship 
in pKa purterbation. That is to say, that modeling an increased pKa of Aspi6, results in 
a decreased pKa of GIU15, and vice versa (Fig. 4.9c). Because amino-acid side chains far 
from their equilibrium may not behave according to Henderson-Hasselbalch transitions, 
the concept of pKi/2 is introduced as the pH at which the acid is half protonated. This 
value is similar to the value of the pKa but does not imply knowledge of protonation 
state occupancy at other pH conditions, because, especially in protein, other acid-base 
transitions may be taking place. The pK\/2 of Aspi6 is predicted to be at pH = 4.2, 
changing GIU15 -» Arg (i.e. modeling this residue as a base with pKa = 13, see figure 
4-9d) changes this value to pKi/2 = 3.4, indicating stabilization of the deprotonated 
species. Further changing Asn22 -» Arg (shown in gray) increases this difference, with 
the predicted pK 1/2 = 3.1. Thus arginine substitutions at residues 15 and 22 is likely to 
stabilize Aspi6 in the deprotonated state giving 5.3 a decreased positive charge at similar 
pH than would be present with an alternative spatial arrangement of charges. 
Next we examined the modeled structure of 5.3 obtained from PEPSTR. Interaction 
energies examined in PKATOOL revealed no new interactions with energies |fcT/e| > 1. 
The energies of interaction of Glui5-Aspi6 and Glui5-Argi9 previously seen were now 
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Figure 4.9: Modeling arginine interactions reveals subtly perturbed side-chain pK„'s, 
but these interactions stabilize deprotonated carboxylic acids, making protonation state 
transitions less likely to occur during endosomal acidification, (a) X-ray structure (PDB 
code lPPT) showing Aspi6, GIU15, and Arg 19 are closely approximated in space, (b) 
Modeled pH titration of Aspi6, GIU15, and Argi9 with color coding as shown in panel 
a, Aspi6 and GIU15 become protonated (and neutrally charged) as the pH drops from 
7 to 3. (c) The pK„ of GIU15 and Aspi6 are linked. GIU15 as more basic (shift shown 
by green arrow) stabilizes the deprotonated form of Asp 16 resulting in a lower modeled 
pKa (blue arrow). The modeled pKa of Argi9 remains unchanged, (d) Modeling GIU15 
and Asn22 as arginine residues is predicted to increase the acidity of Asp 16 and Argi9-
(e) His34 is the only residue predicted to become protonated within the early endosome. 
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decreased bewteen both Argi5 and Aspi6 (kT /e  = —0.252) as well as Argi5 and Argi.9 
(kT/e = 0.347). Decreasing the threshold for significant interactions |JcT/e| > 0.5 re­
vealed a continued interaction between Asp23 and Aspi6 whose strength is increased 
slightly from kT/e = 0.402 to kT/e = 0.501, as well as new interactions present be­
tween Arg25 and Tyr2i (kT/e = —0.504) as well as Arg26 and Asp23 (kT/e = —0.578). 
Searching for side-chains whose pKa's were perturbed by molecular interactions revealed 
that residues Argi.5, Aspi6, Argi9, Asp23, and Arg25 showed the greatest deviation of 
\ApKa\ > 0.5, while Tyr2i and Arg26 were perturbed less. Given that cationic miniature 
protein 5.3 can escape from the moderatly acidic early endosome, we searched for effects 
that would shift protonation state changes seen under acidic conditions to a more neutral 
pH range. Removing the influence of Argi9 lead to a decrease in the predicted acidity 
of Aspi6 from pKi/2 = 3.6 to pKi/2 = 4.2 suggesting that Argi9 stabilizes the deproto­
nated form of Asp 16. A similar effect is seen on Asp23, where removing Argi9 resulted 
in a predicted shift of pKi/2 = 3.9 to pKi/2 = 4.2. Removing either or both Arg25 and 
Arg26 also was predicted to destabilize Aspi6 and Asp23, though the predicted effect is 
smaller. These results suggest that stabilization of the deprotonated forms of Aspi6 or 
Asp23 is improved in the presence of the additional arginine residues, and that arginine 
leads to a more acidic transition rather than one that would take place at a more neutral 
pH. 
Finally, we asked whether any side chains of 5.3 would be predicted to undergo 
signficant protonation state changes between pH 8 and pH 5, roughly the pH transition 
that takes place between the extracellular space and the late endosomal compartment. 
The only residue of 5.3 that is predicted to undergo a protonation state transition within 
this range is His34 with a predicted pK\/2 = 5.9, which transitions from a neutral to a 
positively charged species (Fig. 4-9e). The interaction energy prediction matrix shows 
that this residue possesses only minimal interactions with other residues. Removing 
either Argi.5, 19, 22, 25, 26, or 33 resulted in increases in the calculated pKt/2 from -5.9 
to 6.0-6.1. While this difference is small it is consistent with an intuitive model in which 
117 
the presence of each of additional arginines destabilizes the protonated form of the side 
chain. His34 in the context of aPP is predicted to have a pKi/2 = 6.0. 
None of the above outlined predictions identify a new protonation state transition 
that is predicted to take place during acidification of the early endosome. This analysis 
views miniature proteins aPP and 5.3 in isolation, without taking into account known 
interactions with cellular proteins and proteoglycans. Based on this limited view, my 
analysis is unable to identify particular side chain protonation states that predicted to be 
altered between the extracellular pHj environment and the and more acidic endosomal 
environment, any residue within 5.3 whose transition is predicted to take place in the 
early endosome where the analogus residue in aPP is not also predicted to do the same. 
Of course, this does not exclude the possibility that such a change does, in fact, take place 
- interactions between either aPP or 5.3 with cellular proteins could alter the individual 
pKa s of the peptide side chains, leading to the formation of a critical protonated species 
that is able to escape from the endosome. Alternatively, the activity of the endosomal 
V-type ATPase could be required for escape for a separate reason. The activity of V-type 
ATPase contributes to a trans-membrane electrochemical gradient, leads to the influx of 
chloride, across chloride channels, and participates in numerous other physiologic ion 
movements. One or several of these features could regulate the activity an endosomal 
protein required for the cytoplasmic escape of cationic miniature proteins. 
4.3 Discussion 
Coupling a new assay for cytosolic localization with live cell corifocal microscopy al­
lowed us to compare the structural determinants required for efficient endocytosis with 
those required for cytoplasmic escape. This comparison revealed that contrasting struc­
tural determinants control endocytic uptake and endosomal release. Uptake is favored 
by clustered a-helical arginine side chains, whereas release requires a more dispersed 
arginine array. 
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I found that inhibiting endocytosis blocked the ability of miniature protein 5.3, Tat, 
and Arg8 to reach the cytoplasm. This finding strongly suggests against their ability to 
penetrate the plasma membrane directly, and argues for a model in which their pathway 
to the cytoplasm to begin with internalization into cellular vesicles followed by escape to 
the cytosol. I found that the internalization of 4.2,4.3,5.2,5.3 as well as Tat and Arg8 was 
dependent on the activity of dynamin, and was sensitive to cholesterol depletion. My 
finding that the small molecule EIPA blocked internalization suggests that reorganization 
of the actin cytoskeleton is also involved in the internalization of these miniature proteins 
and peptides. Internalization by pinocytic pathways such as the RhoA and Arf6 pathway 
and clathrin mediated endocytosis are consistent with these observations. Accordingly, 
after 30 minutes of internalization I observed the presence 5.3s, TatR and Arg8R within 
Rab5+ vesicles, followed by Rab7+ vesicles. 
Previous studies on the trafficking of various viruses[3i] and clostridial toxins, such 
as botulinum and anthrax toxin[32], have revealed multiple potential release points along 
the endocytic pathway. JC virus[229], SV40I196], and HIV-i[235], all require transport 
beyond early Rab5+ endosomes to gain cytosolic access. Requirements for cytosolic 
access have been extensively studied in the case of SV40: transport from Rab5+ to Rab7+ 
endosomes precedes transport to the golgi, and the endoplasmic reticulum where the 
virus crosses the endoplasmic reticulum membrane to access the cytosol. Botulinum and 
tetanus toxins, however, seem to require only low pH to insert into the membranes[236], 
and thus cytoplasmic access can occur in the absence of endosome maturation. 
Inhibiting Rab5 vesicle maturation either through the addition of wortmannin or ex­
pression of a Rab5 dominant negative mutant had no effect on the ability of 5.3 to reach 
the cytoplasm, indicating that 5.3 enters into and efficiently escapes from early (Rab5+) 
endosomes. In contrast, Tat and Arg8, which are also present in Rab5+ vesicles, require 
Rab protein exchange or the activity of Vps34 (and possibly the subsequent recruitment 
of Rab5 effectors) in order to reach the cytoplasm. Inhibition of endosomal acidifica­
tion through the addition of bafilomycin inhibited cytosolic access of 5.3, Tat and Arg8. 
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Thus, the pathway uncovered here for miniature protein 5.3 bears the greatest resem­
blance to that described for botulinum toxin and anthrax toxin, which also escape from 
early endosomes and require low pH to do so. The pathways followed by Tat and Arg8 
require downstream events or further endosomal acidification that is achieved after the 
early endosome. This distinction implies the existence of alternate signals favoring early 
versus late endosomal release. Identifying these signals and understanding their mech­
anistic basis may allow researchers to target molecules to a desired delivery pathway, 
increasing the rapidity and ease with which designed peptides may access the cytosol. 
This understanding may also shed light on the fundamental nature of the permeability 
barrier presented by lipid bilayers. 
Miniature protein 5.3, with the lowest charge density, was released at the earliest 
common point along the endocytic pathway, whereas Tat and Arg8, which carry higher 
charge density, were released later. The differences in arginine/lysine number and ori­
entation in 5.3, Tat, and Arg8 can affect side chain pKa, and thus overall charge at a 
given pH, as well as affinity for as-yet-unidentified cellular targets. It is possible that the 
distinct arginine array in 5.3 favors the formation of a critical protonated species in the 
moderately acidic environment of the early endosome (pH « 6.5), whereas the lower pH 
present in lysosomes may be required to generate an equivalent state for Tat and Arg8. 
It is equally possible that the discrete arginine array in 5.3 represents an export signal for 
a cellular machinery that has yet been identified. 
4.4 Experimental Methods 
4.4.1 Cell Culture and Transfections. 
HeLa cells (ATCC, Manassas, VA) were grown in T-75 culture flasks containing Dul-
becco's Modified Essential Medium (DMEM, Gibco Cat. #11995-065) supplemented with 
10% FBS, and 100 U/mL each Penicillin and Streptomycin. Transient transfections were 
performed using Fugene 6 or XtremeGene HP (Roche) using the protocols recommended 
120 
by the manufacturer. Plasmids encoding Rab5-GFP and Rab5Q79L-GFP were gifts from 
Pietro DeCamilli. A plasmid containing Rab7-GFP was a gift of Qing Zhong (Addgene 
plasmid # 28047). A plasmid containing GalT-EGFP was a gift of Jeniffer Lippincott-
Schwartz (Addgene plasmid # 11937). A plasmid containing the glucocortcoid receptor 
fused to EGFP (pK7-GR-GFP) was a gift of Ian Macara (Addgene plasmid # 15534). 
4.4.2 Colocalization of miniature proteins with Alexa-488-transferrin and Rab-
GFP fusions. 
To examine the colocalization of rhodamine labeled miniature proteins or peptides with 
Alexa-488-transferrin (Tf488), HeLa cells were plated (200 pL, 104 cells /well, 96 well glass 
bottom plates, Matrical) the day prior to experiments. The media was replaced with 150 
fiL Hepes-Krebs-Ringer's (HKR) buffer (140 mM NaCl, 2 mM KC1, 1 mM CaCl2, 1 mM 
MgCl2, 10 mM Hepes pH 7.4) containing 1 pM miniature protein or 25 nM Alexa-488-
transferrin (Molecular Probes) and the cells incubated at 37°C for 30 min. The cells were 
then rinsed twice with 200 |iL HKR buffer and nuclei were labeled by overlaying 200 (iL 
HKR containing 300 nM Hoechst 33342 (Molecular Probes Cat. # H3570) for 5 minutes. 
Images of cells were acquired using a PerkinElmer LiveView spinning disk confocal mi­
croscope fitted with a 60 x 1.2 NA objective. Colocalization with Rab-GFP fusions was 
examined in an analogous way using HeLa cells transfected with the appropriate expres­
sion plasmid. 
Colocalization between rhodamine and fluorescein labeled miniature proteins and 
peptides, or between rhodamine labeled miniature proteins and markers of endocytosis 
was completed using confocal microscopy. Live cell confocal microscopy was conducted 
using a PerkinElmer LiveView spinning disk confocal microscope fitted with heated mi­
croscope enclosure (maintained at 37°C), a 6ox 1.2 NA objective, laser illumination, a 
Nipkow CSU-iX spinning disk, and a Hammamatsu CS9100 EMCCD camera operated 
using Velocity software. Alexafluor-488-transferrin was detected using a 488 nm laser 
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and a 520 nm long pass filter; tetraethylrhodamine and Alexafluor-546-transferrin were 
detected using a 546 nm laser line and a 580 nm long pass filter, Hoescht 33342 was de­
tected using a 405 nm laser line and a 450 nm long pass filter. Images were processed for 
presentation by using the 'subtract background' option and linear contrast adjustments 
in Image J. All adjustments were applied uniformly to the entire image. Colocalization 
analysis was performed using the JACOP plugin5, available on the ImageJ website. The 
fraction of rhodamine signal overlapping with EGFP signal (R e G) was calculated using 
Mander's coefficient and automatic thresholding. Pearson's correlation coefficient (R) 
was also obtained using the JACOP plugin. 
4.4.3 Effects of inhibitors on cell uptake. 
HeLa cells grown for 24 h in glass bottom plates were incubated with HKR buffer, or 
HKR buffer containing 80 pM dynasore, 50 pM N-ethyl-isopropyl-amiloride, or 5 mM 
methyl-(3-cyclodextrin for 30 min at 37°C prior to the addition of 1 pM rhodamine-labeled 
miniature protein or peptide (Tat and Arg8). The cells were washed twice with DMEM, 
the nuclei labeled with Hoescht, and images acquired as described above for colocaliza­
tion experiments. 
4.4.4 Effect of inhibitors on cytoplasmic access by dex-labeled miniature pro­
teins or peptides. 
HeLa cells transfected with pKy-GR-GFP for 24 - 36 hr were plated (104/well in 200 
pL) the day prior to experiments in 96 well glass bottom plates (Matrical). The media 
was replaced with HKR buffer containing 300 nM Hoescht and the cells incubated for 
30 min at 37°C. The media was then replaced with 150 pL HKR buffer or HKR buffer 
containing 1 pM dexamethasone labeled cationic miniature protein or peptides or 1 pM 
dexamethasone as a positive control. The cells were incubated for a further 30 min at 
37°C before epifluorescence imaging using a Zeiss Axiovert 200M microscope fitted with 
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a mRM digital camera, a 63 x 1.3NA PlanApo objective and an EXFO-Excite illumination 
source. Dual color epifluorescence images were acquired using the following filter sets: 
Hoescht, Zeiss Filter Set #49 (ex G 365 nm, FT 395, em BP 445/50 nm); EGFP, Zeiss Filter 
Set #44 (ex BP 475/50 nm, FT 500, em BP 530/50 nm). 
To examine the effects of various inhibitors on the ability of dexamethasone labeled 
cationic miniature proteins to activate the glucocorticoid receptor, HeLa cells were trans-
fected and plated as above. Thirty minutes prior to the addition of dexamethasone la­
beled cationic miniature proteins and peptides the media was replaced with HKR buffer 
containing 300 nM Hoescht and 80 nM dynasore, 50 jiM N-ethyl-isopropyl-amiloride or 
5 mM methyl-6-cyclodextrin and the cells incubated for 30 min at 37°C after which 1 jiM 
dexamethasone labeled miniature protein or peptide was added. Uptake was allowed to 
proceed for an additional 30 min at 37°C before analysis by epifluorescence images as 
described above. Images were analyzed to determine the ratio of nuclear to cytoplasmic 
GR-GFP using CellProfiler (see § 3.4.5 on page 84). 
4.4.5 pGR-mCherry vector construction. 
The full length glucocorticoid receptor (NR3C1) was subcloned into pmCherry-Ni (Invit-
rogen), generating a C-terminal fluorescent protein fusion, by amplifying the gene from 
PK7-GR-GFP using PCR primers containing Saci and BamHi restriction sites. The ampli­
fied PCR product was digested and ligated into the multiple cloning site of pmCherry-Ni 
digested with the same restriction enzymes. 
4.4.6 Requirement of Rab5 activity for the ability of peptides to reach the 
cytoplasm. 
HeLa cells transfected for 24 - 36 hr with pGR-mCherry and either Rab5-GFP or Rab5®79L-
GFP were plated (104/well in 200 JJL) the day prior to experiments in 96 well glass bot­
tom plates (Matrical). The cells were washed with HKR buffer and the nuclei labeled 
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using Hoescht as above. Then 150 jiL HKR buffer or HKR buffer containing 1 p.M dex­
amethasone labeled cationic miniature protein or peptides or 1 pM dexamethasone as 
a positive control was overlaid into the well. The cells were incubated for a further 30 
min at 37°C before imaging. Cells that had been cotransfected with EGFP fusions were 
identified via their characteristic pattern of green and red fluorescence. To evaluate the 
extent of GR activation, epifluorescence images were obtained as described above, except 
the fluorescence of pGR-mCherry was also visualized using Zeiss Filter Set #43 (ex BP 
545/25 nm, FT 570, em BP 605/70 nm). Images were analyzed to determine the ratio of 
nuclear to cytoplasmic GR-mCherry using CellProfiler. 
4.4.7 Statistical Analysis. 
Comparisons within groups were made using ANOVA. Pairwise comparisons within 
groups were made using Bonferroni's post-test after finding a significant difference us­
ing ANOVA. P-values are adjusted for the number of comparisons (using Bonferroni's 
method[237, 238, 239]) so that the family-wise error rate, FWER = 0.05 as follows. Fol­
lowing the determination of a statistically significant difference using ANOVA, the signif­
icance of a given pairwise comparison from among set containing J groups is calculated 
using the £-stastistic. Let p(t, df) be the significance of a two-tailed t-test between two 
groups with degrees of freedom df. Then the signiciance of the difference using Bonfer­
roni's method p' between two groups from a family containing J groups is distributed 
as 
p '  =  p ( t , N - J ) -
where t is the test statistic from the between group comparison, N is the number of 
degrees of freedom from the ANOVA analysis and / is the number of groups in the 
family. A critical feature of this method of correction is that the number of groups in 
the family from which the pairwise comparison is drawn has a significant effect on the 
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the significance of the result, p'. An alternative way of reporting Bonferroni corrected 
P-values is to alter the significance level a at which a test is considered significant. In 
this case, a is usually set so that a! = ot • j.^iy and the null hypothesis H° is rejected if 
p{t,N — J) > a'. As an example using this second method, a single pairwise comparison 
from a family containing 6 members would need p < 0.003 to be considered significant. 
This alternative method is functionally equivalent to the one used here. The advantage 
of reporting p' is that these values are intuitively understandable and the false-discovery 
rate (in the alternative method, the example comparison with p < 0.003 has a false 
discovery rate of 0.05). One caveat to our approach is that in the case of negative results 
(i.e. when H° is not rejected), it is possible to find p' > 1, which is unphysical. This 
oddity is generally acceptable, because in these cases, the exact value of the significance 
of the test in unimportant. 
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